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ABSTRACT 
Marshall Robert Wilson, Advisor 
Control of chemical reactions becomes especially challenging when chemical processes have to 
work within the complexity of biological environments. This is one of the reasons why the 
ability to design “caged” molecules with structure, reactivity, and biological activity that can be 
activated externally by light continues to draw significant attention, from both the practical and 
fundamental points of view. Possible applications of such molecules include design of molecular 
machines and switches, logic gate mimics, optical sensors, drug delivery systems, etc. 
Since “caged” molecules are of particular use for processes that occur in biochemical systems 
and in the environment, interesting light-sensitive systems, anti-cancer drugs, have been 
developed recently to control DNA cleavage. Caged molecules may interact with or bind with 
DNA and can be classified by their mechanism of action. Each of these classes of molecules has 
a different structure and interacts with DNA in a different way, but some molecules can combine 
several functionalities.  
The preponderance of caged molecules, anti-cancer drugs, capable of DNA cleavage or their 
metabolites incorporate Electron Transfer (ET) functionalities, which play important roles in 
physiological responses. These main groups include quinones (or phenolic precursors), metal 
complexes, aromatic nitro compounds (or reduced derivatives), and conjugated imines (or 
iminium species). Redox cycling with oxygen can occur giving rise to Oxidation Stress (OS) 
through generation of Reactive Oxygen Species (ROS) which can contribute to drug efficacy or 
ii 
can lead to undesirable toxicity. In some cases, ET results in interference with normal electron 
transport chains.  
In this work a series of caged molecules-chiral Pyrene Dihydridioxins (PDHD)-DNA chiral 
DNA intecalators and PDHD-metal complexes bearing masked o-quinone functionality activated 
through intramolecular ET were synthesized. The o-quinone release and intramolecular ET can 
be easily activated by UV-light. The mechanism of o-quinone release and intramolecular ET was 
studied in detail by methods of Ultrafast Transient Absortion Spectroscopy and supported by 
high-level quantum mechanical calculations.  
The binding properties of chiral intercalators based on PDHD to various DNA oligonucleotides 
were studied by various methods and DNA cleavage properties indicating strong binding and 
cleaving ability of the synthesized PDHDs.  
Also, a new method for synthesis of cyclohexa[e]pyrenes which possibly capable of 
intramolecular ET and electron transfer-oxidative stress (ET-OS) DNA cleavage was developed 
and partially accomplished. 
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CHAPTER 1. INTRODUCTION. DNA BINDERS AND INTERCALATORS. DNA 
CLEAVAGE. 
In the 1830's, Theodor Schwann and Mathias Schleiden1 discovered that the nucleus plays a 
chief role in the growth and development of living cells, which was the basis of the cell theory, 
initially founded by Robert Hooke.2 Further insights into cells with advancement of time and 
technology, established that the nuclei of cells contain very long threads of nucleic acids and 
proteins called chromosomes. In the early 1900's, the hypothesis that chromosomes contain 
hereditary information was gaining acceptance from the biological community. Once accepted 
and confirmed that DNA, the main constituent of chromosomes was the source of hereditary 
information, it was a race to discover its structure in hopes of better understanding this 
fascinating molecule. Rosalind Franklin made a significant contribution to the discovery of the 
structure of DNA with the information she gathered using X-ray diffraction.3 At that time 
scientists knew that DNA consisted of sugars (deoxyribose sugar), phosphates, and four different 
nitrogen bases: adenine, guanine, cytosine, and thymine. Scientists also established that the 
number of adenine and thymine molecules was equal, and the number of guanine equals that of 
cytosine molecules in a DNA duplex irrespective of the species of the organism studied. There 
were many people who contributed to the discovery of the structure of DNA, but it was James 
Watson and Francis Crick who ultimately developed the first three-dimensional model of a DNA 
duplex in 1953 by stitching together all the information.3 Watson and Crick's model is still in use 
today. 
After the discovery of the structure of duplex DNA, it was postulated that the nature of base 
stacking could facilitate the migration of a charge through the DNA. The process of interaction 
of anticancer drugs with DNA and the process of charge migration caused by drug-DNA 
2 
interactions have been studied during the last twenty years. Charges moving through DNA may 
result in oxidative damage, which is believed to be responsible for aging, apoptosis, and    
cancer.4-7 A better understanding of the mechanism of charge migration through DNA may lead 
to the discovery of tools required for damage prevention and repair.8 
DNA-binding drugs can be classified according to the type of association with DNA: 
coordinative binding agents, groove-binders, intercalators, and – most recently    classified9 – 
phosphodiester backbone-binders. Non-coordinative interactions rely on electrostatic 
interactions, molecular recognition based on shape and size, and hydrogen bonding. To date, the 
only DNA-targeted metal-containing drugs in clinical use are platinum-based drugs, and these 
are believed to interact with nucleic acids primarily through the formation of coordination 
bonds.10 Some new photoactivatable drugs such as platinum(IV) complexes have been developed 
recently.11 These complexes have improved aqueous solubility, are active only when irradiated 
with certain wavelengths of light and interact with DNA. 
Here we report the synthesis of new chiral photolabile molecules based on dipyridinium 
dihydrodioxins (DHD), which can be used as a template for creation of new photolabile drugs. 
We have performed drug-DNA binding studies of several types of DHDs with DNA and 
observed their DNA cleavage ability.  The products of DNA oxidation by DHD, which were 
studied by electrospray mass-spectrometry (ES-MS), revealed that DHD are intercalators with 
strong oxidation potential.  
1.1. STRUCTURAL COMPONENTS OF DNA. 
Deoxyribonucleic acid, DNA, is chemically a long polymer of simple units called nucleotides 
with a backbone made of deoxyribose (furanose) sugar and phosphate groups joined by ester 
3 
bonds. Attached to each sugar is one of the four types of molecules called nitrogenous bases 
namely Adenine, Guanine, Thymine and Cytosine. 
1.1.1. Sugars. 
The sugar moiety present in DNA is 2’-deoxyribose (aldopentose in its cyclic furanose form). 
The deoxyribose lacks a hyroxyl group in its 2’-position (Figure 1.1). DNA differs from RNA, as 
RNA has the 2’-hydroxyl group. The conformation of the deoxyribose sugar ring is very 
important in determining the overall structure of DNA. The deoxyribose sugar of DNA adopts 
the β-D-conformation with both the substituents at the 1’ and the 4’ position are facing “up”, or 
above the plane of the ring. For most DNA types the C2’ position is puckered above the plane of 

























Figure 1.1: Cyclic Furanose Form of Ribose and 2’-Deoxyribose. 





There are two types of heterocyclic bases in DNA: purine and pyrimidine. Adenine (A) and 
Guanine (G) belong to the purine family, and Thymine (T) and Cytosine (C) are pyrimidines 
(Figure 1.3). In A, an amine group (-NH2) group is attached to the C6 position of the purine, 
whereas G has a carbonyl (-C=O) group at C6 position and an amine group at C2 position. C has 
an amine group at C4 position of pyrimidine, and T has a carbonyl group at C4 and a methyl 
(CH3) group at C5 position of the pyrimidine. Uracil (U), which is a base normally found in 



































































Uracil (C)  





1.1.3. Glycosidic bond. 
The carbon-nitrogen bond between the sugar and the base is a glycosidic bond (Figure 1.4). In a 
nucleoside, the base is attached to the C1 position of sugar. For adenine and guanine, N9 
positions of the bases are attached to the sugar and for thymine and cytosine, N1 position of the 
bases connect to the sugar. 
1.1.4. Phosphate backbone and phosphodiester bond. 
The sugars and phosphates make up the backbone of the DNA with the phosphates attached to 
the 5’-CH2OH and 3’-OH of the sugar, giving rise to 5’ and 3’ termini on DNA single strands 
(Figure 1.4). The O-P bonds between the sugar and phosphates are termed  phosphodiester 




Figure 1.4: Different Components of DNA 
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1.2. DNA DOUBLE HELIX. 
DNA is helical in nature.12, 13 Watson and Crick reported that DNA consists of two helical chains 
coiled around the same axis. One of the most versatile features of the Watson and Crick model 
was the base pairing of adenine with thymine and guanine with cytosine, and that these base 
pairs are held together by hydrogen bonds that are specific for each pair (Figure 1.5). There are 
two hydrogen bonds between A and T, while G and C are held together by three hydrogen bonds. 
In an A-T base pair, the C6-NH2 of A forms a hydrogen bond with C4-O of T and N1 of A and 
N3-H of T forms the other hydrogen bond. For G-C base pairs the three hydrogen bonds involve 
the C6-O of G with C4-NH2 of C, the N1-H of G with N3 of C and lastly the C2-NH2 of G with 
C2-O of C. The elucidation of the secondary structure of DNA explains how DNA could 
possibly be the carrier of genetic information with four base pairs. When both strands are copied, 
a new duplex is formed which has the same sequence as the parent one. The complementarity of 
duplex DNA strands leads to the ability of self-replication, resulting in the creation of duplicate 
pairs of DNA.14 
The characteristic features of the Watson-Crick double helical DNA are as follows: 
1) The complementary polynucleotide chains wind around a common axis to form the DNA 
double helix. 
2) The two polynucleotide chains run in opposite directions i.e. antiparallel to each other, but 
individually they form right-handed helices. 
3) The heterocyclic bases occupy the core of the helix, and are held together with the 
complementary bases by hydrogen bonds. 
4) The sugars and phosphates make up the backbone of the single strands of DNA with the 
phosphates attached to the 5’-CH2OH and 3’-OH of the sugar. The individual sugar phosphate 
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backbone chains run along the periphery, minimizing the repulsions between the negatively 
charged phosphate groups. 
5)  DNA strands wind around each other, leaving gaps between each set of phosphate backbones, 
revealing the bases inside. This gives rise to two grooves of different width: The major groove 
occurs where the backbones are further apart, the minor groove occurs where they are closer 
together. The grooves twist around the molecule on opposite sides (Figure 1.6). 
6) The aromatic heterocyclic bases within the center of the helix stabilize the duplex through 
stacking interactions between the aromatic rings in adjacent bases.15 
7) Metal cations surround the negatively charged phosphate groups in the sugar phosphate 
backbone and offer stability to the DNA duplex. 












































































Figure 1.6: Schematic Illustration of the Major and Minor Groove of DNA. Left View: Grooves 
in Relation to the Functional Groups of the Base Pairs. Right View: Grooves with Respect to the 
DNA Duplex. 
1.3. CONFORMATION OF DNA.  
 
Within the human body, DNA can be found in many conformations, although the three major 
conformations of DNA are the A-form, B-form and Z-form. The conformation and geometry of 
A-, B-, and Z-DNA vary drastically as a result of the hydration of the phosphate backbone, 
differing sugar-pucker conformations and stacking interactions between the base pairs.17 
Characteristics of these DNA conformations are listed in Table 1.1. The different conformations 
of DNA are largely due to the sugar groups which dictate whether the helix is right- or left- 
handed, as the phosphate groups and nucleosides themselves are not chiral. Changes in the sugar 
pucker from a C3-endo to C2-endo base-pair tilt varies the distance between consecutive base-
pairs and the degree of rotation of the helix per residue. The changes in sugar pucker can arise 
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for various reasons, including a change in salt or drug concentration, relative humidity and base-
composition. Intercalation-induced structural changes to DNA have also been examined by near-
infrared Raman spectroscopy, which clearly indicate a structural transition from the B-form to an 
A-like form with increasing intercalator concentration.18 Combined together, these changes in 
DNA secondary structure by intercalators is believed to prevent replication of the DNA and 
thereby inhibit further growth of cancers or cause cell death.  
Geometry  B-DNA Z-DNA A-DNA 
Helix Right-handed  Left-handed  Right-handed  
Rotation (bp) 35.90 60.20 33.60 
Repeating Unit 1 2 1 
Mean (bp/turn) 10 12 10.7 
Rise (bp along axis) 3.32 Ǻ 3.8 Ǻ 2.3 Ǻ 
Inclination (bp to axis) 1.20 -90 190 
Pitch (turn of helix) 33.2 Ǻ 45.6 Ǻ 24.6 Ǻ 
Mean propeller twist 160 00 180 
Glycosyl angle anti C: anti, 
G: syn 
anti 
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Figure 1.7. 3D Generated Picture of a Portion of DNA’s (B, Z and A –DNA’s). 
 
1.3.1. B-DNA. 
B-DNA is a right-handed double helix and is the most common DNA conformation (Figure 1.7). 
The bases of B-DNA are along the axis and the sugar-phosphate backbones are along the 
periphery. The major groove and minor groove are nearly equivalent in depth, with the major 
groove being wider than the minor groove.19 The N7 and C6 of A and G as well as the C5 of C 
and T point towards the major groove, while the N3 of A and G as well as the C2-O of C and T 
point towards the minor groove. Its glycosidic bonds form normal anti-conformations, while its 
sugar puckers form C2’-endo conformations. 
1.3.2. Z-DNA. 
Z-DNA has a left-handed double helical structure in which the phosphates in the backbone are in 
zig-zag pattern (Figure 1.7). It uses two consecutive nonequivalent base pairs as the helical 
repeating unit. Formation of this structure is generally unfavourable, although certain conditions 
can promote it such as alternating purine-pyrimidine sequence, DNA supercoiling or high salt 
concentration and some cations. While no definitive biological significance of Z-DNA has been 





The A-DNA conformation is preferred when the relative humidity is reduced to less than about 
75%. It is also a right-handed double helix, but the helix is wider and shorter than in B-DNA. In 
A-DNA the major groove is very deep and the minor groove is so shallow that it is hardly 
considered a groove at all. The bases in A-DNA are tilted more sharply with respect to the helix 
axis and the sugar puckering is C3’-endo. 
1.4. DNA DAMAGE: CAUSES AND EFFECTS. 
DNA damage occurs at a rate of 1,000 to 1,000,000 molecular lesions per cell per day 22 and is 
caused by attack from different sources which lead to its damage. While this constitutes only 
0.000165% of the human genome's 3 billion base pairs, unrepaired lesions in critical genes can 
impede a cell's ability to carry out its function and appreciably increase the likelihood of 
permanent impairment. DNA base damage that modifies the base structure affects the primary 
structure of the double helix. These modifications can disrupt the regular helical structure of the 
molecule by introducing non-native chemical bonds or bulky adducts that do not fit in the 
standard double helix. DNA is, futhermore, supercoiled and wound around "packaging" proteins 
called histones, and both superstructures are vulnerable to the effects of DNA damage. DNA 
damage can be divided into two main types: 
1. Endogenous damage such as attack by reactive oxygen species produced from normal 
metabolic byproducts especially the process of oxidative deamination 
2. Exogenous damage caused by external agents such as: 
a) Ultraviolet [UV 200-300 nm] radiation from the sun. 
b) X-rays and gamma rays and also cancer chemotherapy and radiotherapy. 
c) Hydrolysis or thermal disruption. 
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d) Plant toxins, and human-made mutagenic chemicals, especially aromatic compounds that act 
as DNA intercalating agents. 
The replication of damaged DNA before cell division can lead to the incorporation of wrong 
bases opposite damaged ones. Daughter cells that inherit these wrong bases carry mutations from 
which the original DNA sequence is unrecoverable. 
There are four main types of damage to DNA due to endogenous cellular processes: 
1. Oxidation of bases [e.g. 8-oxo-7,8-dihydroguanine (8-oxoG)] with generation of 
DNA strand interruptions from reactive oxygen species. 
2. Alkylation of bases, such as formation of 7-methylguanine. 
3 .Hydrolysis of bases, such as deamination, depurination and depyrimidination. 
4. Mismatch of bases, due to errors in DNA replication, in which the wrong DNA base is stitched 
into place in a newly forming DNA strand. 
1.4.1. Oxidative Damage of DNA. 
Oxidative damage of DNA is produced in cells by oxygen-derived species resulting from cellular 
metabolism and from interaction with exogenous sources such as carcinogenic compounds, 
redox-cycling drugs and ionizing radiation.  
DNA damage can be caused by oxygen-derived species including free radicals which are the 
most frequently encountered by aerobic cells. These agents can cause base and sugar lesions, 
strand breaks, form DNA-protein cross-links and produce base-free sites.23-27 Investigations have 
associated oxidative DNA damage with diseases including aging, neurodegenerative disorders 
(Alzheimer’s disease), cancer, multiple sclerosis and many others.28-31 Oxidative damage to 
DNA is a result of interaction of DNA with Reactive Oxygen Species (ROS). 
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 There are also at least three known chemical sources which can oxidize DNA by 
photosensitization: hydrogen atom abstraction by free radicals,32 singlet oxygen or hydroxyl 
radicals generated from an excited photonuclease,33 and loss of an electron from a nucleobase 
generating a radical cation.34 
1.4.1.a. Oxidative Damage of DNA by Hydrogen Abstraction. 
In the hydrogen abstraction process, irradiation in the presence of a hydrogen donating substrate 
causes hydrogen to be transferred from the donating substrate to the excited photosensitizer.35 
The presence of multiple hydrogen donating sites in the deoxyribose sugars often make it a 
hydrogen donor which lead to the formation of sugar radicals. The sugar radicals can ultimately 
rearrange and bring about strand cleavage. Some examples of photosensitizers that cleave DNA 
by hydrogen atom abstraction are activated by cationic metal porphyrins (A),36 photoactive 




















































Figure 1.8. Structure of Photosensitizers used for Hydrogen Atom Abstraction in DNA. 
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1.4.1.b. Oxidative Damage of DNA by Singlet Oxygen. 
Singlet oxygen is formed in the vicinity of DNA when energy transfer takes place from an 
excited photosensitizer to ground state molecular oxygen, provided the excited photosensitizer 
has high enough triplet energy to generate singlet oxygen. This particular species is highly 
reactive and preferentially reacts with the guanine residues in DNA.39 Some well known 
examples of singlet oxygen generating photosensitizers are   porphyrins,40 ruthenium (III) 
complexes41 and vanadium (V) complexes.42 
1.4.1.c. Oxidative Damage of DNA by Loss of Electron from a Nucleobase Generated by  a 
Radical Cation. 
The electron transfer (E.T.) process in DNA is caused by the donation of an electron to an 
excited photosensitizer producing a radical cation (hole) on a nucleobase and a radical or radical 
anion on the photosensitizer. The radical cation formed can migrate into the DNA and damage 
the DNA by reaction with the normal bases to form unwanted mutated products. The migration 
of the radical cation is called hole transfer, hole transport or hole migration and exhibits a wide 
range of mechanistic behaviors. Its exploration has provided us with a detailed understanding of 
the key components of charge transfer: charge injection into the DNA or removal of an electron 
from a DNA base, the charge transfer mechanism (migration of radical cation to distant sites), 
and finally, reactions of the ionized nucleobase resulting in damaged DNA. 
During the oxidative hole transfer, an electron is transferred from the DNA or the final acceptor 
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Figure 1.9. Photoinduced Hole Injection and Oxidative Hole Transfer (HOMO-controlled) in 
DNA (Do = donor, Ac = acceptor, ET = electron transfer). 
1.4.1.d. Reductive Damage of DNA Caused by Laser Photolysis of Water, or Electron 
Transfer. 
Oxidative DNA damage is a well-known process, whereas the related process of reductive DNA 
damage is not well-studied. The recent studies by Lu’s group reveal that reductive DNA damage 
takes place via dissociative ultrafast-electro-transfer (UET) mechanism in water. The active 
species of UET is e pre
- formed in the process of two photon photolysis of water in 266-380 nm 
range44-51 and shown on Figure 1.10. In water, a free electron is rapidly solvated by surrounding 
H2O molecules to form a weakly bound e pre
- at around −1.5 eV that has lifetimes of 
approximately 500 fs.45-49, 52 The e pre
- is the precursor to e hyd
- , a well-known species produced 
by radiolysis of water 53, 54 that has a high efficiency of attachment to some molecules including 
conventional electron scavengers. 55-62 On the other hand, ehyd
- is ineffective at inducing 




H2O H2O + e H2O(ehyd)
H2O + H2O H3O + OH
H2O
* H  + OH(dissociation)  
 
 
Figure 1.10. Two-Photon Photolysis of Water. 
 Two-photon excitation of water readily generates the radicals (epre
- and OH•) from radiolysis of 
water within 10−14 s after irradiation at UV wavelengths of 266–380 nm. The attacks of radicals 
can then cause single-strand and double-strand breaks of the DNA. 
Along with formation of e pre
-, formation of OH• was  observed. It was confirmed by 
femtosecond time-resolved laser spectroscopy (fs-TRLS) measurements 48, 66-72 that UET 
reactions between bare electron (e pre
−) and solvated electron H2O(e hyd
.−) and OH• scavengers is 
taking place: e pre
− ((< 0 eV) + AB → AB−). The oxidizing OH• radical, an ROS, is thought to be 
the main species to induce damage of DNA.63-65 DNA cleavage experiments were performed in 
the presence of OH• and H• scavengers, DMSO and KNO3, since    e pre
- was the only species to 
cause the breaks of double-stranded (DSB) and single-stranded DNA’s under this conditions.64, 65 
It was observed that the yield of reductive DNA strand breaks induced by each  e pre
- is twice the 
yield of oxidative DNA strand breaks induced by OH•  radicals.  
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Electron donors differ significantly in their structure and redox properties.73, 74 Electron transfer 
(electron migration or electron transport) can be initiated by photoexitation of derivatives of 
flavines, stilbene diethers, and pyrenes.  Flavines, stilbene diethers, and pyrenes have been used 
as photoexcitable electron donors and when they are covalently attached to oligonucleotides. 1) 
A flavine derivative can be incorporated synthetically into oligonucleotides as an artificial 
nucleobase.75 In its reduced, deprotonated, and photoexcited state, flavine has a redox potential 
of -2.8 V and is capable of reducing all four DNA bases (Figure 1.11).76, 77 2) Additionally, a 
special T-T dimer lacking phosphodiester bridge bridge between the 3’- and the 5’-hydroxy 
groups of the two ribofuranoside moieties can be incorporated into the oligonucleotides.78 Hence, 
cycloreversion of the T-T dimer, which is initiated by a one-electron reduction, yields a strand 
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Figure 1.11. Chemical Assay for the Investigation of Excess-Electron Migration in DNA. The 
splitting of the T-T dimer is the chemical consequence of the photoinduced electron transfer 
from a distant flavine derivative as the charge donor (Fl). 
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In the case of the reductive electron transfer, the photoexcited electron of the donor is injected 
into the DNA or transferred to the LUMO of the final electron acceptor     (Figure 1.12).43 
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Figure 1.12. Electron  injection and reductive electron transfer (LUMO-control) in DNA (Do = 
donor, Ac = acceptor, ET = electron transfer). 
1.5. TYPES OF CHARGE INJECTION IN DNA. 
To understand the mechanism of charge migration in DNA, knowledge of the charge transfer 
process is required. Close association of the photosensitizers with the DNA base-pairs is 
necessary to facilitate the transfer of an electron from the DNA to the sensitizer. Towards this 
goal, several photosensitizers have been developed that either intercalate between base-pairs, 
bind in the major or minor grooves or are covalently attached to one of the terminal bases in 
order to achieve “end capping” of the terminal base-pairs. Mechanism of charge injection also 
varies from one sensitizer to another. A list of important photosensitizers that have been used in 
charge  injection studies, along with their mechanism of action are given in Table 1.2.25 The 
























































































































Mechanism DNA target 
Riboflavin 1 E.T. GG 
Anthraquinones 2 E.T. GG 
Naphthalimides 3 E.T. GG 
 4 CH3 
oxidation 
T 
Benzophenones 5 E.T. GG 
Benzotriazoles 6 E.T. GG 
Rh complexes 7 E.T. GG 
 8 E.T. G 
Ru complexes 9 E.T. GG 
 10 E.T. G 
 11 1O2 G 
 12 1O2 G 
 13 1O2 G 
methylene blue 14 1O2 G 
Porphyrins 15 1O2 G 
 16 1O2 G 
V complexes 17 1O2 G 
Diazomethanes 18 Alkylation G 
E.T.-electron transfer; 1O2-singlet oxygen 
Table 1.2: List of Photosensitizers used for Charge Transfer in DNA 
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1.6. QUINONE AS A CHARGE ACCEPTOR. 
The photochemistry of quinones has been well established79 and they are excellent electron 
acceptors for the one-electron oxidation of DNA. They absorb light in the near UV- and visible 
spectral region, >350 nm, where DNA is essentially transparent. The anthraquinone (3, Figure 
1.13) moiety can be easily synthesized80 and can be attached covalently to the DNA by standard 
phosphoramidite chemistry. Anthraquinone can be tethered to either the 5’-terminus of a DNA or 
in other intermediate positions in the DNA sequence in the form of Uridine-anthraquinone. 
Figure 1.14 shows the structure of different anthraquinone derivatives used for photosensitization 
of DNA. Attaching anthraquinone to the terminus of a DNA single-strand followed by 
hybridization with its complementary DNA strand results in “end-capping” of the DNA duplex 
(Figure 1.14, 1.15). It has been found that this “end-capping” of the DNA permits π-orbital 



































Figure 1.15: Hyperchem Generated Image showing Q “End-Capping” in DNA. 
Irradiation of the quinone (Q) group at 350 nm promotes it from the ground state to the singlet 
excited state (Figure 1.16). The excited singlet state has a very short lifetime and it rapidly 
intersystem crosses to the excited triplet state. The excited triplet state is capable of abstracting 
an electron from a neighboring base creating a nucleobase radical cation. Since back electron 
transfer (BET) is not efficient, this triplet radical ion pair state is relatively long lived. 
Subsequent reaction of the Q.- with oxygen generates superoxide and neutral Q. The radical 
cation which has been introduced into the DNA can migrate through the DNA base-pair stack 
until it is trapped by reactions at different bases within the DNA. The efficiency of charge 


























Figure 1.16: Charge Transfer Mechanism of Anthraquinone by Irradiation at 350 nm. 
(Abbreviations: ET, Electron Transfer; BET, Back Electron Transfer; ISC, Intersystem 
Crossing). 
1.7. CHARGE MIGRATION THROUGH DNA. 
Introduction of a radical cation into a DNA duplex can result in its migration through the DNA 
up to 200 Å from its site of generation. It was established that the efficiency of charge migration 
depends on the DNA base sequence.83-87 The task of understanding the mechanism of long 
distance radical cation migration in DNA has invited enormous debate for nearly twenty years. 
Initial reports attributed charge migration over more than 40 Å in less than 1 ns to superexchange 
through a bridge orbital of well-stacked bases, referred to as the “π-way”.88 Later, it was 





stacking.89 Subsequent investigations have resulted in reports that include several mechanisms 
for charge migration, including super exchange tunneling and different hopping mechanisms.90-94 
According to the super exchange mechanism, DNA behaves like a wire having a continuous, 
delocalized molecular orbital. In this orbital, each base pair is in electronic contact with every 
other, and charge migration occurs by super exchange.95 In this tunneling mechanism, when the 
distance between the donor and acceptor is short, the electron tunnels in a single step reaction 
between the selected bases and the intervening base pairs do not act as charge carriers. A 
simplified view on a given and static DNA-based donor–bridge–acceptor system shows that the 
energetic level of the DNA bridge medium relative to the levels of donor and acceptor (δEDo and 
dEAc) determines the hole migration mechanism.
96 In the case of the super exchange mechanism 
(Figure 1.17), the DNA bridge states lie above the level of the photoexcited donor or acceptor. 
Consequently, the hole is transferred in one coherent jump to the acceptor and is never localized 
on the bridge. As a consequence, the rates are strongly distance-dependent. Since the results 
were often described according to the Marcus theory for nonadiabatic electron transfer, b was 
applied to characterize the exponential distance dependence of kHT:
97 
 
Equation 1.1. Marcus theory equation for nonadiabatic electron transfer. Where KHT is the rate 
constant for hole transfer, λ- the reorganization energy (both inner and outer-sphere), ΔGET 
 is the 
total Gibbs free energy change for the electron transfer reaction kb is the Boltzmann constant, 
























Figure 1.17. Oxidative Hole Transfer (top) and Reductive Electron Transfer (bottom) through a 
DNA Bridge via the Superexchange Mechanism (Do = Donor, Ac = Acceptor, B = DNA Base, 
HT = Hole Transfer, ET = Electron Transfer). 
In order to overcome the inability of the super exchange and tunneling mechanisms to explain 
numerous aspects of charge migration in different DNA sequences, scientists suggested a 
different model. This model is known as “discrete hopping”, which states that the radical cation 
is localized on one base and has no significant electronic overlap with adjacent bases. The 
localized radical cation migrates (hops) by a thermally activated process to adjacent bases.98 This 
hopping process is a sequential reaction that is characterized by the rates of the electron-transfer 
steps and trapping steps. This theory recognizes that DNA is not a static molecule and the 
continuous thermal motions of the DNA must influence charge transfer efficiency, but it does not 
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offer any explanation as to how these fluctuations are incorporated into the DNA during charge 
transfer. In the hopping model, the electron is not completely delocalized within the bridge 
during the electron hopping. In fact, the localized charge on the DNA bridge states plays an 
important role as an intermediate during the charge transfer process. Thus, charge hopping 
occurs via a multi-step process consisting of charge injection, several charge transport steps and 
charge trapping. If each single hopping step occurs over the same distance then the dynamics of 
hopping display a shallow distance dependence with respect to the number of hopping steps N:96 
 
Equation 1.2. Dynamics of Hopping ( of Electron Transfer, N - Number of 
Hopping Steps, η the Influence of the Media). 
The value of η represents the influence of the medium and typically lies between 1–2. Among 
the four different DNA bases, guanine (G) can be most easily oxidized.99, 100 The guanine radical 
cation G.+ plays the role of the intermediate charge carrier during the hopping process.101 The 
guanine hopping model was extended by the adenine hopping model if guanines are not present 




































Figure 1.18. Photoinduced Hole Hopping (top) and Electron Hopping (bottom) in DNA (Do = 
Donor, Ac = Acceptor, HOP = Hopping). 
 The inability of the hopping mechanism to explain some of the observations led to a more 
advanced mechanistic model. This model is known as “Phonon Assisted Polaron- like 
Hopping”.103-105 This theory involves delocalization of the radical cation, followed by a hopping 
mechanism, where the charge resides on the bridge. After formation of the radical cation, the 
bases around the radical cation distort themselves to accommodate the charge. This rapid 
distortion results in a change in the normal inclination angle of the neighboring bases, which 
bring them closer to the radical cation, thus delocalizing and stabilizing it (Figure 1.19).  A 
second structural change is a decrease in the twist angle by rotation around the z axis of the 
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DNA. This unwinding will increase the π-electron overlap between bases and will stabilize the 
radical cation. Another possible distortion is a shift in proton donation of the hydrogen bonds 
that form the base pairs. The pKa of a localized base radical cation is different from that of the 
neutral base.106, 107 The pKa of bases carrying delocalized (partial) positive charge also will 
change, and hydrogen bonds in duplex DNA will shift to accommodate this change. It is the total 
of these structural changes that are known as the polaron-like distortion.108 The extent of the 
delocalization is governed by the energy required to distort the DNA and the energy gained by 
delocalizing the radical cation, which depends on the base sequence of the DNA involved in the 
charge migration. The base radical cation can be considered as a polaron, which is defined as a 
radical ion self-trapped by structural distortion of its containing medium.109 Strictly, it is a 
polaron-like species, but not an ideal polaron, since the detailed properties of the distortion are 
sequence dependant. This polaron can extend to that point where the energy required to distort 
the DNA will just balance the stabilization. The polaron hopping model requires that the radical 
cation exist as a detectable entity during its migration through the bridge. Charge transfer studies 
have been carried out with 2’-deoxy-N6-cyclopropyl-adenosine located between the charge 
injection site and a distant guanine site. It was found that the radical cation interacts with the 
bridge as evident from the ring opening of the cyclopropyl ring.109 This experiment supports the 






























Figure 1.19. Schematic of Phonon-Assisted Polaron like Hopping Mechanism of Charge 
Migration in DNA. 
1.8 CHARGE TRAPPING. 
Table 1.3 reveals oxidation potential of the various DNA bases G or GG steps stibilize the 
radical cation migration in the DNA most effectively. The radial cation prefers to be delocalized 
on guanine bases. The oxidation potential of guanine is lowest among the four bases (Table 1.3) 
and oxidation potentials of repeating G’s such as GG and GGG are even lower. During the 
hopping through the DNA, the radical cation resides at Gn (n = 1-3) and forms guanine radical 
cations. The radical cation then can react with H2O and/or O2 to form 8-oxoguanine (8-oxodG) 


























































Figure 1.20. Reaction of Guanine Radical Cation with Water and Oxygen. 
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In order to examine the mechanism of charge migration and oxidation of DNA, development of a 
method for determining the charge transfer efficiency is important. Treatment of the oxidized 
DNA strands with piperidine leads to strand cleavage at sites of guanine oxidation. Gel 
electrophoresis separates the DNA strands based on their size to charge ratio and the mobility of 
the cleaved DNA can be visualized by dye staining or autoradiography. The cleavage and 
separation technique involving the charge trapping of the migrating radical cation allows for the 
accurate quantification of charge migration efficiency. Besides guanine oxidation, which lead to 
the formation of 8-oxoguanine, oxidation of other bases is also possible depending on the 
sequence of the DNA undergoing charge migration. The migrating cation can be trapped by all 
the bases forming irreversible trapping products, though their rate of formation might be low in 
comparison to the formation of oxoG lesions. The C4-C5 double bond of pyrimidine is 
particularly sensitive to attack by hydroxyl radical. Some pyrimidine damage products are 
thymine glycol, uracil glycol, urea residue, 5-hydroxyuracil, 5- hydroxycytosine, hydantoin and 
others. Even adenine is prone to oxidation and 8-oxoA has been isolated in many charge transfer 
studies. Formamidopyrimidines (fapy-dG, fapy-dA) and other less characterized purine oxidative 
products are also formed.25 
1.9. DNA INTERCALATION. 
Small molecules can interact with various morphologies of nucleic acids at multiple sites to alter 
nucleic acid function.110,111,112 There are several possibilities for how a drug that binds to DNA 
(alkylation, intercalation, minor/major groove binding, outside binding) or to DNA dependent 
enzymes – such as topoisomerases bound to DNA - achieves its biological activity.113 In the 
recent years, drug design was focused on DNA targeting through the development of code 
reading molecules, inhibitors of transcription factors, new topoisomerases I inhibitors and on 
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compounds targeting the quadruplex. In the case of duplex DNA, one drug class binds within the 
minor groove, and a second class intercalates between existing base pairs of the nucleic acid 
structure.113,114,115 Intercalators and groove binders have distinctive thermodynamic signatures 
that indicate different driving forces for binding.116 The minor groove is a particularly attractive 
target for small molecules, since this site has less competition from proteins and polymerases, 
which typically interact with the major groove.117 The closer proximity of the strands in the  
minor groove compared to the major groove allows more contact surface area for a small 
molecule to bind tightly.118 The unfavorable geometry of the major groove is another reason why 
few drugs target this groove.110 Two well-known and well-characterized minor groove binders 






















Figure 1.21. Structures of Pentamidine and the Antiviral drug Distamycin. 
 There are an enormous number of studies of intercalating DNA drugs. Intercalation describes 
the reversible insertion of a guest molecule into the lamellar host structure.  Lerman first 
proposed intercalation to explain the strong affinity and binding of planar aromatic 
chromophores to DNA,119, 120 and there is now a large body of evidence which validates, refines 
and extends this concept.120-122 In specific terms, intercalation is the insertion of a planar 
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aromatic ring system in between consecutive base-pairs of DNA. Partial intercalation can also 
occur where the introduction of bulky substituents on flat aromatic molecules prevents their full 
insertion between the base-pairs.123, 124 DNA-drug intercalation is essentially stabilised by π-
electron overlap, hydrophobic and polar interactions, as well as the electrostatic forces of 
cationic intercalators with polyanionic nucleic acid.125, 126 The insertion of an intercalator 
between adjacent base-pairs results in a change in DNA structure, causing lengthening, stiffening 
and unwinding of the DNA helix.127 Intercalation extends the DNA helix and shifts the base pairs 
flanking the binding site in opposite directions along the helical axis (Figure 1.22).128-132     As a 
result of intercalation, DNA undergoes a loss of regular helical structure in its backbone; as 
indicated by CD spectra and fiber diffraction patterns, which exhibit a loss of resolution in their 
inner layer lines to give a spacing greater than 10.2 Å. The sugar-phosphate torsional angles 
change in order to accommodate the aromatic compound, causing separation of the base-pairs 
with a lengthening of the double helix and a decrease in the helix diameter (i.e. unwinding) at the 
intercalation site. 133 In the classical model of intercalation the helix is lengthened by the 
theoretical length of 3.4 Å per intercalated drug. 134 In contrast, electric dichroism measurements 
suggest a range of possible helix extensions from 2.0 to 3.7 Å depending on the intercalating 
compound. 135 The usual rotation of approximately 36º of one base-pair with respect to the next 




Figure 1.22. Schematic diagram of DNA intercalation (The intercalator is red). 
1.10. CHEMICAL INTERCALATORS. 
1.10.1. Organic Intercalators. 
Thousands of reported organic intercalators hahave been reported over the past 20 years, but, in 




anthracenes, (20) acridines, (21) anthraquinones, (22) phenanthridines, (23) phenanthrolines, 
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Figure 1.23. Some Examples of Organic Intercalators Showing the Basic Chemical Structures of 
(19) Anthracenes, (20) Acridines, (21) Anthraquinones, (22) Phenanthridines, (23) 
Phenanthrolines, (24) Ellipticines, (25) Phenanthrene and (26) Pyrene. 
Currently there are four organic intercalators approved by the FDA for the treatment of human 
cancers (Figure 1.24). Daunorubicin (27) is a natural product produced by the bacterium 
Streptomyces coeruleorubidus and is used in the treatment of nonlymphocytic leukaemia in 
adults and acute lymphocytic leukaemia in children and adults.140-142 Doxorubicin (28) is a 
natural product obtained from the bacterium Streptomyces peucetius var. caesius and is used in 
the treatment of a large number of human cancers. Mitoxantrone (29) is primarily used to treat 
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Multiple Sclerosis (MS), but is also used in conjunction with other anticancer drugs for the initial 
treatment of acute nonlymphocytic leukaemia in adults.143-145 Amsacrine (30) has previously 






































Figure 1.24. Some Examples of Organic Intercalators used as Clinical Agents (27) 
Daunorubicin, (28) Doxorubicin, (29) Mitoxantrone and (30) Amsacrine.  
These organic drugs all bind by intercalation from the DNA minor groove, where binding is 
stabilised by electrostatic interactions between positive charges on the drug (charge on nitrogen 
atoms at pH<7) and the negatively charged phosphate backbone,146 although some, like 
mitoxantrone have also been shown to bind DNA by non-intercalating, electrostatic 
interactions.147-151 Organic intercalators are also known to act by inhibiting topoisomerase (a 
nuclear enzyme that regulates DNA topology through single- (topoisomerase I) or double-
stranded (topoisomerase II) breaks).152-155 Recently, researchers have synthesised new organic 
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intercalators,156-158 examined ways to increase the localization of organic intercalators in cancer 
cells159 and studied the interactions of organic intercalators with DNA to a much greater 
extent.158, 160-163 
1.10.2. Metallointercalators. 
1.10.2.a. Octahedral Metallointercalators. 
The ability of octahedral transitional metal complexes to intercalate into DNA was debated 
extensively. Dwyer showed a difference in the biological activity of the Δ- and Λ-enantiomers of 
[Ru(phen)3]
2+, phen = 1,10-phenanthroline (Figure 1.25, 31).164 From these observations, it was 
inferred that the interaction of these metal complexes within the body was physical, rather than 
chemical. Rehmann and Barton were the first to suggest that binding of these complexes to DNA 
could occur through two possible modes - intercalation and surface interaction.165, 166 
For the metal complexes [Ru(phen)2dppz]
2+ and [Ru(bipy)2dppz]
2+ (32) (dppz=dipyrido 
[3,2a:2’,3’-c]phenazine, bipy = 2,2’-bipyridine), a number of theories emerged regarding their 
DNA binding preference.167 Friedman demonstrated that metal complexes containing dppz bind 
to DNA by intercalation,167 with a binding constant greater than 106 M-1.168 Barton and 
Dupureur169, 170 demonstrated, by nuclear magnetic resonance spectroscopy (NMR), that the 
binding of both the Δ - and Λ -enantiomers of [Ru(phen)2dppz]
2+ to the hexanucleotide 
d(GTCGAC)2 occurred by intercalation from the DNA major groove.
170 In contrast, Nordén and 
coworkers proposed that the binding of [Ru(phen)2dppz]
2+ occurred to DNA in the minor 
groove.171, 172 To characterize of DNA adduct, Dupureur and Barton experimented with selective 
deuteration of the ligands used to form the metal complexes.170 By focusing on the dppz ligand, 
they determined that the complex bound to the DNA oligonucleotide in the major groove.170 
Octahedral intercalators containing the dpq ligand have also been shown to readily intercalate 
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with DNA, but with more base sequence selectivity than dppz.173 Δ-[Ru(phen)2 dpq]
2+ was 
shown to exhibit some sequence selectivity for purine-purine and pyrimidine-pyrimidine 
sequences, although the specific binding model could not be determined due to the exchange 
broadening of many of the resonances in 1H NMR spectra.173 The addition of methyl groups to 
the non-intercalating ligand in [Ru(dmphen)2dpq]
2+ (33) (dmphen = 2,9-dimethyl-1,10-
phenanthroline) provided a better binding model for the complex with DNA. The results from 
DNA binding experiments suggested that both enantiomers of [Ru(dmphen)2dpq]
2+ intercalate in 




























Figure 1.25. Some Examples of Octahedral Metallointercalators of Ruthenium(II).  
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Unfortunately, octahedral metallointercalators have not shown particular promise in overcoming 
drug resistance, but still they are used in cancer therapy. [Ru(phen)2dppz]
2+ and [Ru(bipy)2 
dppz]2+ have been shown to act as “molecular light switches” for DNA.167 Octahedral 
metallointercalators that are sequence-selective might be developed as diagnostic agents, where 
in a simple in vitro test they fluoresce strongly in the presence of cells with DNA markers for 
cancers. 
1.10.2.b. Square-Planar Metallointercalators (Figure 1.26). 
The intercalation of square-planar transition metal complexes was first demonstrated by Jennette 
with [Pt(terpy) S(CH2)2 OH)]
+ ([Pt(terpy)(HET)]+)175 (Figure 1.26, 34). This metallointercalator 
was demonstrated to intercalate double stranded DNA by UV-vis spectroscopy, viscosity, 
circular dichroism (CD), fluorescence displacement and unwinding experiments.175 It reversibly 
bound to calf thymus DNA (ct-DNA), increasing the helical length, stiffness and DNA stability 
(as measured by DNA melting temperature which increased by 5 to 6 oC).175, 176 
[Pt(terpy)(HET)]+ was found to bind ct-DNA with a binding constant in the order of 2 x105 M-
1.175 Other ligands containing planar, π-electron rich rings have shown to intercalate DNA 
including: phenanthroline177 and 2,2’-bipyridine (bipy),178 when incorporated into square-planar 
platinum complexes; however, when coordinated onto non-square planar metals, such as copper, 
these ligands do not intercalate with DNA.178 
Square-planar metallointercalators, particularly of platinum, show a strong DNA sequence 
selectively for 5’-GpC sites.177 GpC sites are preferred because of their higher dipole moment. 
By studying platinum complexes with different intercalating ligands, Howe-Grant and Lippard 
demonstrated that whilst most platinum metallointercalators exhibit similar binding constants (~ 
10 4 M-1), the binding strength decreased in the order phen>terpy>bipy.172 The increased binding 
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of phenanthroline-platinum complexes appears to be a function of its extended aromatic system 
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Figure 1.26. Some Examples of Square-Planar Metallointercalators Showing Platinum(II) 
Complexes with Phenanthroline and Terpyridine Intercalating Ligands (* - Indicates a chiral 
centre (R or S)).  
Square-planar metallointercalators can bind DNA in a number of orientations from either the 
DNA major or minor grooves, or by partial intercalation. From the crystal structure of a 
dinucleotide (CpG) with [Pt(terpy)(HET)]+ Wang showed that the platinum intercalator bound in 
the DNA major groove.179 Intercalation induced a C3’-endo pucker of the deoxycytidine instead 
of the normal C2’-endo pucker. This change may be stabilised by the hydrogen bond observed 
between the ancillary ligand hydroxy group to the cytosine O atom. In contrast to these results, 
Collins demonstrated via two dimensional NMR that platinum metallointercalators, containing 
phenanthroline and phenanthrenequinone diamine, bound the oligonucleotide d(GTCGAC)2 in 
the DNA minor groove.180 Nuclear overhauser effect (NOE) cross peaks to DNA major groove 
protons were observed from the leading edge protons of the intercalating ligands as well as NOE 
cross peaks from the ancillary ligand to the minor groove sugar protons. Jaramillo have 
demonstrated that the inclusion of 1,3-diamino1,2,2-trimethylcyclopentane (Figure 1.25, 36, R,S- 
and S,R-tmcp) prevented full insertion of the methylated phenanthroline ligand into the DNA 
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helix to differing extents.181 The metallointercalators instead bound by partial intercalation and in 
a “side-on” fashion.181 
To improve the extent of intercalation, square-planar metallointercalators with extended aromatic 
ring systems, similar to those used for the octahedral metallointercalators, have been used. 
Recently, these have included dpq,182 dppz,182-185                                                          
benzodipyrido [b:3,2-h:2’,3’-f]phenazine (bdppz),182 naptha[2,3-f][1,w]phenanthroline (np),183 
naphtho[2,3-f][1,10]phenanthroline-9-carbo-nitrile (CN-np),183 naphtha[2,3-
f][1,10]phenanthroline-9,14-dicarbonitrile (CN2-np),
183 benzo-[f][1,10]phenanthroline (bp),183 
and a terpyridine derivative: 2,6-(bis[benzimidazo-2-yl)pyridine (bzimpy).185 Interestingly, 
despite the extended ring systems of the metallointercalators incorporating np, CN2-np, dppz and 
CN-np some demonstrate reduced binding constants (103 and 104 M-1) with DNA.183 Most 
platinum(II) intercalators have binding constants in the range of 104 to 107 M-1.177, 186, 187 
1.10.3. Bis-Intercalators. 
Some groups have begun to examine the utility of bis-intercalators (two sets of polyaromatic 
rings joined via a linking chain) for both metallointercalators and organic compounds. Bis-
intercalators may have improved cytotoxicity because of their ability to bind a greater number of 
DNA basepairs simultaneously, and their increased DNA binding affinity. By binding a larger 
number of base-pairs, bis-intercalators may have improved DNA specificity and selectivity over 
mononuclear intercalators, allowing for the design of drugs that can target specific gene 
sequences, and through this, specifically target cancerous cells. The increased DNA binding 
affinity of bis-intercalators may increase the number of DNA-drug adducts formed and/or make 
DNA-drug adducts harder to repair? The improved DNA binding affinity may also induce 




Nordén’s work focused primarily on two bis-intercalators derived from [Ru(phen)2dppz]
2+, 
[{Ru(phen)2}2µ-(didppz)2]
4+ (Figure 1.27, 37 and 38) and [{Ru(phen)2}2µ-C4(cpdppz)2]
4+, 
where didppz = 11,11’-bis (dipyrido[3,2-a:2’3’-c]phenazinyl, and C4(cpdppz)2 = N,N’-bis(12-
cyano-12,13-dihydro-11H-8-cyclopenta[b]dipyrido[3,2-h:2’,3’-j]phe-nazine-12-carbonyl) 
(Figure 1.27, 39).188-193  Using CD, linear dichroism (LD) and luminescence spectroscopy, all 
three stereoisomers of [{Ru(phen)2}2µ-(didppz)2]
4+ (40) ΔΔ -, ΛΛ - and meso- (ΔΛ / ΛΔ -) have 
been shown to form an groove-bound adduct with calf thymus DNA.194 The geometry of the 
intercalative binding subsequently reorganizes slowly, taking almost a day to reach 
equilibrium.189 This mode of binding with ct-DNA has also been observed with poly(dA-dT)2, 
poly(dG-dC)2 and poly(dI-dC)2, although with poly (dA-dT)2, no initial groove bound species 
was detected (Figure 1.28).191 The dissociation of the bound bis-intercalator from DNA has been 
shown to be slow, with the complex requiring several days for SDS-induced (sodium dodecyl 
sulfate) dissociation to occur.191 The rearrangement from groove to intercalative binding was 
proposed to occur via the threading of one of the Ru(phen)2 moieties through the DNA duplex. 
The final geometry of the DNA-bound bis-intercalator is characterized by the intercalation of the 
didppz ligands in an anti-conformation, with a small rotation around the central bond bridging 
the two dppz ligands. 191 The complex intercalates asymmetrically, with one of the ruthenium 
centres situated deeply in the minor groove, while the other center projects through the core of 









































































Figure 1.27. Some Examples of Octahedral Ruthenium(II) Bis-Intercalators with Inflexible and 





Figure 1.28. Model Illustrating Geometry of Δ,Δ –[{Ru(phen)2}2µ-(didppz)2]
4+ (40) at Final 
Binding in Poly(dA-dT)2 ((a) View along 2-fold Axis of Δ,Δ -[{Ru(phen)2}2µ-(didppz)2]
4+ (40) 
(Minor Groove to the Left), (b) View along Helix Axis of the DNA Showing Asymmetric 
Binding (b’), Complex Viewed from top in Absence of DNA, Arrangement of the Ru(phen)2 
Moieties in Major (c) and Minor Groove (d) with B(A2) Phenanthroline Transitions Moments 
Included. (e) Sense of Roll Defined as Viewed into Minor groove: Intercalated dppz of Minor 
Groove Bound Ru(phen)2dppz Moiety is Rotated Clockwise Relative to Perpendicularity to 
Helix Axis, while that of the Ru(phen)2dppz Moiety in the Major Groove is Rotated 
Counterclockwise as a Consequence of Twist Around Internuclear Bond). 
The binding constants of ΔΔ - and ΛΛ-[{Ru(phen)2}2µ(didppz)2]
4+, and ΔΔ - and ΛΛ -
[{Ru(bipy)2}2µ-(didppz)2]
4+ were determined by CD, LD and UV-vis spectrophotometry, 
together with displacement experiments on intercalated [Ru (dpq)2dppz]
2+ (measured by 
emission quenching).188-191 For the didppz complexes, the binding constants were found to be 
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1.10.3.b. Platinum Bis-Intercalators. 
Lowe has developed a series of bisplatinum intercalators, with substituted terpyridine 
intercalating ligands  linked via a variety of rigid, variable length hydrophobic and hydrophilic 
chains (Figure 1.29).195-198 Their cytotoxicity was examined in a panel of human ovarian cancer 
cell lines.195 The degree of cytotoxicity is dependent on the variables: chain length, charge 
density and counter ions. Bis-intercalators with shorter chains were more cytotoxic than those 
with longer chains. Highly charged bis-intercalators were more cytotoxic than those with lower 
charges, or lower charge density. Tetrafluoroborate salts were generally more cytotoxic than 
their corresponding water soluble nitrate salts. 195 Bis-intercalators synthesized by Lowe appear 
to derive their anticancer activity from non-classical DNA intercalation mechanisms. For one, 
the linking chains of the bis-intercalators appear to be labile, yielding a reactive electrophile in 
solution that is able to form coordinate covalent bonds with DNA.199 In a study with 
[{Pt(terpy)}2µ-4,4’-vinylenedipyridine]
2+ and the oligonucleotide d(CGTACG), the bis-
intercalator broke apart, with a terpyridine-platinum group forming a coordinate covalent adduct 
through the N7 position of guanosine.199 Chan has reported the synthesis, DNA binding and 
cytotoxicity of three bis-intercalators linked via a flexible alkane chain 44.200 These metal 
complexes were shown to intercalate into DNA by viscosity experiments, with binding constants 
between 106 to 107 M-1, considerably higher than that of the corresponding mononuclear 
intercalator (104 M-1), have cellular uptake rate equal to cis platin, and cytotoxicity levels equal 
to cis platin in five human tumor cells lines (KB-3-1, KB-V1, CNE3, Hep G2, and HL60). 
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Figure 1.29. Some Examples of Square-Planar Platinum(II) Bis-Intercalators with Flexible and 
Inflexible Linking Chains. 
1.10.3.c. Organic Bis-Intercalators. 
Some groups have synthesized bis-intercalating organic drugs 201-208 (Figure 1.30). These include 
compounds with rigid and variable chains joining acridine and phenanthridium           
intercalators 203, 205 and daunorubicin intercalators linked via a flexible chain.202, 204, 207, 208 In the 
latter case, two lead bis-intercalators, WP631 (45) and WP762, were designed and synthesised 
based on the binding characteristics of the natural compound daunorubicin (27).206, 209 It was 
found that two daunorubicin molecules bound a six base oligonucleotide with the amino groups 
of each compound pointing into the DNA minor groove,209 such that the intercalators were 
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separated by 7 Å. Two daunorubicin intercalators cross-linked through their sugar amino group 
with a p-xylenyl linker produced WP631, while those linked together with a m-xylenyl linker 
produced WP762.204 WP631 and WP762 intercalate DNA with binding constants of 3.1 x 1011 
and         7.3 x 1012 M-1,    respectively,204, 208 and have been shown to bind DNA via intercalation 
using UV melting, differential calorimetry and viscosity experiments,202, 204 and a series bis-
napthalimide compounds have been shown to unwind DNA by a much greater extent (36-41o) 
than the mononuclear equivalent (19o).201 The bis-intercalators WP631 and WP762 have also 

























Figure 1.30. Some Examples of Organic Bis-Intercalators with Flexible and Inflexible Linking 
Chains. 
1.10.4. Synergistic Intercalators.  
For twenty years, many groups of researchers have examined the synergistic properties of 
combining a DNA intercalating compound with other functionalities (Figure 1.31), organic 
intercalators210-227 and metallointercalators linked to cis platin-like    molecules,228-234 organic 
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intercalators linked to trans platin-like molecules235-237, organicintercalators linked to DNA-
alkylating agents such as mustards,238-242 and metallointercalators linked to carborane cages for 
use in radiation therapy.243-246 These synergistic intercalators have been developed in an attempt 





















Figure 1.31. Some Examples of Synergistic Intercalators which Combine a Functional Group 
Capable of Forming Covalent or Coordinate Covalent Bonds with DNA and an Intercalating 
Functional Group. 
Synergistic intercalators are also much more effective DNA binding agents, resulting in 
increased DNA damage.213 In DNA transcription assays, synergistic intercalators produced more 
intense and a greater number of blockages compared to the native intercalators and platinum 
complexes.213, 217 In the human cancer cell line P388, phenanthridium-platinum complexes 
induce a six-fold enhancement in DNA damage compared to cis platin at the same 
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concentration.217 Interestingly, the ability to induce DNA damage appears to correlate directly 
with linker chain-length. Unlike coordinate covalent binding multinuclear platinum drugs which 
cause more DNA damage with increasing chain length,247, 248 synergistic intercalators exhibit 
greater DNA damage with shorter linker lengths.217 Organic intercalators, including 
phenanthridinium,238, 23 and 9-aminoacridine240, 241 have also been coupled to alkylating agents 
(Figure 1.31, 47, 48). These compounds derive their anticancer activity by binding purine bases 
in DNA, particularly at the N7 site, leading to depurination. Attachment of the intercalator, via a 
variable length polymethylene chain (n = 4, 5, 6, 8 or 10) to the alkylators significantly modifies 
the DNA sequence selectivity. Like natural alkylators, these compounds target guanosine and 
adenosine, but the actual binding site on DNA is dependent on the linker length. For 
phenanthridinium compounds, short chains (i.e. n = 4) target GpA sites, but longer chains target 
GpT sites.238 In contrast, for those compounds that utilize 9-aminoacridine, the short-chain 
compounds target GpT sites while the longer-chain compounds target ApC sites.242 Interestingly, 
while attachment of the intercalator increases the DNA affinity, only ten per cent of the 
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CHAPTER 2. INTRODUCTION. INITIAL MOLECULAR MODELING AND 
SYNTHESIS OF SYNERGISTIC INTERCALATORS BASED ON PYRENE 
DIHYDRODIOXINS (PDHD) AND CYCLOHEXA[e]PYRENES (PCH). 
As mentioned in Chapter 1 (Part 1.10.4), application of synergistic intercalators results in more 
effective DNA binding by utilizing several functionalities to increase the DNA binding affinity. 
By verifying the structure of the substituents we can possibly control the type of damage in 
DNA. The main goal of this work is to synthesize a synergistic water-soluble DNA intercalator 
bearing planar groups with a chemically activated DNA-cutting photomasked functionality.  
The common requirements for the photolabile groups are: 
 1). Reasonable stability in ambient light; 
2). A photochemically generated excited state with a lifetime shorter than the dissociation of the 
DNA-intercalator complex; 
3). An unambiguous photochemistry to provide a well-defined DNA cutting agent. 
Another important aspect of DNA cutting agents is the ability to cut DNA at specific sites which 
can be achieved by introduction of one or several chiral centers. Irradiation of the photomasking 













Scheme 2.1. Strategy for Design of Efficient Photoactivated Intercalating DNA-Cutting Agent. 
 
In order to choose a planar group and DNA-cutting functionality we should refer to polycyclic 
aromatic hydrocarbons (PAHs). PAH are cytotoxic, mutagenic, and carcinogenic agents and can 
induce cancers in humans.1-4 It is widely accepted that PAHs require metabolic activation in 
order to exert their biological activities, including carcinogenicity.1-5 After entering the cell, 
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PAHs are either metabolized into diol epoxides, quinones, or free-radical intermediates, all of 
which can react with cellular DNA to form PAH-DNA covalent adducts and cause other forms 
of DNA damage.1-7 Some DNA adducts can produce mutations and are considered to be a source 
of carcinogenicity.8-10 
The first product of benzo[a]pyrene (B[a]P) oxidation by cytochrome P-450 (P450) 1A1/1B1 
and epoxide hydrolase is the trans-dihydrodiol, (-)-B[a]P-7,8-dihydro-7,8-diol (B[a]P-7,8-
dihydrpdiol).11,12 After this dihydrodiol is oxidized to air-sensitive catechol by a dihydrodiol 
dehydrogenase member of aldo-keto reductase (AKR) family,13 it undergoes two 1-electron 















-forms stable N2-dGuo & N6-dAdo adducts
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Scheme 2.2. Activation of PAH to Mutagens by Aldo-Keto Reductases. 
PAH o-quinones are reactive Michael-acceptors,  produce significant amounts of reactive oxygen 
species (ROS)15, 16 and can give rise to covalent DNA adducts as well as oxidative DNA lesions 
(Scheme 2.3). For example, BP-7,8-dione produces N2 or N6 stable adducts with 2′-dGuo and 
2′-dAdo by Michael addition that can hydrate and cyclize, respectively (Scheme 2.4).17, 18 In 
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addition, BP-7,8-dione reacts with guanine to form N7-depurinating guanine adducts in vitro 
























Covalent PAH o-quinone adducts





































































































Scheme 2.5. BP-7,8-dione Reaction with Guanine with Formation of N7-depurinating Product.  
Park et al22 have recently shown that in the presence of Cu(II) and cellular reducing equivalents 
(e.g. NADPH), nanomolar concentrations of PAH o-quinones produced significant amounts of 8-
oxo-dGuo and that the oxidant responsible was singlet oxygen (1O2). The ROS produced by 
pyrene PAH o-quinones may also oxidize deoxyribose leading to the formation of propenal 
which can react to form M1-dGuo adducts. 23 Additionally, the ROS produced may attack 
polyunsaturated fatty acids (PUFA) leading to the formation of lipid peroxides which decompose 
to electrophiles such as 4-hydroxy-2-nonenal and 4-oxo-2-nonenal to form etheno-adducts and 
heptano-ethenoadducts, respectively.24, 25 Which of these adducts dominate in DNA exposed to 
pyrene PAH o-quinones in vitro and in vivo remains to be determined. From these data, we can 
conclude that PAH’s with quinone functionality are promising templates for synthesis of the 
photoactivated DNA-oxidizing  synergistic intercalators. 
Synergistic intercalation agents based on pyrene dihydrodioxins (PDHD), which release pyrene-
4,5-diones (pyrene o–quinines) photochemically, were developed by the Wilson group at the 
University of Cincinnati.26, 27 The reversibility of the masking is shown in Scheme 2.6 and is 















Scheme 2.6. Schönberg-Mustafa reaction: The Forward Reaction Occurs with Visible Light 
(425-514 nm), while the Reverse Reaction Occurs with UV Light (350 nm).  
Upon visible light irradiation of pyrene o-quinone in the presence of olefin, the formation of 
PDHD is observed. When the PDHD is irradiated by UV light, formation of the initial olefin and 
o-quinone will be observed. The structure and chirality of the PDHD    (Scheme 2.6) formed 
depends on the structure of the initial olefin. If the initial structure of the olefin is trans-, we have 
formation of the two isomers –R, R and –S,S (chiral center denoted with *).  
2.1. SYNERGISTIC INTERCALATORS BASED ON TRANS-10,11-DI-(4-PYRIDYL)-
10,11-DIHYDRO-9,12-DIOXABENZO[e]PYRENE (10, 11-DIPYRIDYLPDHD) ONIUM 
SALTS AND METHYLATED N-OXIDE. 
The Schönberg-Mustafa reaction with pyrene o-quinone can accommodate any stilbene 
containing tertiary amines or aromatic nitrogen containing rings, which can be converted later 
into onium salt (quaternary salt) or methylated N-oxides.28   
The advantages of synthesis of synergistic PDHD intercalators based on trans-10,11-di-(4-
pyridyl)-10,11-dihydro-9,12-dioxabenzo[e]pyren (10, 11-DiPyridylPDHD) (1) onium salts 
including N,N-Dimethyl trans-10,11-di-(4-pyridinium)-10,11-dihydro-9,12-dioxabenzo[e]pyren 
di-tetrafluroborate (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4) (2) and the methylated N-
oxide, N,N-Dimethoxy trans-10,11-di-(4-pyridinium)-10,11-dihydro-9,12-dioxabenzo[e]pyren 
71 
 
di-tetrafluroborate (N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4) (3) (Scheme 2.7) are as 
follows: 
1) By introduction of a charge we increase the solubility of the intercalator in water; 
2) The positive charge on the nitrogen is attracted by the negative charge of the phosphate groups 
in the DNA backbone; 
3) The positive charge on the quaternary nitrogen acts as a charge acceptor for the electron from 
of the pyrene in the pyrene radical cation formation during photochemical excitation. This 
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Scheme 2.7. Conversion of 10, 11-DiPyridylPDHD into its Onium Salt and Methylated N-oxide. 
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2.1.1. Synthetic Routes to Intercalators Based on N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 and N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4.  
The synthetic route for synthesis of 10, 11-DiPyridylPDHD (R, R-enatiomer (1) and S, S-
enatiomer (1’)) is based on the reaction of trans-1,2-di(4-pyridyl)ethylene with pyrene o–
quinones (o–quinones) (5) (Scheme 2.8 ).26, 27, 29 O-qiunone (5) is synthesized by modified Ru(II) 
chloride catalyzed oxidation of pyrene (4) with NaIO4.
30
 The photochemical reaction of o-
qiunone and trans-1,2-di(4-pyridyl)ethylene affords symmetrical 10, 11-DiPyridylPDHD as a 
mixture of enatiomers, R, R-enatiomer (1)  and  S, S-enatiomer (1’). The separation of the 
enatiomers was achieved by converting them into the mixture of diastereomers by reaction with 
(-)-(R)-camphorsulfonic acid: R,R; R,R (6) –diastereomer and S,R; S,R (6’)- diastereoisomer 
(Scheme 2.8). (-)-(R)-camphorsulfonic acid also functions as a chiral mobile phase additive 
(CMPA)31 and essentially increases the solubility of 10, 11-DiPyridylPDHD by forming a salt 
with it.32 The synthesized diastereomers are very soluble in a mixture of methanol/water (50/50) 
and they can be separated using an isocratic regime on reversed phase-cellulose tris(4-
methylbenzoate) coated on silicagel (Chiracel OJ-R® phase).33 We especially want to thank 
David Ellis and the Chiral Technologies Company of donation of this phase to us. During 
separation by HPLC, the nitrogens are deprotonated and the pure R, R-enatiomer (1) and S,S-
enatiomer (1’)  are isolated directly from the column. This method is especially valuable, 
because of the fact that almost all chiral phases are limited by the number of applicable solvents 
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Scheme 2.8. Synthesis of Chiral 10, 11-DiPyridylPDHD. 
The formation of 1 and 1’ also is accompanied by formation of several by-products caused by the 
















The separated isomers 1 and 1’ are quaternized by trimethyloxonium terafluroborate (Scheme 
2.9).34 The isomers of the dimethylated salts of 10, 11-DiPyridylPDHD, N,N-Dimethyl 10, 11-
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Scheme 2.9. Synthesis of Chiral N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4. 
The products 9 and 9’ decompose at elevated temperature (> 60 0C) with formation of (pyrene o-
qiunone) (5), N,N-Dimethyl 1,2-di(4-pyridinium)ethylene and some high-molecular weight 
compounds.   
10, 11-DiPyridylPDHD (1 and 1’) can be oxidized to their N-oxides, trans-10,11-di-(4-N-oxo-
pyridine)-10,11-dihydro-9,12-dioxabenzo[e]pyrene (10, 11-Di-N-oxo-PDHD) (R,R-somer-10 
and S,S-isomer- 10’), at room temperature by 1M H2O2/CH3CN  in the presence of catalytic 
amounts of methyltrioxorhenium (MTO) (Scheme 2.10). 35-44 The methylation of 10 and 10’ 
affords methylated N-oxides, N,N-Dimethoxy trans-10,11-di-(4-pyridinium)-10,11-dihydro-
75 
 
9,12-dioxabenzo[e]pyrene di-tetrafluroborate (N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4) 









































Scheme 2.10. Synthesis of Chiral N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4. 
2.1.2. Molecular Modeling Calculations. 
Molecular modeling studies indicate that R,R-isomer (9) and S,S-isomer (9’), both of which have the 
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Figure 2.2.  A. Diequatorial and Diaxial Conformations of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (9).  B. Binding of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 
Enantiomers (S,S- and R,R-) (9 and 9’) in the Major Groove of Duplex DNA.  
This diaxial geometry seems to be strongly favored to the virtual exclusion of the diequatorial 
geometry (6.55 kcal/mol, DFT B3LYP 6-31G*) by the steric and electronic repulsions between the 
two large pyridinium groups. This geometry should impart a high degree of chirality to 9, 9’, 11 and 
11’ that might give them special DNA binding   properties.45  As can be seen in Figure 2.3, both 
enantiomers 9 and 9’ span the major groove of DNA, the expected binding site,46 with the 
pyridinium salts in close proximity to the negatively charged phosphate ridges of the DNA back 
bone on either side.  From this preliminary analysis, it appears that the SS isomer will be bound in 
the major groove more effectively than will the RR isomer. 
Extensive molecular mechanics calculations47 have proved that the S,S- enantiomer usually forms 














Figure 2.3. Binding of Enantiomeric N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 9’) in 













Figure 2.4.  Theoretical Binding of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 Enantiomers   




An example of this type of comparison is shown in Figure 2.4.  In this example, the diaxial 
conformation of the S,S- enantiomer binds as shown in Figure 2.3 (results from the minimization 
procedure).  While the R,R- enantiomer adopts a diequatorial conformation, which leads to a much 
less stable complex.  This is the usual outcome of these comparisons. The S,S- enantiomer seems 
to cause far less distortion of the DNA duplex and seems to form much more stable complexes 
than does the R,R- enantiomer.  However, it should be mentioned that many different types of 
complexes have been found in these calculations depending upon the base-pair sequence and the 
proximity of the pyrene intercalation to the end of the duplex strand.  Some complexes were 
calculated with both pyridinium rings bonded to the same DNA strand.  Thus, while a duplex DNA 
strand can bind to more than one N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4, these theoretical 
considerations indicate that the strand will become saturated when it is bound to several molecules 
of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (saturation number = number of DNA base 
pairs)/N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 = 3).  This limit is consistent with 
experimental binding studies, vide infra.  Because of the fact that N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 is a synergistic intercalator, N,N-Dimethyl 10, 11-DiPyridiniumPDHD-
BF4 /DNA binding model consists of coordinated intercalative and electrostatic binding which 







2.2. SYNTHESIS OF SYNERGISTIC INTERCALATORS BASED ON 10, 10-BIS-(2-
PYRIDYL)-10,11-DIHYDRO-9,12-DIOXABENZO[e]PYRENE COMPLEXES WITH 
METAL (10, 10-BISPYRIDYLPDHD-METALm+ COMPLEXES). 
The preparation of “donor-acceptor” compounds, in which a chromophoric donor and an electron 
acceptor are covalently bound or coordinated within a single molecule, affords intramolecular 
control of charge separation and recombination processes.48-60  
 For inorganic systems, there exist examples of intramolecular electron transfer producing 
charge-separated states after optical excitation of Ru(II)50-57 and Re(I)58,59 metal-to-ligand charge 
transfer (MLCT) and porphyrin π→π* chromophores.58-60 An example of a charge-separated 
state created after visible excitation of Cu(I) bipyridyl donor-acceptor compounds was 
reported.61 
Iron and copper complexes are known to be useful for oxidative cleavage of DNA involving 
nucleobase oxidation and/or degradation of sugar by abstraction of deoxyribose hydrogen 
atom(s), while complexes containing strong Lewis acids like copper (II) and zinc(II) are suitable 
for hydrolytic cleavage of DNA. Oxidative cleavage of DNA could take place by chemical or 
photochemical means. Recently, Chakravarty reported photocleavage of DNA by ternary 
copper(II) complexes with amino acids complexes, ternary copper(II) complexes with NSO-
donor ligands and dipyridoquinaxoline(dpq)-Cu(II) complex.62 All of them are A-Cu(II)-B 
complexes, where A-ligand and B-photosensitizer with long wavelength DNA cleavage activity. 
Photo-excitation of   dpq-Ci(II) complex at 312 nm could involve dpq-based bands and the 
LMCT band forming     3(n-π*) and/or 3(π-π*). The type of DNA cleavage initiated by these 




Since, another synthetic target in our research is synthesis of dioxins which form complexes with 
transition metals. In this case the electron donated by the pyrene radical cation is transferred to 
transition metal cation by electron transfer (ET) producing long-lived charge-separated states 
(their photochemistry will be discussed in Chapter 3).  Dihydrodioxin can play the role of a 
photosensitizer excited at 350 nm and a donor of electrons, and Cu(II), Fe(III), Ni(II), Co(II) can 
be acceptors. The synthetic scheme for synthesis of 10, 10-Bis-(2-pyridyl)-10,11-dihydro-9,12-
dioxabenzo[e]pyrene (10, 10-BisPyridylPDHD) (14) and   10, 10-BisPyridylPDHD-Metallm+ 


















Cat= Cu2+, Fe3+, Ni2+, Co2+
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Scheme 2.11. Synthesis of 10, 10-BisPyridylPDHD-Metalm+Complexes. 
The synthesis of the starting olefin 13 is achieved by carbonyl olefination of  di-2-pyridyl ketone 
(12) by the Wittig reaction or by Ti-based olefination using the Petasis reagent.
63 
Dimethyltitanocene is synthesized from titanocene dichloride.64 The photochemical Schönberg-




dioxabenzo[e]pyrene (10, 10-BisPyridylPDHD) (14). Along with 14, the ketone oxetane 16 was 
formed, which transforms into 14 upon heating (Scheme 2.12). By mixing 14 with different 


















Scheme 2.12. Formation of Pyrene Ketone Oxetane and its Transformation into 10, 10-
BisPyridylPDHD. 
The calculated metal binding constants for 10, 10-BisPyridylPDHD-Metalm+complexes are 
presented in Table 2.1. 
Titrated PDHD Titrating Salt Solvent Binding Constant, 
Kb 
14 Cu(ClO4)2 Acetonitrile 11.08*10
4 
14 AgNO3 Acetonitrile No binding 
14 Ni(NO3)2 Acetonitrile 8.025*10
3 
14 Co(NO3)2 Acetonitrile 1.1*10
2 
14 Fe2(NO3)3 Acetonitrile No binding 




2.3. SYNTHESIS OF ANALOGS OF N,N-DIMETHYL TRANS-10, 11-
DIPYRIDINIUMPDHD-BF4. 
It would be interesting to synthesize a stable analog of 10, 11-DiPyridiniumPDHD-BF4, 
tetrahydrocylohexa[e]pyrene (17) (Figure 2.5), since this might undergo intramolecular electron 







Figure 2.5. Dihydrocylohexa[e]pyrene. 
There are several strategies which can be applied for synthesis of 17. These are described in 
Section 2.3 below. 
2.3.1. Synthesis of Pyridine Substituted Cyclohexa[e]pyrenes by Diels-Alder Reactions 
under Radical Cation Conditions. 
In cases where the ethylene does not add to the diene (even with the help of Lewis acids which 
may reduce the electron density of one reactant by complexation), one electron oxidation (by an 
oxidizing agent or by photoinduced electron transfer (PET)65 may accelerate the reaction. This 
approach has been termed “hole catalysis” by Bauld.66 The radical cation reactions, which do not 
need to be electrocyclic reactions as well, generally have low activation energies but nevertheless 
show high degrees of peri-, regio-, and stereoselectivity.67 The radical cation reactions thus 
complement the neutral reactions, and there are a number of applications of synthetic     




butadiene radical cation and ethylene were reported by Hofmann.73 Some chemistry of  pyrene 
derivatives prepared by intramolecular Diels-Alder reactions under radical cation conditions 
were investigated by Winter.74 An analogous approach for intermolecular reaction between 2,3-











DBAHA  = Br
Br Br
 
Scheme 2.13. Diels-Alder Reaction Between Pyrene and 2,3-Bis(pyridine) under Radical Cation 
Conditions.   
To determine the feasibility of this the reaction, we performed some model reactions between 
isoprene and pyrene in the presence of tris(2,4-diBromophenyl)ammonium 
hexachloroantimonate (DBAHA), but due to the large number of products we decided to apply a 
different methodology for synthesis of 17. However this approach might be investigated further. 
2.3.2. Synthesis of Pyridine Substituted Cyclohexa[e]pyrenes and Their Onium Salts via 
1,2-Dihydrocyclobuta[e]pyrene (20). 
The synthesis of substituted cyclohexa[e]pyrenes was reported by Wada.75 This formation of 
cyclohexa[e]pyrenes goes through ortho-quinone methide (21) (o-quinodimethane), which  
84 
should be formed by heating 1,2-dihydrocyclobuta[e]pyrene (20) (Scheme 2.14).75 The 
temperature required for this reaction to proceed is 180 0C.  
20 21
180 0 C
Scheme 2.14. Formation of o-Quinodimethane. 
The published synthesis of 20 is multistep (Scheme 2.15).75 The starting material for synthesis of 
1,2-bis(p-vinylphenyl)ethane (22) can be meta-chloromethylstyrene 3076-78 (Scheme 2.16-last 
step) or 3-bromoacetophenone ethylene ketal (Scheme 2.17).79-81 Meta-chloromethylstyrene can 
be separated from the commercial mixture of para- and meta- isomers by radical 
hydrobromination of the mixture meta-chlomethylstyrene and para-chlomethylstyrene and 
separation of hydrobrominated isomers.82 The overall yield for all steps of separation is about 
8%. The synthesis of pure meta-chlomethylstyrene is described by Montheard.83 It includes 
several steps and starts with meta-bromobenzylmethyl ether, which can be synthesized from 1, 3-
dibromobenzene (Scheme 2.16).84 One of the last steps of the synthesis of 20 is intramolecular 
[2+2] photocycloaddition in 1,2-bis(m-vinylphenyl)ethane (22) (Scheme 2.15).75, 79, 85-89 Overall, 
the published synthesis of 20 from commercially available compounds is long and, as a result, 
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Scheme 2.17. Synthesis of 1,2-Bis(m-vinylphenyl)ethane from 3-Bromoacetophenone Ethylene 
Ketal.  
The synthesis of 20 from 3-(chloromethy)benzaldehyde is also impractical due to the high cost of 
the starting materials.  
Another path for the synthesis of 20 was used (Scheme 2.18). It involves oxidation of 
commercially available pyrene (4) to pyrene monoozonide (4,7-dihydro-4,7-
epoxyphenanthro[1,2]dioxocin) (35) with the following reduction to phenanthrene-4,5-
dicarboxaldehyde (36).90 Wittig reaction91 of 36 affords 37, which can suffer intramolecular 
[2+2] photocycloaddition with formation of 4,5-ethano-4,5-dihydropyrene (25).  The last steps of 
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A thermal cycloaddition reaction of 20 and trans-1,2-di(4-pyridyl)ethylene might afford  the 
pyridine substituted cyclohexa[e]pyrenes 39 and 40. Quaternization in presence of 
trimethyloxonium terafluroborate should give onium salts (41 and 42) (Scheme 2.19). This work 
is still in progress. 
N
N∆












Scheme 2.19. Synthesis of Modified Cyclohexa[e]pyrenes. 
2.4. SUMMARY OF SYNTHESIS OF PYRENE INTERCALATORS. 
The synthesis of new chiral intercalators based on trans-10,11-di-(4-pyridyl)-10,11-dihydro-
9,12-dioxabenzo[e]pyrene (10, 11-DiPyridylPDHD) and 10, 10-BisPyridylPDHD-
Metalm+complexes (Metalm+-Cu2+, Ni2+) was performed. The binding constants for 10, 10-
BisPyridylPDHD-Metalm+ were determined.  A new approach to the synthesis of 1, 2-
dihydrocyclobuta[e]pyrene, the starting compound for the synthesis of stable analogs of 10, 11-
DiPyridylPDHD, was developed. Molecular modeling studies (DFT B3LYP 6-31G*) indicate 
that intercalators based on 10, 11-DiPyridylPDHD-BF4 should form stable complexes with 
DNA. Futhermore because the binding force constants consist of combined intercalative and 
electrostatic binding components, the binding of these molecules to DNA should greatly stabilize 
DNA duplexes to which they are bound. 
2.5. MATERIALS AND METHODS.  
Materials were obtained from commercial suppliers and were used without further purification 




the use by a well-known procedures.92,93 Methyltrioxorhenium(VII) (71.0-76.0 %) was purchased 
fron Sigma-Aldrich. Cacodylic Buffer was prepared by dissolving 1.071 g of sodium cacodylate 
trihydrate, 0.015 g of NaCl and 0.093 g of EDTA in deionized water and adjusting pH to 7.  
UV spectra were obtained on a Varian Cary 5000 UV-vis-NIR spectrophotometer. NMR spectra 
were recorded on a Bruker ARX-500 spectrometer at 500.13 MHz for 1H and 125.76 MHz for 
13C and Bruker ARX 300 spectrometer at 300.13 MHz for 
1
H and at 75 and 100.6 MHz 
13
C. All 
Chemical shifts are given in ppm relative to TMS as an internal standard. DEPT, COSY-45, 
gTOCSY, gHSQC, gHMQC, gHMBC, spectra were recorded using standard Bruker pulse 
sequences. 
 TLC analyses were made on Aluminum oxide 60 F
254 
(Merck) plates or Silica Gel GF 20x20 cm 
2000 microns preparative layer with UV254 plates, and visualized with UV Spectroline (short 
wave ultraviolet 254 nm light). Photochemical irradiation was performed using a Rayonet 
Photochemical Reactor with RPR419 lamps. 
 UV spectra were recorded with UV cell operating in the range of 200-700 nm.  For VCD 
determination of absolute configuration, VCD spectrum were recorded in 1 mm and    10 mm 
pathlength cell using fourier transform VCD spectrometer from ABB Bomem/BioTools 
(Quebec, Canada) (the parameters of the experiment were optimized).  
 Electrospray ionization mass-spectrometry experiments were performed on a Thermo Fisher 
Scientific LTQ-FT, a hybrid instrument consisting of a linear ion trap and a Fourier transform 
ion cyclotron resonance (ICR) mass spectrometer. The sample was introduced into the LTQ-FT 
using the standard electrospray ionization source for the instrument with a spray voltage of 5 kV 
and a capillary temperature of 275°C. Autogain control was used and set at 500,000 with a 




MS/MS, was executed in the linear trap with an autogain control setting of 10,000 and a 
maximum injection time of 250 ms. FT-ICR full scans were acquired in the positive ion mode at 
100,000 resolving power at m/z 400. The positive-ion MS/MS experiments were performed in 
the linear trap portion of the instrument using helium as a collision gas, isolation widths of 2 
atomic mass units, normalized collision energies of 20 to 35 %, a q value of 0.250, and an 
excitation time of 30 ms. 
 Analytical chiral chromatography was performed on a CHIRALCEL®  OJ-R 150 x 4.6 mm ID 
analytical column ( Particle size 5μ) equipped with Rainin solvent delivery system (Model 
HPXL,cat. No. 48-00XL)-software version Dynamax 1.4.6., Rainin Pressure Module (Rainin 
Instrument Co., Maximum Pressure: 4600 psi, No. 147737), Rheodyne Injector (Model 7125) 
and Agilent 8453 UV-visible spectroscopy system (Agilent flow cell part number 5062-2476, 
path length 10 mm). The software version used was Agilent UV-Visible ChemStation 
(Rev.A.09.01.). Separation of dimethyl trans-10,11-di-(4-pyridinium)-10,11-dihydro-9,12-
dioxabenzo[e]pyrene ditetrafluroborate (10, 11-DiPyridiniumPDHD-BF4) (9 and 9’) was 
performed on Bio-Rex®70 Cation Exchange Resin(Bio-Rad®) using acetonitrile/deionized water 
= 20/80. 
 Preparative chiral chromatography was perfomed on a custom-made HPLC system equipped 
with  glass column (I. D. 25 mm, efective length 300 mm) packed with 42 g of CHIRALPAK®  
OJ phase (Part Number 17020, Particle size 20μ) with Rainin solvent delivery system (Model 
HPXL, cat. No. 48-00XL), Rainin Pressure Module (Rainin Instrument Co., maximum pressure: 
8700 psi, No. 130339), Rheodyne Injector (Model 7125) and Agilent 8453 UV-visible 
spectroscopy system (Agilent flow cell part number 5062-2476, path length 10 mm). The 




 Our femtosecond spectrometer is based on a Ti: Sapphire regenerative amplifier, which 
generates 800 nm pulses with a 1 kHz repetition rate. Pulse energy is about 900 μJ, and a pulse 
width is 90 femtoseconds. The amplified beam is divided into two beams using a 50/50 beam 
splitter. One beam is sent to the TOPAS-C (Light Conversion Lt.) optical parametrical amplifier, 
which generates 350 nm excitation pulses. Excitation beam energy was 6 μJ per pulse at the 
sample position. The second beam is sent to the optical delay line, and then focused onto the 3 
mm thick CaF2 window where it produces a continuum of white light. After the CaF2 window, 
this beam is divided into two beams: reference and probe. Only probe beam is sent through 
sample. The probe beam after passing through the sample and the reference beam are sent to the 
monochromator/spectrograph, and then registered by the dual-diode array detector. The angle 
between probe and pump beams is 80. Polarization planes of pump and probe beams were set at 
magic angle using a Berek compensator. The sample was measured in 0.2 mm thick flow cell. 
All measurements were performed at a temperature of 22 0C. 
 CD measurements were performed in an AVIV model 62A DS spectropolarimeter (Aviv 
Associates, Lakewood, NJ) equipped with a thermoelectrically controlled cell holder and a 
cuvette with a path length of 0.1 cm. The wavelengths studied ranged from 240 to 400 nm.  
A scan of solvent alone was recorded to provide a baseline.  
Computational Chemistry—Ab initio calculations were performed at DFT-B3LYP level with 
Gaussian basis set 6–31G(*).94 All geometries were fully optimized without geometry 
constraints. Vibrational frequency calculations were used to characterize the minima stationary 
points (zero imaginary frequencies). The software package Spartan 3.1 (Wavefunction Inc., 
Irvine, CA) was used for all quantum mechanical calculations. The optimized geometry and the 




purpose, the Superimposition/Similarity facility to Spartan 4.0 (Wavefunction Inc., Irvine, CA) 
was employed for the alignment of molecular structures. Optimized alignments were achieved by 
maximizing the electrostatic potential field and steric overlap of three-dimensional structures.  
2.6. EXPERIMENTAL PART. PROCEDURES. 
2.6.1. Preparation of Pyrene o-Quinone (5). 
The synthesis of pyrene o-quinone (5) was done using a procedure reported by Hu96  (Scheme 5) 
with minor changes.  In this procedure the oxidation of pyrene into pyrene o-quinone (5) was 
achieved in one step with high yield. In comparison, the multistep synthetic procedure published 
by Young97 was much more involved and afforded lower yields.  In Young’s procedure, 
extremely toxic WO4 was used for the oxidation of pyrene into 4, 5-phenanthrenedicarboxylic 
acid followed by recyclization with an acyloin condensation.  In the method reported by Hu, 
ruthenium catalyst (RuCl3 x H2O) in water
96 was used in combination with the oxidizing agent 
NaIO4.  
To a solution of pyrene (4) (2.322 g, 10.000 mmol) in 40 mL CH2Cl2 and 40 mL CH3CN were 
added RuCl3 x H2O (0.200 g, 0.96 mmol) in 50 mL H2O and after 30 minutes, NaIO4 (10.000 g, 
46.8 mmol) was added. The dark brown suspension was stirred at room temperature overnight. 
The reaction mixture was poured into 100 mL of CH2Cl2 and filtered. The filtrate was collected 
and the organic layer was separated from the dark water layer.  Thin-layer chromatography 
(TLC) of the organic layer, using an ethyl acetate/hexanes (2/5) mixture, indicated the presence 
of several materials. This mixture was resolved by column chromatography eluting with CH2Cl2 
to afford pure product pyrene o-quinone as bright orange crystals (1.523 g, 6.560 mmol, 57 %).  
1H NMR (300 MHz, CDCl3): δ 8.52 ppm (dd, J = 7.8, 1.3 Hz, 2 H), δ 8.20 (dd, J = 7.8,              




DMSO-d6):  δ 180.1, 135.4, 132.1, 131.0, 129.1, 128.4, 128.2, 127.6 ppm; HRMS (ESI Q-
TOFMS) calculated  for C16H8O2 m/z 232.0512, found m/z 232.0515. 
 The side products of the reaction were a dimer of pyrene, pyrene-4,5,9,10-tetraone and some 
unidentified compounds. 
2.6.2. Preparation of 10, 11-DiPyridylPDHD (1 and 1’) (Scheme 2.8). 
A solution of pyrene-4,5-dione (0.090 g, 0.770 mmol) (5) in 150 mL of benzene and of trans-
1,2-Di(4-pyridyl) ethylene (0.206 g, 1.130 mmol) was purged with Ar and placed in a Rayonet 
Photochemical Reactor. The reaction mixture was irradiated at 419 nm in a water bath with the 
temperature kept at the freezing point of benzene +4o C. The final color of the reaction mixture 
was yellow. After 4 hour of irradiation, the benzene was evaporated and 150 mL of methanol 
added. Immediate formation of white powder-like crystals was observed. The solution was left 
for 24 hours in the dark. The crystals were collected by filtration (1st filtration) and washed with 
a small amount of CHCl3. The collected crystals were partially redissolved in 7 mL of CHCl3 
with slight heating. The insoluble material was again collected by filtration (2nd filtration). These 
collected crystals again were partially dissolved in 3 mL of CHCl3 and the insoluble material 
collected by filtration (3rd filtration). TLC analysis (ethyl acetate/ hexane 1/5) of this third set of 
crystals indicated that no pyrene-4,5-dione (4) or trans-1,2-bis(4-pyridyl) ethylene was present, 
and afforded a single striking spot of 10, 11-DiPyridylPDHD (1 and 1’).  These crystals were 
combined with the residue from evaporation of the CHCl3 wash solution to afford 0.082 g of 10, 
11-DiPyridylPDHD (0.082 g, 0.200 mmol) (1 and 1’). The CHCl3 solutions from the 1
st and 2nd 
filtrations were combined and TLC indicated the presence of pyrene-4,5-dione (4), trans-1,2-
bis(4-pyridyl)ethylene and 10, 11-DiPyridylPDHD (1 and 1’). Column chromatography of this 




CH3OH/CH3Cl) afforded  10, 11-DiPyridylPDHD (0.059 g, 0.14 mmol) (1 and 1’) for a 
combined yield 43% (0. 141 g, 0.340 mmol) of a mixture of R,R- and S,S-isomers: 1H NMR (300 
MHz, CDCl3) (Figure 2.7) δ 8.65 ppm (d, J = 4.70 Hz, 4 H), 8.46 (d, J  = 7.8 Hz, 2 H),  8.19 (d, 
J = 7.53 Hz, 2 H), 8.12 (s, 2 H), 8.05 (dd, J = 7.69 Hz, J’ = 7.69 Hz, 2 H), 7.21 (d, J = 5.54 Hz, 
4 H), 5.23 (s, 2 H); 1H NMR (500 MHz, DMSO d6 ) δ 8.58 (d, J = 5.9, 4 H), 8.39 (d, J = 7.8, 2 
H), 8.29 (d, J = 7.6 Hz, 2 H), 8.18 (s, 2 H), 8.09 (dd, J = 7.7 Hz, J’ = 7.7 Hz, 2 H), 7.44 (d, J  = 
5.9, 4 H), 5.94 (s, 2 H); 13C NMR (75 MHz, DMSO-d6) (Figure 2.8) 149.1, 143.9, 132. 8, 129.7, 
126.6, 125.7, 123.6, 123.5, 121.7, 119.3, 117.0, 76.5; 1H-1H COSY NMR (Figure 2.9); 1H-1H 
NOESY NMR (Figure 2.10); 1H-13C HSQC NMR (Figure 2.11); HRMS (ESI Q-
TOFMS)calculated  for C28H19N2O2
+ m/z 415.1447, found m/z 415.1431. 
UV of 10, 11-DiPyridylPDHD (racemic mixture of 1 and 1’) in methanol (Figure 2.6). UV of 10, 
11-DiPyridylPDHD calculated ε at 350 nm is 33316 M-1cm-1.  
It should be mentioned that the reaction works much better on the smaller scale, because the 
yield of this smaller reaction was as high as 78%, using pyrene-4,5-dione (0.025 g, 0.077 mol) 
and trans-1,2-bis(4-pyridyl)ethylene (0.412 g, 0.226 mmol) with a reaction time of 1 hour, and 
only one filtration with further recrystallization of the product 10, 11-DiPyridylPDHD (1 and 1’) 
from CH3OH. Also, the color of that reaction mixture was only slightly yellowish. Still the NMR 
quality was acceptable.    
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Figure 2.6. UV-Spectrum of 10, 11-DiPyridylPDHD (1 and 1’) in methanol.  





























Figure 2.7. 1H NMR-Spectrum of 10, 11-DiPyridylPDHD (1 and 1’) (500 MHz, DMSO d6). 
95 








































C9,C10, C11and C12 
are denoted as *
Figure 2.8. 13C NMR-Spectrum of 10, 11-DiPyridylPDHD (1 and 1’) (500 MHz, DMSO d6). 
Figure 2.9. 1H-1H COSY NMR spectrum of 10, 11-DiPyridylPDHD (1 and 1’) (500 MHz, 
DMSO d6). 
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Figure 2.10. 1H-1H NOESY NMR Spectrum of 10, 11-DiPyridylPDHD (1 and 1’) (500 MHz, 
DMSO d6). 
Figure 2.11. 1H-13C HSQC NMR Spectrum of 10, 11-DiPyridylPDHD (1 and 1’) (500 MHz, 
DMSO d6). 
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2.6.3. Preparation of trans-10,11-Di-(4-Pyridyl)-10,11-dihydro-9,12-dioxabenzo[e]pyrene 
(10, 11-DiPyridylPDHD) Di-(1R)-(-)-10-Camphorsulfonic Acid Salt (10, 11-DiPyridylPDHD 
Di-(1R)-(-)-10-Camphorsulfonic Acid Salt) (6 and 6’) (Scheme 2.8). 
An enantiomeric mixture of 10, 11-DiPyridylPDHD (1 and 1’) (0.050 g, 0.12 mmol) was placed 
in a 500 mL beaker and 300 mL of ethyl acetate was added. When the clear solution formed, 
0.168 mg (0.72 mol) of (1R)-(-)-10-Camphorsulfonic acid salt was added. An immediate 
formation of white a precipitate 10, 11-DiPyridylPDHD di-(1R)-(-)-10-Camphorsulfonic acid 
salt (6 and 6’) was observed. The precipitate was removed by filtration and dried under high 
vacuum affording pure 10, 11-DiPyridylPDHD di-(1R)-(-)-10-Camphorsulfonic acid salt (0.071 
g, 0.11 mmol,  92%): 1H NMR (500 MHz, CD3OD) (Figure 2.12, 2.13a, b, c): δ 8.92 (dd, J = 6.5  
Hz, J’ = 1.5 Hz, 4H), 8.53 (dd, J = 7.8 Hz, J’ = 1.0 Hz, 2H), 8.37 (dd, J = 6.5 Hz, J’ = 1.5 Hz, 
4H ), 8.28 (dd, J = 7.8 Hz, J’ = 1.0 Hz, 2H), 8.18 (s, 2H), 8.13 (dd, J = 7.8 Hz, J’ = 7.8 Hz, 2H), 
6.68 (d, J = 4 Hz, 2H), 3.32 (d, J = 14.8 Hz, 2H), 2.79 (d, J = 14.8 Hz, 2H), 2.65 (ddd, J = 14.0 
Hz, J’ = 14.0, J’’ = 4.4, 2H), 2.33 (ddd, J = 18.3 Hz, J’ = 4.4 Hz, J’’ = 3.4, 2H), 2.03(m, 4H), 
1.88 (d, J = 18.3 Hz, 2H), 1.64 (m, 2H), 1.40 (ddd, J = 14.0, J’ = 9.5, J’’ = 4.4, 2H), 1.22 (s, 6H), 
1.12 (s, 6H); 13C NMR (75 MHz, CD3OD) (Figure 2.14 a, b, c, d): δ 218.5, 158.2, 143.9, 134.5, 
132.7, 128.8, 127.0, 127.2, 126.4, 125.6, 122.8, 119.9, 77.4, 67.0, 59.7, 49.0, 48.3, 44.1, 43.7, 
27.9, 25.9, 20.5, 20.2;  1H-1H COSY NMR (500 MHz, Methanol d3) (Figure 2.15 a, b, c); 
1H-13C 
HSQC NMR (500 MHz, Methanol d3) (Figure 2.16 a, b, c); 
1H-13C HMBC NMR (500 MHz, 
Methanol d3) (Figure 2.17 a, b, c); HRMS (ESI Q-TOFMS) (Figure 2.18 a, b, c) calculated  for 
C28H20N2O2
2+ m/z 208.0752, found m/z 208.0765; calculated for m/z C28H19N2O2
+  m/z 
415.14410, found m/z 415.14421; calculated for C10H15O4S



























































8.92 (dd, J=6.5  Hz,
 J'=1.5 Hz, 4H )
8.37 (dd, J=6.5 Hz,
 J'=1.5 Hz, 4H )
8.53(dd, J=7.8 Hz,
 J'=1.0 Hz, 2H)
8.13 (dd, J=7.8 Hz, 
J=7.8 Hz, 2H)
8.28(dd, J=7.8 Hz,
 J'=1.0 Hz, 2H)
8.18 (s, 2H)
6.63 (d, J=2.0 Hz, 
2H)
1
3.32(d, J=14.8 Hz, 2H)
2.79(d, J=14.8 Hz, 2H)
2.65(ddd, J=14.0 Hz,
 J'=14.0, J''=4.4 Hz, 2H)
2.30(ddd, J=18.3 Hz, J'=4.4 Hz,
J''=3.4 Hz, 2H)
1.88(d, J=8.3 Hz, 2H)2.03(m, 2H)
2.00(m, 2H)
1.64(m, 2H)
1.40(ddd, J = 14.0, 
J' = 9.5, J'' = 4.4, 2H)





Figure 2.12. Assignments of 1H NMR(500 MHz, Methanol d3) Signal Peaks for 10, 11-








































Figure 2.13 (a, b, c). 1H NMR (500 MHz, Methanol d3) Spectra 10, 11-DiPyridylPDHD Di-


























































Figure 2.14 (a, b, c, d). 13C NMR (500 MHz, Methanol-d3) Spectra of 10, 11-DiPyridylPDHD 






Figure 2.15 (a, b, c). 1H-1H COSY (500 MHz, Methanol d3) COSY NMR Spectra of 10, 11-






Figure 2.16 (a, b, c). 1H-13C HSQC (500 MHz, Methanol d3) HSQC NMR Spectra of 10, 11-






Figure 2.17 (a, b, c). 1H-13C HMBC (500 MHz, Methanol d3) HMBC NMR Spectra of 10, 11-
DiPyridylPDHD Di-(1R)-(-)-10-Camphorsulfonic Acid Salt (6 and 6’). 
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a. 
Wilson-878-20101123-R01 #1-227 RT: 0.00-1.27 AV: 46 NL: 1.88E5
F: ITMS + p ESI Full ms [191.00-2000.00]





































324.08 829.00525.17393.25 489.33 765.50
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C10H15O4S
- anion
(unprotonated molecule is M)
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[M + 2H+] • ACN (part of solvent system) LTQ – positive ion
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R01#11-504  RT: 0.10-3.61  




C28 H19 N2 O2: 
C28 H19 N2 O2
p (gss, s /p:40) Chrg 1




Error = 254 ppb
FT-ICR – positive ion
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c. 
Wilson-878-20101123-R01 #95-298 RT: 1.28-1.38 AV: 27 NL: 2.62E4
F: ITMS - p ESI Full ms [191.00-2000.00]
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Supports compound with 
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R01#102-386  RT: 1.38-2.31  




C10 H15 O4 S: 
C10 H15 O4 S1
p (gss, s /p:40) Chrg -1





Error = -192 ppb
FT-ICR – negative ion
 Figure 2.18 (a, b, c). HR MS/MS (ESI Q-TOFMS) spectra of 10, 11-DiPyridylPDHD Di-(1R)-   
(-)-10-Camphorsulfonic Acid Salt (6 and 6’). 
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Figure 2.19. UV-spectrum of 10, 11-DiPyridylPDHD Di-(1R)-(-)-10-Camphorsulfonic Acid Salt 
(6 and 6’) in methanol.  
2.6.4. Separation of 10, 11-DiPyridylPDHD (1 and 1’) Enantiomers (Scheme 2.8). 
2.6.4.a. Analytical Separation of 10, 11-DiPyridylPDHD (1 and 1’) Enantiomers          
(Figure 2.20).  
Aliquots of 100 µg of 10, 11-DiPyridylPDHD di-(1R)-(-)-10-Camphorsulfonic acid salt in 
methanol-water mixture (9:1) in 30 μL were injected and eluted with methanol-water 
9:1(isocratic mode, solvent velocity  1mL/min, Detection: wavelength- 260 nm and 280 nm, run 
total time 3000 sec, cycle time-10 s, Background correction- None). Two fractions were 
collected: 1st Fraction (Isomer 1) - tr from 500 to 1000 s, 2d Fraction (Isomer 2)-  tr from 2000 to 
2500 s. Both fractions were vacuum dried and CD spectra were measured (Figure 2.21).  
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Figure 2.20. HPLC-Profile of Analytical Separation of 10, 11-DiPyridylPDHD (1 and 1’) 
Enantiomers. 
Figure 2.21. CD Spectra of 10, 11-DiPyridylPDHD (1 and 1’) Enantiomers. 
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~270 uM sol-n in MeOH, T = 25C,
Collection parameters:
optical pathlength = 0.1 cm,
integration time = 1 s/nm,




The Kronig-Kramer transform 98 gave the specific rotation at 589 nm of +2.383 deg cm2 g-1 and   
-2.383 deg cm2 g-1 for fraction 1 and fraction 2, respectively. All in all, CD shows nearly mirror 
spectra, if concentration corrections are made, the CD spectra will be exactly mirror images, 
which is indicative of pure stereoisomers.            
2.6.4.b. Preparative Separation of 10, 11-DiPyridylPDHD (1 and 1’) Enantiomers (Figure 
2.22).    
Aliquots of 2.0 mg of 10, 11-DiPyridylPDHD di-(1R)-(-)-10-Camphorsulfonic acid salt in 
methanol-water mixture (9:1) in 250 μL were injected and eluted with methanol-water 9:1        
(isocratic mode, solvent velocity 3 mL/min, Detection: wavelength- 260 nm and 280 nm, run 
total time 3000 sec, cycle time-10 s, Background correction- None). Two fractions were 
collected: 1st Fraction (Isomer 1)- tr from 6000 to 10000 s, 2d Fraction (Isomer 2)-  tr from 
22000 to 30000 s. Both fractions were vacuum dried and CD spectra were measured.  







   Fraction 2      












2.6.5 Preparation of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 9’) (Scheme 2.9). 
To a stirred solution of 10, 11-DiPyridylPDHD (racemic mixture or individual isomers 1 and 1’) 
(0.120 g, 0.29 mmol) in CH2Cl2 (300 mL freshly distilled from P2O5) at room temterature was 
added solid trimethyloxonium tetrafluoroborate (0.257 g, 1.74 mmol). The reaction was refluxed 
for 36 h at 40 0 C whereupon a finely divided precipitate formed. The solvent was evaporated. 
The solid was recrystallized from acetonitrile-diethyl ether (9/1) to yield a fine white powder      
(0.135 g, 0.22 mmol, 75% yield). Extra purification on Bio-Rex®70 Cation Exchange Resin(Bio-
Rad®) using acetonitrile/deionized water = 20/80 afforded analytically pure N,N-Dimethyl l0, 11-
DiPyridiniumPDHD-BF4: 
1H NMR (500 MHz, Acetonitrile-D3) (Figure 2.23): δ 8.19 (d, J = 7.0 
Hz, 4H), 8.10 (dd, J =7.5 Hz, J’ =1 Hz,  2H), 7.93 (dd, J =7.5 Hz, J =1 Hz, 2H), 7.81 (s, 2H), 
7.76 (dd, J =7.5 Hz, J’ =7.5 Hz, 2H), 7.72 (d,  J = 7.0 Hz, 4H), 5.96 (s, 2H), 4.30 (s, 6H); 1H 
NMR (500 MHz, D2O) (Figure 2.27 a, b): δ 8.75 (d, J = 6.6, 2H), 8.54 (d, J = 7.5 Hz, 2H), 
8.31(d, (J = 7.5 Hz, 2H), 8.19 (m, 6H), 8.13 (m, 2H), 6.57 (s, 2H), 4.30 (s, 6H); 13C NMR (100.6 
MHz, Acetonitrle-D3) (Figure 2.24): δ 146.9, 134.0, 132.2, 128.7, 127.9, 127.2, 126.9, 126.3, 
125.3, 122.3, 119.2, 76.7, 49.3; 1H-1H COSY (500 MHz, Acetonitrile-D3)      (Figure 2.25 a, b); 
1H-13C HSQC (500 MHz, Acetonitrile-D3) (Figure 2.26); 
1H-1H COSY (500 MHz, D2O) (Figure 
2.28 a, b); HRMS (ESI Q-TOFMS) (Figure 2.29 a) calculated  for C28H20N2O2
2+ m/z 208.0752, 
found m/z 208.0765; calculated for C30H24N2O2
2+·BF4
 m/z 531.18668, found m/z 531.18633; 
calculated for C30H24N2O2
2+ m/z 222.09134 found  m/z 222.09141. 
UV of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 in Cacodylic Buffer (Figure 2.30),  
calculated ε345 is 77459 M
-1cm-1 (Table 2.2, Graph 2.1). CD spectra of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (9 and 9’) (Figures 2.31 and 2.32). 
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Figure 2.23. 1H NMR (500 MHz, Acetonitrile-D3) of N,N-Dimethyl 10, 11-





Figure 2.24. 13C NMR(500 MHz, Acetonitrile-D3) of  N,N-Dimethyl 10, 11-
















Figure 2.25 (a, b). 1H-1H COSY NMR (500 MHz, Acetonitrile-D3) of N,N-Dimethyl 10, 11-





Figure 2.26. 1H-13C HSQC NMR (500 MHz, Acetonitrile-D3) of N,N-Dimethyl 10, 11-



















Figure 2.27 (a, b). 1H NMR (500 MHz, D2O) of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 










Figure 2.28 (a, b). 1H-1H COSY NMR (500 MHz, D2O) of N,N-Dimethyl 10, 11-



















































R01#85-226  RT: 0.93-1.19  




C30 H24 N2 O2 BF4: 
C30 H24 N2 O2 B1F4
p (gss, s /p:40) Chrg 1





Error = 342 ppb














































R01#85-226  RT: 0.93-1.19  




C30 H24 N2 O2: 
C30 H24 N2 O2
p (gss, s /p:40) Chrg 2




Error = 312 ppb
FT-ICR – positive ion
 
Figure 2.29 (a, b). FT-ICR MS Spectra N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 
9’). 
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Figure 2.30. UV Spectrum of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 9’) in 
Cacodylic Buffer. 
Molar concentration of N,N-Dimethyl 
10, 11-DiPyridiniumPDHD-BF4             
(9 and 9’), mol/L 






Table 2.2. Absorbances at 346 nm for Different Concentrations of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (9 and 9’) in Cacodylic Buffer. 
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Molar concentration of dDHD, mol/L
Equation y = a + b*x
Adj. R-Square 0.99535
Value Standard Error
a Intercept 0.0151 0.08443
b Slope 76876.28866 2624.44207
Graph 2.1. Linear Regression Analysis for Absorbance (346 nm) versus Molar Concentration of 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 9’) in Cacodylic Buffer. 






































Figure 2.32. CD Spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (9 and 9’) 
Enantiomers (275 nm to 450 nm range). 
The Kronig-Kramer transform98 gave the specific rotation at 589 nm of +2.178 deg cm2 g-1 and   
-2.178 deg cm2 g-1 for Fraction 1 (product of dimethylation of Fraction 1-Figure 2.20 and 2.22) 
and Fraction 2 (product of dimethylation of Fraction 1-Figure 2.20 and 2.22), respectively. All in 
all, CD shows nearly mirror spectra, if concentration corrections are made, the CD spectra will 
be exactly mirror images, which is indicative of pure enantiomers.            
Also the formation of monomethylated product- methyl trans-10-(4-pyridinium)-11-(4-pyridyl)-
10,11-dihydro-9,12-dioxa-benzo[e]pyren tetrafluroborate (N-Methyl 10-pyridyl-11-
PyridiniumPDHD-BF4) was observed: 
1H NMR (500 MHz,Acetonitrile-D3): δ 8.66 (d, J = 6.6 Hz, 2H), 8.55 (d, J = 7.5 Hz, 2H), 8.47 
(dd, J = 7.5 Hz, J’ = 1Hz, 2H), 8.29 (d, J = 7.5 Hz, 2H), 8.18 (s, 2H), 8.13 (m, J = 7.0 Hz, 4H), 
8.09 (d,  J = 6.6 Hz, 2H), 6.34 (s, 2H), 4.23 (s, 3H); 13C NMR: (100.6 MHz, CDCl3) δ 155.6, 




C), 122.3 (2 C), 119.3, 119.1, 76.4 (2 C), 49.3; HRMS (ESI Q-TOFMS) calculated  for 
C29H21N2O2
+ m/z 429.15975, found for C29H21N2O2
+ m/z 429.15974. 











Figure 2.33. CD Spectra of Methyl N-methyl trans-10-(4-Pyridinium)-11-(4-pyridyl)-10,11-
dihydro-9,12-dioxa-benzo[e]pyren tetrafluroborate (N-methyl 10-Pyridyl-11-PyridiniumPDHD-
BF4). 
2.6.6. Preparation of trans-10,11-Di-(4-N-oxo-pyridine)-10,11-dihydro-9,12-dioxa-
benzo[e]pyren (10, 11-Di-N-oxo-PDHD) (10 and 10’) (Scheme 2.10).  
A solution of 10, 11-DiPyridiniumPDHD-BF4 ((racemic mixture or individual isomers 1 and 1’) 
(0.100 g, 0.240 mmol) dissolved in an oxidizing solution of 1.0 M H2O2/CH3CN (8.0 mL, 8.00 
mmol), and crystalline methyltrioxorhenium (VII) (MTO) (9.42 mg, 0.034 mmol) was mixed 
with stirring. MTO dissolved immediately along with a change of color of the solution to yellow, 
which bleached within 3 minutes. After the reaction solution was stirred at 0 0C for 1 h, extra 















 10-pyridyl-11-PyridiniumPDHD-BF4 1 st Isomer




MTO (9.42 mg, 0.034 mmol) was added to the mixture. After stirring for an additional 4 h, the 
solution was poured into brine, and products were extracted with acetonitrile (20 mL x3). The 
combined extracts were freeze-dried and chromatographed (silica gel, acetonitrile) affording 
pure 10, 11-Di-N-oxo-PDHD (0.070 g, 0.156 mmol, 65% yield): 1H NMR (300 MHz, 
CD3OD+acetonitrile-D3, 1:1) (Figure 2.34 a, b): δ 8.51 (dd, J=7.2 Hz, J’=1 Hz, 2H), 8.32 (dd, 
J=7.2 Hz, J‘=1 Hz, 2H), 8.31 (s, 2H), 8.30 (dd, J=7.2 Hz, J’=7.1 Hz, 2H), 8.23 (d, J=6.9, 4H), 
7.65 (d, J=7.0 Hz, 4H), 6.31 (s, 2H); 13C NMR (100.6 MHz, CD3OD+acetonitrile-D3, 1:1) 
























Figure 2.34 (a, b). 1H NMR (300 MHz, CD3OD+Acetonitrile-D3, 1:1) of 10, 11-Di-N-oxo-





Figure 2.35. 13C NMR (100.6 MHz, CD3OD+acetonitrile-D3, 1:1) of 10, 11-Di-N-oxo-PDHD) 
(10 and 10’). 
2.6.7. Preparation of N,N-Dimethoxy trans-10,11-di-(4-pyridinium)-10,11-dihydro-9,12-
dioxa-benzo[e]pyren Di-tetrafluroborate (N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4) 
(11 and 11’) (Scheme 2.10). 
Trimethyloxonium tetrafluoroborate (0.097 g, 0.660 mmol) and 10, 11-Di-N-oxo-PDHD (10 and 
10’) (0.050 g, 0.110 mmol) were stirred in 10 mL of acetonitrile for 4 h. Recrystallization from 
acetonitrile/diethyl ether (9:1) afforded (N,N-Dimethoxy 10, 11-DiPyridiniumPDHD-BF4) (11 
and 11’) (0.035 g, 0.056 mmol, 45%): 1H NMR (300 MHz, CD3OD+Acetonitrile-D3, 1:1) 
(Figure 2.36) δ 8.54 (d, J=7.1 Hz, 2H), 8.30 (d, J=7.1 Hz, 2H), 8.17 (s, 2H), 8.16 (dd, J=7.1 Hz, 
J’=7.1 Hz, 2H), 8.13 (d, J=6.9, 4H), 7.62 (d, J=6.9, 4H), 6.36 (s, 2H), 4.59 (s, 6H); 13C NMR 
129 
(100.6 MHz, acetonitrle-D3) (Figure 2.37): δ 139.8, 134.6, 129.4, 128.3, 127.9, 126.8, 126.2, 
125.8, 125.4, 122.3, 119.2, 76.8, 49.9.  
Figure 2.36. 1H NMR (300 MHz, CD3OD+acetonitrile-D3, 1:1) of N,N-Dimethoxy 10, 11-
DiPyridiniumPDHD-BF4 (11 and 11’). 
Figure 2.37. 13C NMR (100.6 MHz, CD3OD+acetonitrile-D3, 1:1) of N,N-Dimethoxy 10, 11-




2.6.8. Preparation of 2, 2’-Ethenylidenebispyridine (13) (Scheme 2.11). 
The typical procedure for the synthesis of 2, 2’-ethenylidenebispyridine (13) by a Wittig reaction 
is the following: Butyllithium (17.93 mmol, 1.7 M in hexane) was added to a tetrahydrofuran 
(THF, 85 mL) solution of methyltriphenylphosphonium bromide (5.790 g, 16.3 mmol) at -78 0C 
and the solution was stirred for 1.5 h at room temperature. To this solution was added a THF (18 
mL) solution of di-2-pyridyl ketone (12, 3.000 g, 16.3 mmol) at -78 0C. After 20 h at room 
temperature, the resulting mixture was neutralized with 1M HCl aqueous solution (120 mL x 5). 
The combined aqueous layers are neutralized by K2CO3 and extracted again with 
dichloromethane (120 mL x 5). The organic layers were combined, dried over anhydrous 
Na2SO4 and evaporated. The residue was purified by column chromatography on silica (ethyl 
acetate/hexane = 1/9) to give 2,2’-ethenylidenebispyridine (13) as colorless crystals (1.5 g, 8.23 
mmol, 46% yield): 1H NMR (300 MHz, CDCl3) (Figure 2.38) δ 8.63 (ddd, J = 5.0 Hz, J’ = 1.7 
Hz, J = 1.0 Hz, 2H), 7.68 (ddd,     J = 7.7 Hz, J’ = 7.7 Hz, J = 1.7 Hz, 2H), 7.38 (ddd, J = 7.7 Hz, 
J’ = 1.0 Hz, J’’ = 1.0 Hz, 2H), 7.23 (ddd, J = 7.7 Hz, J’ = 5.0 Hz, J’’ = 1.0 Hz, 2H), 6.06 (s, 2H). 
The typical procedure for the synthesis of 2, 2’-ethenylidenebispyridine (13) with a Petasis 
reagent99 is the following: A 50-mL, nitrogen-purged, round-bottomed flask was charged with 
di-2-pyridyl ketone (12, 3.00 g, 13.6 mmol), dimethyltitanocene in toluene (36 mL of a 20% w/w 
solution in toluene), and titanocene dichloride (210 mg, 0.83 mmol). The red–orange mixture 
was heated to 80°C and aged in the dark for 5.5 h, and then cooled to ambient temperature. 
Sodium bicarbonate (1.80 g), methanol (27 mL), and water (1 mL) were added, and the mixture 
was heated to 40°C for 14 h. The hot aqueous methanol treatment was done to decompose the 
titanium residues into an insoluble solid. The decomposition was judged to be complete when 




residues were removed by filtration. The solution was evaporated under reduced pressure and 
flushed with methanol. The crude material was recrystallized by dissolving in hot (60 0C) 
methanol 60 mL), cooling to ambient temperature, and then adding water (7.2 mL) over 2 h. The 
material was stirred for 18 h and then isolated via filtration at ambient temperature. The filter 
cake was washed with 25% aqueous methanol (20 mL), and the solid was purified by column 
chromatography on silica (ethyl acetate/hexane=1/9) to give 2,2’-ethenylidenebispyridine (13) as 
colorless crystals (1.2 g, 6.59 mmol, 48% yield). 
 














Figure 2.38. 1H NMR (300 MHz, CDCl3) of 2, 2’-Ethenylidenebispyridine (13). 
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2.6.9. Preparation of 10, 10-Bis-(2-Pyridyl)-10,11-Dihydro-9,12-dioxa-benzo[e]pyrene (10, 
10-BisPyridylPDHD) (14) (Scheme 2.11).27d 
To a stirred solution of 2,2’-ethenylidenebispyridine (13) (1.094 g, 6.0 mmol) in benzene (400 
mL) was added solid pyrene-4,5-dione (4) (0.464 g, 2.0 mmol). The solution was heated to reflux 
to dissolve the quinone, then cooled, degassed by sparging with argon and placed in a Rayonett 
Photochemical Reactor. The solution was irradiated for 15 hours at 419 nm in a water bath with 
the temperature kept at the freezing point of benzene +4 0C. The reaction mixture was placed in 
ultrasonic bath for 10 min, and then heated for 5 hours at 50 0C in argon atmosphere. The solvent 
was removed to yield a dark oily residue, which was purified by column chromatography (silica 
gel, 25 % EtOAc in hexanes). The resulting solid was recrystallized from EtOAc and hexanes to 
obtain PDHD 14 as lightly tan crystals (0.100 g, 0.24 mmol, 12 % yield): 
C28H18N2O2; 414.45 g/mol; Rf = 0.11 (25% EtOAc in hexanes); m.p. 176-178 
oC; 1H NMR (400 
MHz , CDCl3) δ 8.75 (dd, J = 1.2 Hz, J = 7.2 Hz, 1H), 8.68 (m, 2H), 8.39 (dd, J = 8.0, J = 1.2 
Hz, 1H), 8.16-8.01 (m, 5H), 7.93 (dd, J = 8.0 Hz, J = 8.0 Hz, 1H), 7.81 (m, 2H), 7.60 (m, 2H), 
7.15 (m, 2H), 5.49 (s, 2H); 13C NMR (100.6 MHz, CDCl3) δ 159.2, 149.4, 136.9, 134.8, 132.4, 
131.0, 130.8, 127.5, 127.2, 126.1, 125.9, 125.9, 125.8, 125.3, 123.9, 123.8, 122.8, 121.2, 121.1, 
120.8, 118.7, 117.5, 81.8, 69.4; IR (CCl4) νmax 3055 w, 1637 m, 1610 m, 1591 m, 1434 m, 1418 
m, 1314 s, 1132 m, 1101 m cm-1; HRMS (ESI Q-TOFMS) calcd for C28H18N2O2+H
+ [M + H+] 




Figure 2.39. UV Spectra of 10, 10-BisPyridylPDHD (14) for Different Concentrations in 
Acetonitrile. 
Mass of 10, 10-
BisPyridylPDHD (14) 
Volume of Acetonitrile Absorbance at 346 nm 
0.198 25 0.27659 
0.636 25 0.87279 
0.929 25 1.31910 
Table 2.3. Absorbances at 346 nm of 10, 10-BisPyridylPDHD (14) for Different Concentrations 
in Acetonitrile. 
2.6.10. Titration of 10, 10-BisPyridylPDHD with Metal Salts and 10, 10-BisPyridylPDHD-
Metalm+ Complexes with Herring Sperm DNA (HS DNA). 
It is commonly known that the magnitudes of hypochromism are correlated with the strength of 
the intercalative binding interaction. 100 Equilibrium constants can be determined according to 
previously reported procedures.100 When the ratio of bound 10, 10-BisPyridylPDHD to Metalm+





Kb, based upon these absorption titrations may be determined from a double-reciprocal plot of 
the changes in the apparent extinction coefficient of 10, 10-BisPyridylPDHD versus Metalm+ or 
10, 10-BisPyridylPDHD-Metalm+ to HS DNA concentration. The following equation represents 
this relationship: 
1 / ∆εap = 1/∆εKb[c] + 1/∆ε, 
 [c]=[ Metalm+], for titration of  10, 10-BisPyridylPDHD with Metalm+, 
[c]=[ HS DNA +], for titration of  10, 10-BisPyridylPDHD-Metalm+  with HS DNA 
Equation 2.1. Equation for Calculation of Binding Constant (Kb) of 10, 10-BisPyridylPDHD to 
Metalm+ and 10, 10-BisPyridylPDHD-Metalm+ to HS DNA.  
Where ∆εap = |εa – εf|, ∆ε = |εb – εf|. The apparent extinction coefficient, εa, is obtained by 
calculating Aobs/[10, 10-BisPyridylPDHD]. εb and εf are extinction coefficients of 10, 10-
BisPyridylPDHD free and 10, 10-BisPyridylPDHD fully bound form respectively. Multiplying 
by [c] puts the equation in the half-reciprocal plot form:  
[c]/∆εap = (1/∆ε)*[c] + 1/∆εKb 
Equation 2.2. Half-Reciprocal Plot Form of Equation for Calculation of Binding Constant (Kb) 
of 10, 10-BisPyridylPDHD to Metalm+ and 10, 10-BisPyridylPDHD-Metalm+ to HS DNA.  
  A plot of [c]/∆εap versus [c] will have a slope of 1/∆ε and a y-intercept equal to 1/(∆εKb). Kb is 
then given by the ratio of the slope to intercept.  
Titration of 10, 10-BisPyridylPDHD (14) with Metal Salts in Acetonitrile (Common 
Procedure). 
UV-Vis spectra were measured using a 100 CARY-BIO UV-Visible spectrophotometer (Varian 
Inc.) equipped with a thermoelectrically controlled cell holder and a cuvette with a 1.00 cm path 
length. Experiments were conducted at 20° C in acetonitrile pH =7.1 buffer by manually 
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injecting  aliquots of metal salt solution in  acetonitrile into 3 mL of 10, 10-BisPyridylPDHD 
(14) samples and recording spectra between 200 and 500 nm.













Scheme 2.20. Titration of 10, 10-BisPyridylPDHD (14) with Cu(ClO4)2 in Acetonitrile. 
V10, 10-BisPyridylPDHD, 


































C  Final Cu(ClO4)2, 
(Final 





BisPyridylPDHD /  ν
Cu(ClO4)2, 
(mol/mol) 
3 0.000031199 0 0.002 0.000031199 3.000 0 1:0 
3 0.000031199 4.68 0.002 0.000031199 3.00468 0.0000031 1:0.1 
3 0.000031199 14.04 0.002 0.000031199 3.001404 0.0000093 1:0.3 
3 0.000031199 23.4 0.002 0.000031199 3.00234 0.0000156 1:0.5 
3 0.000031199 32.76 0.002 0.000031199 3.003276 0.0000218 1:0.7 
3 0.000031199 46.79 0.002 0.000031199 3.004679 0.0000312 1:1 
3 0.000031199 56.16 0.002 0.000031199 3.006516 0.0000374 1:1.2 
3 0.000031199 70.2 0.002 0.000031199 3.00702 0.0000468 1:1.5 
3 0.000031199 79.56 0.002 0.000031199 3.007956 0.000053 1:1.7 
3 0.000031199 93.6 0.002 0.000031199 3.00936 0.0000624 1:2 
Table 2.4. Titration of 10, 10-BisPyridylPDHD (14) with Cu(ClO4)2 in Acetonitrile. 
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of  Cu(ClO4)2=0.002 M in MeCN
Final Concentration











[10, 10-BisPyridylPDHD] =31.2 mM in 3mL ACN








C  10, 10-BisPyridylPDHD,
(Initial 















on  of 
Cu(ClO4)2),
M 
































/  ν Cu(ClO4)2, 
(mol/mol) 
3 0.000031199 0 0.002 0.000031199 0 100 0 0.4524 1:0 
3 0.000031199 4.68 0.002 0.000031199 0.0000031 91 10 0.5487 1:0.1 
3 0.000031199 14.04 0.002 0.000031199 0.0000093 77 23 0.4649 1:0.3 
3 0.000031199 23.4 0.002 0.000031199 0.0000156 67 33 0.4850 1:0.5 
3 0.000031199 32.76 0.002 0.000031199 0.0000218 59 41 0.5073 1:0.7 
3 0.000031199 46.79 0.002 0.000031199 0.0000312 50 50 0.5269 1:1 
3 0.000031199 56.16 0.002 0.000031199 0.0000374 46 54 0.5442 1:1.2 
3 0.000031199 70.2 0.002 0.000031199 0.0000468 40 60 0.5451 1:1.5 
3 0.000031199 79.56 0.002 0.000031199 0.000053 37 63 0.5464 1:1.7 
3 0.000031199 93.6 0.002 0.000031199 0.0000624 33 67 0.5485 1:2 
Table 2.5. Titration of 10, 10-BisPyridylPDHD (14) with Cu(ClO4)2 in Acetonitrile. 
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εf=  ε10, 10-BisPyridylPDHD =14500 M
-1cm-1
 εap=Abs(343)/[10, 10-BisPyridylPDHD] 
εb-from graph Abs343-% Cu(ClO4)2 (for Cu(ClO4)2 100%) 
From fitting: Abs(343)=0.52619+% Cu(ClO4)2*3.256*10
-4 
Cu(ClO4)2→100%  Abs(343)b=0.5588=A(343)b
Graph 2.2. Graphical Determination of A(343)b for Titration of 10, 10-BisPyridylPDHD (14) 
with Cu(ClO4)2 in Acetonitrile. 






C  Final Cu(ClO4)2, 
(Final 
Concentration  of 
Cu(ClO4)2),
M 
% final 10, 10-
BisPyridylPDHD, 




% Final Cu(ClO4)2, 








at 343 nm) 













0.000031199 0 100 0 0.4524 0.5588 14500 17910 14500 
0.000031199 0.0000031 91 10 0.5487 0.5588 14500 17910 17587 
0.000031199 0.0000093 77 23 0.4649 0.5588 14500 17910 14901 
0.000031199 0.0000156 67 33 0.4850 0.5588 14500 17910 15545 
0.000031199 0.0000218 59 41 0.5073 0.5588 14500 17910 16260 
0.000031199 0.0000312 50 50 0.5269 0.5588 14500 17910 16888 
0.000031199 0.0000374 46 54 0.5442 0.5588 14500 17910 17443 
0.000031199 0.0000468 40 60 0.5451 0.5588 14500 17910 17472 
0.000031199 0.000053 37 63 0.5464 0.5588 14500 17910 17513 
0.000031199 0.0000624 33 67 0.5485 0.5588 14500 17910 17581 




C  Final Cu(ClO4)2, 
(Final Concentration  of 
Cu(ClO4)2), 
M 
[εap – εf ], 
M-1cm-1 
 
[εb – εf ], 
M-1cm-1 
 
C  Final Cu(ClO4)2 /[εap – εf ], 
                M2cm-1 
 
0 0 3410 - 
0.0000031 3087 3410 1.00421*10-9 
0.0000093 401 3410 2.3192*10-8 
0.0000156 1045 3410 1.49282*10-8 
0.0000218 1760 3410 1.23864*10-8 
0.0000312 2388 3410 1.30653*10-8 
0.0000374 2943 3410 1.27081*10-8 
0.0000468 2972 3410 1.5747*10-8 
0.000053 3013 3410 1.75904*10-8 
0.0000624 3081 3410 2.02532*10-8 
Table 2.7. Titration of 10, 10-BisPyridylPDHD (14) with Cu(ClO4)2 in Acetonitrile. 























[C Final Cu(ClO4)2], M
 
y-intersept (1/[εb – εf ])=2.6255*10
-9 





Graph 2.3. Graphical Determination of Kb  for Titration of 10, 10-BisPyridylPDHD (14) with 
Cu(ClO4)2 in Acetonitrile. 




2.6.10.b. UV-Vis Absorption Spectroscopy. Titration of 10, 10-BisPyridylPDHD with 














Scheme 2.21. Titration of 10, 10-BisPyridylPDHD (14) with AgNO3 in Acetonitrile. 
Large ratios: 
V10, 10-BisPyridylPDHD, 














































3 0.0000245 0 0.2 0.0000245 3.00000 0 1:0 
3 0.0000245 0.37 0.2 0.0000245 3.00037 24.66 1:1 
3 0.0000245 0.74 0.2 0.0000245 3.00074 49.32 1:2 
3 0.0000245 1.48 0.2 0.0000245 3.00148 98.61 1:4 
3 0.0000245 2.22 0.2 0.0000245 3.00222 147.89 1:6 
3 0.0000245 2.96 0.2 0.0000245 3.00296 197.13 1:8 
3 0.0000245 3.7 0.2 0.0000245 3.00370 246.36 1:10 
3 0.0000245 4.44 0.2 0.0000245 3.00444 292.90 1:12 
3 0.0000245 5.18 0.2 0.0000245 3.00518 344.73 1:14 
3 0.0000245 5.92 0.2 0.0000245 3.00592 393.90 1:16 
3 0.0000245 6.66 0.2 0.0000245 3.00666 443.01 1:18 
3 0.0000245 7.4 0.2 0.0000245 3.00740 492.12 1:20 















of  AgNO3=0.2 M in MeCN
Final Concentration














[1,1'-DPyDHD]=0.024 mM in 3ml ACN
Figure 2.41. Titration of 10, 10-BisPyridylPDHD (14) with AgNO3 in Acetonitrile (Large 
Ratios). 
Small ratios: 
V10, 10-BisPyridylPDHD,  














































3 0.000024 0 0.02 0.000024 3.00000 0 1:0 
3 0.000024 0.36 0.02 0.000024 3.00036 2.39 1:0.1 
3 0.000024 0.72 0.02 0.000024 3.00072 4.80 1:0.2 
3 0.000024 1.08 0.02 0.000024 3.00108 7.20 1:0.3 
3 0.000024 1.44 0.02 0.000024 3.00144 9.60 1:0.4 
3 0.000024 1.8 0.02 0.000024 3.00180 11.2 1:0.47 
3 0.000024 2.16 0.02 0.000024 3.00216 14.40 1:0.6 
3 0.000024 2.52 0.02 0.000024 3.00252 16.79 1:0.7 
3 0.000024 2.88 0.02 0.000024 3.00288 19.18 1:0.8 
3 0.000024 3.24 0.02 0.000024 3.00324 21.58 1:0.9 
3 0.000024 3.6 0.02 0.000024 3.00360 23.97 1:1 
3 0.000024 3.96 0.02 0.000024 3.00396 26.37 1:1.1 
3 0.000024 4.32 0.02 0.000024 3.00432 28.75 1:1.2 
3 0.000024 4.68 0.02 0.000024 3.00468 31.15 1:1.3 
3 0.000024 5.04 0.02 0.000024 3.00504 33.54 1:1.4 
3 0.000024 5.4 0.02 0.000024 3.00540 35.93 1:1.5 
3 0.000024 5.76 0.02 0.000024 3.00576 38.33 1:1.6 
3 0.000024 6.12 0.02 0.000024 3.00612 40.72 1:1.7 
3 0.000024 6.48 0.02 0.000024 3.00648 43.12 1:1.8 
Table 2.9. Titration of 10, 10-BisPyridylPDHD (14) with AgNO3 in Acetonitrile (Small Ratios). 
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of  AgNO3=0.02 M in MeCN
Final Concentration




















[1,1DPyDHD]=24 mM in 3mL  MeCN
Figure 2.42. Titration of 10, 10-BisPyridylPDHD (14) with AgNO3 in Acetonitrile (Small 
Ratios). 
No isosbestic point is observed, since binding constant is not calculated. 














Scheme 2.22. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 
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C  initial 10, 10-
BisPyridylPDHD, 
(Initial 







































3 0.000098372 0 0.01 0.000098372 3.0000 0 1:0 
3 0.000098372 2.9 0.01 0.000098372 3.0029 9.65 1:0.098 
3 0.000098372 5.8 0.01 0.000098372 3.0058 19.29 1:0.2 
3 0.000098372 8.7 0.01 0.000098372 3.0087 28.91 1:0.29 
3 0.000098372 11.6 0.01 0.000098372 3.0116 38.51 1:0.39 
3 0.000098372 14.5 0.01 0.000098372 3.0145 48.10 1:0.49 
3 0.000098372 17.4 0.01 0.000098372 3.0174 57.67 1:0.58 
3 0.000098372 20.3 0.01 0.000098372 3.0203 67.21 1:0.68 
3 0.000098372 23.2 0.01 0.000098372 3.0322 76.74 1:0.78 
3 0.000098372 26.1 0.01 0.000098372 3.0261 86.25 1:0.87 
3 0.000098372 29 0.01 0.000098372 3.0290 95.74 1:0.97 
3 0.000098372 31.9 0.01 0.000098372 3.0319 105.21 1:1.07 
3 0.000098372 34.8 0.01 0.000098372 3.0348 114.67 1:1.17 
3 0.000098372 37.7 0.01 0.000098372 3.0377 124.11 1:1.26 
3 0.000098372 43.5 0.01 0.000098372 3.0435 142.93 1:1.45 
3 0.000098372 60.9 0.01 0.000098372 3.0609 200.00 1:2.02 
Table 2.10. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 
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of Ni(NO3)2=0.1 M in MeCN
Final Concentration


















 [Ni(NO3)2]=98.4 mM in ACN
[10, 10-BisPyridylPDHD]=98.4 mM in 3mL ACN
Figure 2.43. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 
V10, 10-BisPyridylPDHD, 




C  initial 10, 10-
BisPyridylPDHD, 
(Initial 





























% Final 10, 10-
BisPyridylPDHD, 

















/ ν Ni(NO3)2, 
(mol/mol) 
3 0.000098372 0 0.01 0.000098372 0 100 0 1.4264 1:0 
3 0.000098372 2.9 0.01 0.000098372 9.65 91 9 1.4514 1:0.098 
3 0.000098372 5.8 0.01 0.000098372 19.29 84 16 1.4607 1:0.2 
3 0.000098372 8.7 0.01 0.000098372 28.91 77 23 1.4680 1:0.29 
3 0.000098372 11.6 0.01 0.000098372 38.51 72 28 1.4809 1:0.39 
3 0.000098372 14.5 0.01 0.000098372 48.10 67 33 1.4888 1:0.49 
3 0.000098372 17.4 0.01 0.000098372 57.67 63 37 1.4997 1:0.58 
3 0.000098372 20.3 0.01 0.000098372 67.21 59 41 1.558 1:0.68 
3 0.000098372 23.2 0.01 0.000098372 76.74 56 44 1.5096 1:0.78 
3 0.000098372 26.1 0.01 0.000098372 86.25 53 47 1.5299 1:0.87 
3 0.000098372 29 0.01 0.000098372 95.74 51 49 1.5368 1:0.97 
3 0.000098372 31.9 0.01 0.000098372 105.21 48 52 1.5471 1:1.07 
3 0.000098372 34.8 0.01 0.000098372 114.67 46 54 1.5492 1:1.17 
3 0.000098372 37.7 0.01 0.000098372 124.11 44 56 1.5484 1:1.26 
3 0.000098372 43.5 0.01 0.000098372 142.93 41 59 1.5569 1:1.45 
3 0.000098372 60.9 0.01 0.000098372 200.00 33 67 1.5637 1:2.02 
Table 2.11. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 
144 




















 εap=Abs(343)/[ 10, 10-BisPyridylPDHD] 
εb-from graph Abs343-% Ni(NO3)2 (for Ni(NO3)2 100%) 
From fitting: Abs(343)=1.461+% Ni(NO3)2 *0.001 
Ni(NO3)2 →100%  Abs(343)b=1.561=A(343)b
Graph 2.4. Graphical Determination of A(343)b for Titration of 10, 10-BisPyridylPDHD (14) 
with Ni(NO3)2 in Acetonitrile. 
C  Final 10, 10-
BisPyridylPDHD, 
(Final 









% final 10, 10-
BisPyridylPDHD, 




% Final NiNO3, 








at 343 nm) 










C Final 10, 10-
BisPyridylPDHD, 
M-1cm-1
0.000098372 0 100 0 1.4264 1.561 14500 15868 14500 
0.000098372 9.65 91 9 1.4514 1.561 14500 15868 14754 
0.000098372 19.29 84 16 1.4607 1.561 14500 15868 14848 
0.000098372 28.91 77 23 1.4680 1.561 14500 15868 14922 
0.000098372 38.51 72 28 1.4809 1.561 14500 15868 15054 
0.000098372 48.10 67 33 1.4888 1.561 14500 15868 15134 
0.000098372 57.67 63 37 1.4997 1.561 14500 15868 15245 
0.000098372 67.21 59 41 1.558 1.561 14500 15868 15837 
0.000098372 76.74 56 44 1.5096 1.561 14500 15868 15345 
0.000098372 86.25 53 47 1.5299 1.561 14500 15868 15552 
0.000098372 95.74 51 49 1.5368 1.561 14500 15868 15622 
0.000098372 105.21 48 52 1.5471 1.561 14500 15868 15727 
0.000098372 114.67 46 54 1.5492 1.561 14500 15868 15748 
0.000098372 124.11 44 56 1.5484 1.561 14500 15868 15740 
0.000098372 142.93 41 59 1.5569 1.561 14500 15868 15827 
0.000098372 200.00 33 67 1.5637 1.561 14500 15868 15896 
Table 2.12. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 
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C Final NiNO3,   
(Final Concentration  of 
Ni(NO3)2),
μM 
[εap – εf ], 
M-1cm-1
[εb – εf ], 
M-1cm-1
C  Final Cu(ClO4)2 /[εap – εf ], 
  M2cm-1
0 0 1368 - 
9.65 254 1368 3.799218*10-8 
19.29 348 1368 5.5431*10-8 
28.91 422 1368 6.85071*10-8 
38.51 554 1368 6.95126*10-8 
48.10 634 1368 7.58675*10-8 
57.67 745 1368 7.74094*10-8 
67.21 1337 1368 5.02693*10-8 
76.74 845 1368 9.08166*10-8 
86.25 1052 1368 8.19867*10-8 
95.74 1122 1368 8.53298*10-8 
105.21 1227 1368 8.57457*10-8 
114.67 1248 1368 9.1883*10-8 
124.11 1240 1368 1.00089*10-7 
142.93 1327 1368 1.07709*10-7 
200.00 1396 1368 1.43266*10-7 
Table 2.13. Titration of 10, 10-BisPyridylPDHD (14) with Ni(NO3)2 in Acetonitrile. 























[C Final Ni(NO3)2], M
y-intersept (1/[εb – εf ])=5.1214*10
-8





Graph 2.5. Graphical Determination of Kb  for titration of 10, 10-BisPyridylPDHD (14) with 
Ni(NO3)2 in Acetonitrile. 
The calculated binding constant (Kb) 8.025*103. 
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2.6.10.d. UV-Vis Absorption Spectroscopy. Titration of 10, 10-BisPyridylPDHD with 













Scheme 2.23. Titration of 10, 10-BisPyridylPDHD (14) with Co(NO3)2 in Acetonitrile. 
V10, 10-BisPyridylPDHD, 




































C  Final NiNO3,  
(Final 








3 0.0000614 0 0.001 0.000614 3.0000 0 1:0 
3 0.0000614 18.4 0.001 0.0000610 3.0184 6.095 1:1 
3 0.0000614 36.8 0.001 0.0000607 3.0368 12.11 1:0.2 
3 0.0000614 55.2 0.001 0.0000603 3.0552 18.06 1:0.3 
3 0.0000614 73.6 0.001 0.0000599 3.0736 23.95 1:0.4 
3 0.0000614 92 0.001 0.0000596 3.0920 29.75 1:0.5 
3 0.0000614 110.4 0.001 0.0000592 3.1104 35.49 1:0.6 
3 0.0000614 128.8 0.001 0.0000589 3.1288 41.17 1:0.7 
3 0.0000614 147.2 0.001 0.0000585 3.1472 46.77 1:0.8 
3 0.0000614 165.6 0.001 0.0000582 3.1656 52.31 1:0.9 
3 0.0000614 184 0.001 0.0000579 3.1840 57.79 1:1.0 
3 0.0000614 202.4 0.001 0.0000575 3.2024 63.20 1:1.1 
3 0.0000614 220.8 0.001 0.0000571 3.2208 68.55 1:1.2 
3 0.0000614 239.2 0.001 0.0000569 3.2392 73.84 1:1.3 
3 0.0000614 257.6 0.001 0.0000565 3.2576 79.07 1:1.4 
3 0.0000614 276 0.001 0.0000562 3.2760 84.25 1:1.5 
Table 2.14. Titration of 10, 10-BisPyridylPDHD (14) with Co(NO3)2 in Acetonitrile. 
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[10, 10-BisPyridylPDHD]=61.4 mM in 3 mL MeCN
Figure 2.44. Titration of 10, 10-BisPyridylPDHD (14) with Co(NO3)2 in Acetonitrile. 
Isobestic point is observed, but the binding constant (Kb) is low 1.1*102. 
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2.6.10.e. UV-Vis Absorption Spectroscopy. Titration of 10, 10-BisPyridylPDHD with 













Scheme 2.24. Titration of 10, 10-BisPyridylPDHD (14) with Fe(NO3)3 in Acetonitrile. 
V10, 10-BisPyridylPDHD, 





















C  Final 10, 10-
BisPyridylPDHD, 
(Final 













C  Final Fe(NO3)3, 
(Final 






/  ν Fe(NO3)3, 
(mol/mol) 
3 0.0000155 0 0.001 0.0000155 3.0000 0 1:0 
3 0.0000155 4.6 0.001 0.0000155 3.0046 1.53 1:0.1 
3 0.0000155 9.2 0.001 0.0000154 3.0092 3.06 1:0.2 
3 0.0000155 13.8 0.001 0.0000154 3.0138 4.59 1:0.3 
3 0.0000155 18.4 0.001 0.0000154 3.0184 6.12 1:0.39 
3 0.0000155 23 0.001 0.0000154 3.0230 7.65 1:0.49 
3 0.0000155 27.6 0.001 0.0000154 3.0276 9.19 1:0.59 
3 0.0000155 32.2 0.001 0.0000153 3.0322 10.71 1:0.69 
3 0.0000155 36.8 0.001 0.0000153 3.0368 12.25 1:0.79 
3 0.0000155 41.4 0.001 0.0000153 3.0414 13.78 1:0.89 
3 0.0000155 46.0 0.001 0.0000153 3.0460 15.31 1:0.99 
3 0.0000155 50.6 0.001 0.0000152 3.0506 16.64 1:1.07 
3 0.0000155 55.2 0.001 0.0000152 3.0552 18.37 1:1.19 
3 0.0000155 59.8 0.001 0.0000152 3.0598 19.90 1:1.28 
3 0.0000155 64.4 0.001 0.0000152 3.0644 21.43 1:1.38 
3 0.0000155 69 0.001 0.0000152 3.0690 22.96 1:1.48 
3 0.0000155 92 0.001 0.0000150 3.092 30.62 1:1.98 
Table 2.15. Titration of 10, 10-BisPyridylPDHD (14) with Fe(NO3)3 in Acetonitrile. 
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[1,1'-DPyDHD]=15.503 mM in 3 mL MeCN
Figure 2.45. Titration of 10, 10-BisPyridylPDHD (14) with Fe(NO3)3 in Acetonitrile. 
No isosbestic point is observed, since the binding constant is not calculated. 
2.6.11. An Attempt of Synthesis of Substituted Cyclohexa[e]pyrene by Diels-Alder Reaction 








DBAHA  = BrH
Br Br
Scheme 2.25. Synthesis of Substituted Cyclohexa[e]pyrene by Diels-Alder Reaction under 
Radical Cation Conditions.  
150 
A solution of pyrene (4) (0.100 g, 0.490 mmol) in 40 mL CH2Cl2 in a two-neck flask equipped 
with a dry ice condenser was sparged with argon. After addition of DBAHA97 the reaction was 
stirred at room temperature until the green color of DBAHA disappeared. After disappearance of 
the green color, 0.060 mL (0.040 g, 0.590 mmol) of isoprene (43) was added. The reaction 
mixture became bright orange. After 1 hour hexane was added to terminate the reaction. The 
solvent was evaporated and the residue was treated with an excess of methanol and stirred. 
Methanol was removed and reaction mixture was checked by TLC. The presence of 9 bands was 
observed.  The products were not analyzed. 
2.6.12. Preparation of Pyrene Monoozonide (4,7-Dihydro-4,7-epoxyphenanthro[4,5-
def][1,2]dioxocin) (35) (Scheme 2.18).90  
A solution of pyrene (7.000 g, 34.610 mmol) (4) in CH2Cl2 (200 ml) was cooled to -70 
0C and 
the stoichiometric amount of ozone was bubbled through. The solution was flushed with N2 to 
eliminate the unreacted ozone and then the solvent evaporated. The residue was 
chromatographed (silica gel, hexane/CH2Cl2 =3:2) to afford pyrene monoozonide as white 
crystals (slightly yellowish (4.00  g, 16.00 mmol, 46 %), which was used immediately in the next 
step without analysis. 
2.6.13. Preparation of Phenanthrene-4,5-dicarboxaldehyde (36) (Scheme 2.18).  
A solution of pyrene monoozonide (2.000 g, 7.990 mmol) (35) and NaI (4.000 g, 26.690 mmol) 
in    90 mL of AcOH was stirred at room temperature for 4 h. Then, saturated Na2S2O3 solution 
was added to reduce the I2 formed, and the mixture was extracted with CH2Cl2. The organic 
layer was washed with NaHCO3 solution, dried over Na2SO4, and concentrated. The precipitated 
4-hydroxyphenanthro[4,5-cde]oxepin-6(4H)-one was removed by filtration, and the filtrate
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chromatographed (silica gel, CH2Cl2) affording phenanthrene-4,5-dicarboxaldehyde, 36, as 
slightly yellow crystals (0.650 g, 2.780 mmol, 34.7%):1H NMR (300 MHz, CDCl3) (Figure 
2.46): δ 10.08 (s, 2H), 8.28 (dd, J = 7.8 Hz, J’ = 1.3 Hz, 2H), 8.22 (dd, J = 7.8 Hz, J’ = 1.3 Hz, 
2H), 7.92 (s, 2H), 7.87 (dd, J = 7.8 Hz, J’ = 7.8 Hz, 2H). 
Figure 2.46. 1H NMR (300 MHz, CDCl3) of Phenanthrene-4,5-dicarboxaldehyde (36). 
2.6.14. Preparation of 4, 5-Divinyl Phenanthrene (37) (Scheme 2.18). 
 Butyllithium (9.10 mmol, 1,7 M in hexane) was added to a tetrahydrofuran (THF, 85 mL) 
solution of methyltriphenylphosphonium bromide (3.030 g, 8.540 mmol) at -78 0C and the 
solution was stirred for 1.5 h at room temperature. To this solution was added a THF (18 mL) 
solution of phenanthrene-4,5-dicarboxaldehyde, 36, (2.000 g, 8.540 mmol) at -78 0C. After 20 h 
at room temperature, the resulting mixture was extracted with 1M HCl aqueous solution          
(60 mL x 5). The combined aqueous layers were neutralized by K2CO3 and extracted again with 
dichloromethane (60 mL x 5). The organic layers were combined, dried over anhydrous Na2SO4 
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and evoparated. The residue was purified by column chromatography on silica (ethyl 
acetate/hexane=2/5) to give 4, 5-divinyl phenanthrene, 37, as colorless crystals (0.700 g, 3.040 
mmol, 33% yield): mp 168.0-172.0 0C; 1H NMR(500 MHz, CDCl3) (Figure 2.47): δ 8.41 (dd, J 
= 7.5 Hz,  J’ = 1.5 Hz, 2H), 8.17 (dd, J=7.5 Hz, J’ = 1.5 Hz, 2H), 8.00 (dd, J=7.8 Hz, J’ = 1.4 
Hz, 2H), 7.82 (s, 2H), 7.80 (dd, J=7.5 Hz, J’ = 7.5 Hz, 2H), 7.71 (dd, J = 7.8 Hz, J’ = 7.8 Hz, 
2H), 7.66 (dd, J = 7.8 Hz, J’ = 1.4 Hz, 2H); 13C NMR (75 MHz, CDCl3) (Figure 2.48 a, b) δ 
171.0, 133.6, 133.2, 132.9, 132.5, 129.7 (2C), 129.2, 127.4 (3C), 127.3, 127.1, 126.8; 1H-1H 
COSY NMR (500 MHz, CDCl3) (Figure 2.49 a, b); 
1H-13C HSQC NMR (500 MHz, CDCl3) 
(Figure 2.50 a, b);     1H-13C HMBC NMR (500 MHz, CDCl3) (Figure 2.51 a, b). 
















Figure 2.51 (a, b). 1H -13C NMR HMBC (500 MHz, CDCl3) of 4, 5-Divinyl Phenanthrene (37). 
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2.6.15. Preparation of 4,5-Ethano-4,5-dihydropyren (25) (Scheme 2.18). 
A solution of 4, 5-divinyl phenanthrene (0.500 g, 2.170 mmol) (37) in 150 mL of anhydrous 
benzene was irradiated for 14 h with 400 W high-pressure mercury lamp through a Pyrex filter 
under a nitrogen atmosphere. The solvent was removed and the residue was chromatographed on 
silica gel. Elution with cyclohexane gave 4,5-ethano-4,5-dihydropyren (25) (0.200 g, 0.870 
mmol, 40 % yield). Recrystallization of this chromatography fraction from ethanol gave an 
analytically pure sample of 4, 5-ethano-4,5-dihydropyren (25): mp 97.8-98.3 0C; 1H NMR (500 
MHz, CDCl3) (NMR signals were identical to that published in reference 75): δ 7.64 (dd, J = 
6.4, J‘ = 1.5 Hz, 2H), 7.67 (s, 2H), 7.54 (dd, J = 7.5 Hz, J‘ = 7.5 Hz, 2H), 7.31 (dd, J= 5.6, J‘ = 
1.4 Hz, 2H), 4.07 (m, 2H), 2.67 (m, 2H), 2.25 (m, 2H); 13C NMR (75 MHz, CDCl3) (NMR 
signals were identical to the published in reference 75): δ 137.8,134.2, 131.3, 131.1, 
127.0,126.9,126.0,36.8,31.7; IR (KBr) 2932, 1446, 1173, 831, 765,729 cm-1; UV (λmax (nm) (log 
ε)), 224.2 (4.72), 267.6 (4.56), 301.2 (4.10).  
2.6.16. Preparation of Dihydrocyclobuta[e]Pyrene (20) (Scheme 2.18).75
A round bottom flask was charged with 4,5-ethano-4,5-dihydropyren (25) (0.100 g, 0.430 
mmol), DDQ (0.195 g, 0.860 mmol) in 100 mL of benzene. The reaction mixture was stirred and 
heated at 90°C for 24 h, being monitored by TLC. Then, after the mixture had been cooled, 
benzene is removed under vacuum, dichloromethane was added to the resulting solid and this 
solution was filtered through celite. The filtrate was evaporated under reduced pressure and 
dihydrocyclobuta[e]pyrene (20) was obtained as white crystals ( 0.068 mg, 0.300 mmol, 70 % 
yield): mp 171.0-171.8 0C; 1H NMR(500MHz, CDCl3) (500 MHz, CDCl3) (NMR signals were 
identical to the published in reference 75): δ 8.15 (dd, J = 7.1 Hz, J = 1.8 Hz, 2H), 8.07 (dd, J = 
7.4, 1.8 Hz, 2H), 8.06 (s, 2H), 8.03 (dd, J = 7.0 Hz, J = 7.0 Hz, 2H), 3.60 (s, 4H); 13C NMR(75 
158 
MHz, CDCl3) (500 MHz, CDCl3) (NMR signals were identical to the published in reference 75): 
δ 140.6 (2 C, C4), 132.0 (2 C, C10a), 127.7 (2 C, C3a), 127.5 (2 C, C9), 125.6 (2 C, C2), 124.6 
(2 C, C10b), 124.4  (2 C, C1), 119.2 (2 C, C3), 28.3 (2 C, CCB); IR (KBr) 2914, 1602, 1179,828, 
756,714 cm-1; UV (λmax (nm) (log ε)), 243.9 (4.45), 267.9 (4.31), 278.4 (4.43), 327.6 
(4.30),343.2 (4.38); MS (M.+) m/z 228.  
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CHAPTER 3. INTRODUCTION. INVESTIGATION OF RETRO-SCHÖNBERG-
MUSTAFA REACTION OF SUBSTITUTED PYRENE DIHYDRODIOXINS(PDHD). 
Since its discovery in the 1920s,1 the nature of the transition state (TS) and the mechanism of the 
Diels-Alder reactions have remained the subject of intensive experimental and theoretical studies 
and debates.2,3 In principle, there are two possible reaction mechanisms involving different TS 
structures:4-11 a concerted mechanism, where the two bonds in the TS are formed in one step, at 
the same time (if at different times, then it is concerted asynchronous), or a stepwise mechanism 




















Figure 3.1.a. Schematic of the Reaction Path as the Length R of the Two Bonds Changes in the 










Figure 3.1.b. Cut Along the Potential Energy Surface Depicting the Two Reaction Coordinates 
and their Energetics. The Energy of the Diradical Pathway (dashed) is Adapted from ref. 2. 
In Chapter 2.3, we introduced some aspects of radical cation chemistry. In its simplest form, the 
mechanism of radical cation mediated cycloadditions starts with one of the addends undergoing 
electron transfer to a one-electron oxidant (Equation 3.1) with formation of radical cation X
+.
. 
This radical cation X
+. 
then reacts with Y with formation another radical cation XY
+.. After 
back-electron transfer (BET) the final product of cycloaddition product XY is formed.  
X +Y X      +Y XY XY+e-e   
Equation 3.1. Chemical Pathway for Radical Cation Diels–Alder reaction. 
Radical cation Diels–Alder reactions are generally considered to be stepwise reactions,12–14 as 
demonstrated by experimental15, 16 and   computational17–31 studies. The stepwise mechanism is 





electron to the antibonding orbital in the case of radical anions), weakening the bond and making 
the bond easier to break. At the same time, the concerted radical cation pathway becomes 
energetically less favorable, because the concerted transition state is no longer subject to 
aromatic stabilization on account of an odd number of electrons. The symmetry preserving 
pathway is subject to Jahn–Teller distortions that increases the activation energy.24, 32 The overall 
result is an acceleration of slow or symmetry forbidden cycloadditions,33–35 electrocyclic 









Scheme 3.1. Thermodynamic Representation of Radical Cation Cycloaddition Reaction 
Acceleration. 
An explanation for the increased reaction rates observed for radical cation Diels–Alder reactions 
has been proposed by Bauld and is shown in Scheme 3.1.47 The butadiene cation radical is 
formed by removing an electron from the HOMO of the diene, which is according to Koopman’s 
theorem48 equal to the ionization energy (IE). This radical cation reacts with neutral ethylene 
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forming the distonic, acyclic radical cation. The energy gained from BET to form the acyclic 
diradical is of equal magnitude to the ionization energy required to remove an electron from the 
nonbonding 2p atomic orbital of a carbon in a hypothetical 1, 6-diradical. Because the electron is 
removed from a nonbonding orbital, the IE required is much smaller than the energy initially 
required to remove an electron from the π-bonding molecular orbital of the butadiene. 
Recently for retro-Diels-Alder reaction femtosecond (fs) transient, real-time studies of formation 
of norbornene (NB) and norbornadiene (NBD), products of the cycloaddition of cyclopentadiene 
with ethylene and acetylene, were performed.49 The reactions were studied in a molecular beam 
in order to isolate the elementary processes, free of solvent perturbations.50 The dynamics of the 
reaction from a well-defined initial geometry, a precursor of Diels-Alder products, were 
examined. The fs-resolved mass spectrometry experiments allowed studying the transition of 
reactants to final products. For NB, there are only two peaks present: one at mass 94 amu 
corresponding to the precursor NB species and another at mass 66 amu corresponding to the 
“cyclopentadiene” intermediate. These observations are consistent with the retro-Diels-Alder 
products found in thermal,51 photochemical,52 and shock-wave53 studies. For NBD, three peaks 
were observed, two representing the parent and intermediate and the third one for the parent 
minus 1 amu corresponding to the hydrogen elimination channel. 51, 52, 54 From these data it is 
obvious that transient spectroscopy is powerful tool for studying retro-Diels-Alder reaction 




3.1. O-QUINONE RELEASE. INVESTIGATION OF RETRO-SCHÖNBERG-MUSTAFA 
REACTION (QUANTUM YIELDS AND FEMTOSECOND TRANSIENT 
SPECTROSCOPY STUDIES).  
The reversibility of the masking o-quinone shown on the Scheme 2.6 (Chapter 2) and based on 
the analog of Diels-Alder reaction, the Schönberg-Mustafa reaction, was studied by Mack and 
co-workers et al.55a-c Photochemical decomposition of [3-(4-{10-[4-(3-trimethylaminopropoxy)-
phenyl]10,11-dihydro-9,12-dioxabenzo[e]pyren-10-yl}-phenoxy)propyl] trimethylammonium 
dichloride salt (PDHD) (1) (Figure 3.2) revealed that the relative quantum yields for o-qiunone 










    
Figure 3.2. [3-(4-{10-[4-(3-Trimethylaminopropoxy)phenyl]-10,11-Dihydro-9,12-
Dioxabenzo[e]Pyren-10-yl}phenoxy)propyl] Trimethylammonium Dichloride Salt (PDHD) 1. 
The initial quantum yield for o-quinone release in CCl4 is 0.078 ± 0.003, 23 times more efficient 
than that in benzene, and the isolated/purified yield of 3 is 78% (Scheme 3.2). Direct excitation 
of 1 with UV light also leads to the formation of radical cation 4 by photochemical electron 
ejection-photoassisted electron transfer (PET). This process can be observed by transient 
absorption spectroscopy. In the case of 4, the band at λ max = 453 nm, due to the to the pyrene 
radical cation, was observed by transient absorption spectroscopy in different solvents.55a The 
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reported lifetime of photochemically generated 4 tends to be much shorter than when it is 
generated using the DBAHA method. This is certainly due to the occurrence of reverse electron-







































Scheme 3.2. O-Quinone Release Mechanism from PDHD. 
3.1.1. Photochemical Decomposition of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4. 
The synthesized derivatives of 10,11-DiPyridinePDHD and pyridine substituted 
cyclohexa[e]pyrene (5, 6, 7, 8) (Figure 3.3), also, have the same electron transfer feature. The 
positive charge on the quaterniary nitrogen works as a charge “stabilizer” for the electron 
donated from the pyrene to form the pyrene cation during photochemically induced electron 
transfer (ET). The pyrene ring plays the role of a photoactivated electron donor group and the 
pyridinium rings are electron acceptors. Intramolecular electron transfer between them is 
indicated with arrows in Figure 3.3. The metal complexes of 10, 10-BisPyridylPDHD (9, 10, 11 
and 12) also contain a “charge stabilizing”-transition metal in a high oxidation state. In the case 





pyridinium ring and then to the metal ion may occur (Figure 3.3). This property of pyridinum 
and pyridine substituted PDHD to undergo intramolecular charge transfer should facilitate 









































Figure 3.3. ET in Derivatives of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4, 10, 10-
DiPyridinePDHD metal complexes and Pyridine Substituted Cyclohexa[e]Pyrene. 
The products of retro-Schönberg-Mustafa reaction of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-
EA-Electron Acceptor Group 
EA-Electron Acceptor Group 
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BF4 and 10,10-DiPyridinePDHD after irradiation at 334 nm were separated and analyzed.  
Reversed-phase HPLC showed presence of four products in case of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5). These were collected and analyzed by NMR. These products 
(Scheme 3.3) are o-quinone (3), dimethyl cis-1,2-di(4-pyridinium)ethylene tetrafluroborate (13), 
dimethyl trans-1,2-di(4-pyridinium)ethylene tetrafluroborate (14), and 1,10-Phenanthrolinium 


























Scheme 3.3. Products of Photochemical Decomposition of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) Separated by HPLC (Column-Phenomenex
® Hypersil 50DS       
250 x 4.6 mm, Mobile Phase Composition-40 mM KH2PO4 (pH = 4)/Methanol = 40/60
56). 
Quantum yields for release of 3 from N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) via 
photodecomposition were determined from a decrease in intensity of the absorption band at 345 













5 CW He-Cd Buffer 442 No K3[Fe(C2O4)3] 0.0170 





Buffer 325 Yes K3[Fe(C2O4)3] 3.2* 
9 CW He-Cd Acetonitrile 325 Yes K3[Fe(C2O4)3] 28.9 
10 CW He-Cd Acetonitrile 325 Yes K3[Fe(C2O4)3] 0.4 
11 CW He-Cd Acetonitrile 325 Yes K3[Fe(C2O4)3] 0.9 




CW He-Cd Acetonitrile 325 Yes K3[Fe(C2O4)3] 11.4 
Table 3.1. Quantum Yields for DHD’s (Continuous wave He-Cd laser, Pulsed Ti:sapphire- Pulse 
Ti:sapphire Laser, Buffer-Cacodylic Buffer (Sodium Cacodylate Trihydrate-10 mM,   NaCl-0.5 mM, 
EDTA-0.5 mM, pH = 7.1)). *- see experimental part. 
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The ultrafast time-resolved absorption spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 
(5) in acetonitrile and cacodylic buffer at pump/probe wavelengths 350/340-615 nm were
measured between 0 and 1200 ps time delays (Figure 3.4, 3.5 and 3.6). Two absorption bands 
centered at 450 and 530 nm form within the instrumental response time of 250 fs. In Mack’s 
work it was observed that the PDHD radical-cation 4 species with absorption maxima at ca. 
450-455 nm was very long-lived in acetonitrile, τ = 6.3 μs.55a In ultrafast experiments with
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) in acetonitrile and cacodylic buffer, 2 ps 
time range (Figure 3.5) and 500 ps time range (Figure 3.6), the 450 nm band persists into the ms 
time domain. In acetonitrile and cacodylic buffer the 450 nm absorption band of N,N-Dimethyl 
10, 11-DiPyridiniumPDHD-BF4 (5) forms within the excitation pulse (0.3 ps). The 450 nm band 
in transient spectra of PDHD  in acetonitrile 55a  and the 450 nm absorption band in transient 
spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) in acetonitrile and cacodylic 
buffer are similar, since the 450 nm absorption band  in ultrafast time-resolved absorption 
spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) was assigned to the pyrene radical-
cation of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5). In cacodylic buffer, the 
instantaneously formed 530 nm absorption decays within 6 ps forming a long-lived (μs time 































































































A  B 
Figure 3.4. Transient Absorbtion Spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
in Acetonitrile (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) Concentration 12 μM) (A) 
and Cacodylic Buffer (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) Concentration 24 μM) 
(B) ) (λ probe = 340-615 nm, λ pump = 350 nm, E = 7 µJ/pulse, ND = 0.03, 1 mm flow cell).
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 5 in Cacodylic Buffer





Figure 3.5. Short-Time Transient Absorption Spectra of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Acetonitrile (Concentration 12 μM) and Cacodylic Buffer (N,N-
Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) (Concentration 24 μM) (λ probe = 340-615 nm, 
λ pump = 350 nm, E = 7 mJ/pulse, ND = 0.03, 1 mm flow cell). 
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 5 in Cacodylic Buffer
 5 in ACN
 ACN
500 ps
Figure 3.6. Long-Time Transient Absorption Spectra of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Acetonitrile (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
Concentration 12 μM) and Cacodylic Buffer (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
Concentration 24 μM) (λ probe = 340-615 nm, λ pump = 350 nm, E = 7 µJ/pulse, ND = 0.03, 1 
mm flow cell). 
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Both bands of 450 and 530 nm in ultrafast time-resolved absorption spectra of N,N-Dimethyl 10, 
11-DiPyridiniumPDHD-BF4 in cacodylic buffer have the very similar behavior within the first
10 ps. The three exponential fits of ∆A kinetic traces performed at 450 and 530 nm to 
characterize the temporal evolution of transient species derived from N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 are shown in Figure 3.7 and Figure 3.8, respectively. The decay 
parameters for the 450 nm and 530 nm transients using the triple exponential mode: ∆Αabs = A0 
+ A1 *exp(-t/τ1) + A2 *exp(-t/τ2) + A3 *exp(-t/τ3) are summarized in Table 3.2.










Figure 3.7. Three-Exponential Fitting of the 450 nm Band of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Cacodylic Buffer (24 μM) (λ probe= 450 nm (single kinetics), 
1 mm flow cell, λ pump = 350 nm, E = 7 µJ/pulse, ND = 0.03). 
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Figure 3.8. Three-Exponential Fitting of the 530 nm Band of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Cacodylic Buffer (24 μM) (λ probe= 530 nm (single 
kinetics), 0.2 mm flow cell,    λ pump = 350 nm, E = 7 µJ/pulse, ND= 0.03). 
∆Amax 
(nm) A0 (%) A1 (%) t1 (ps) A2 (%) t2 (ps) A3 (%) t3 (ps) 
450 5.6±0.07 92±1 1.28±0.02 1.4±0.1 6.3±0.6 0.5±0.1 115±11 
530 8.5±0.2 56±3 0.94±0.07 28±3 4.4±0.5 8.5±0.5 93±11 
Table 3.2.  Decay Parameters for the 450 nm and 530 nm Transients Using the Three 
Exponential Model: ∆Aabs = A0 + A1 *exp(-t/t1) + A2 *exp(-t/t2) + A3 *exp(-t/t3). 
After analysis of transient absorption spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 
(5) in cacodylic buffer, it was proposed, that the second transient absorption band with a
maximum at 530 nm corresponds to the pyridine radical fragment (Figure 3.9).  
181 
Figure 3.9. Band assignment in transient absorbtion spectra of
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) in Cacodylic Buffer (Concentration of N,N-
Dimethyl 10, 11-DiPyridiniumPDHD-BF4 is 24 μM). 
Moreover, it was noticed that up to ca 3 ps, the 450 nm band (radical-cation) and 530 nm band 
(pyridine radical) decay simultaneously. Therefore, at the short time (< 3 ps) the direct charge 
recombination process is observed. Then, the 530 nm band transforms into a broad absorption 
signal in the range 500-610 nm. It is known that solvated electron in water has a broad 
absorption in a red part of visible range.57-59 Due to the fact that water is a good electron acceptor 
(Part 1.4.1, Figure 1.11, Chapter 1), it was assumed that the re-shaping of 530 nm band into the 
broad absorption signal corresponds to the ET from the pyridine radical to the bulk water on the 
timescale of several picoseconds. Thus, at the long times transient absorption signals can be 


















































of the formation of solvated electron due to the double photon excitation of water because of the 
timescale for the band appearance in transient spectra (< 10 ps).  In acetonitrile solution the 530 
nm band does not transform into a broad signal as in water. At times longer than 6 ps it becomes 
a peak centered at 475 nm (Figure 3.6). Simultaneous decay of these two signals can be 
explained by a charge transfer of electron from the water (solvated electron) to the pyridine 
radical-cation.  
The following mechanism for photolysis of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
(Scheme 3.4.) can be proposed. Excitation of 5 at a 350 nm wavelength leads to rapid formation 
of the species with pyrene radical-cation and radical on pyridine (16) within 1 ps with absorption 
bands centered at 450 nm and 530 nm, respectively (Path 1). Back electron transfer (BET) can 
lead back to 5. Also, once formed, 16 has two pathways of decay: the major pathway (Path 3) is 
ET from pyridine radical to water producing solvated electron and to pyrene radical-cation (17) 
which annihilates within 100 ps to reform 5 (Path 4), and the minor pathway (Path  2), which is 







































































Scheme 3.4. Proposed Mechanism for Photolysis of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-




















Scheme 3.5. Release of o-Quinone (3) from N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5). 
 In order to investigate the hypothesis about the mechanism of photochemical decomposition 
shown in Figure 3.4, to discern the nature of the band at 535 nm, and to confirm that it belongs to 
the pyridinium radical, we performed an experiment similar to the experiment designed by Viera 
et al.60 For this purpose we selected dimethyl 1, 2-dipyridinium ethane ditetrafluoroborate 
(Dimethyl 1, 2-DiPyEt) (18). Photoinduced electron transfer (PET) between duroquinone (DQ) 
(19), 1,4-diazabicyclo[2.2.2]octane (DABCO) (20) and Dimethyl 1, 2-DiPyET-BF4 (18) and 
DABCO (20) (Figure 3.10 and Scheme 3.6) is possible upon radiation at 330 nm. The transient 
absorption spectroscopy experiment was performed in these systems in acetonitrile and water 

















Figure 3.10. Dimethyl 1, 2-Dipyridinium Ethane Ditetrafluoroborate (Dimethyl 1, 2-DiPyEt-
BF4) (18), Duroquinone (DQ) (19), 1,4-Diazabicyclo[2.2.2]Octane (DABCO) (20). 
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The possible photo-induced reactions are presented on Scheme 3.6. Each time we have only two 
components in the mixture in order to exclude side processes and avoid band overlapping. We 
had three solutions: 1) Acceptor (DQ) (19) + Donor (DABCO) (20), 2) Acceptor (DQ) (19) + 
Probe Dimethyl (Dimethyl 1, 2-DiPyEt-BF4) (18) and 3) Donor (DABCO) (20) + Probe 
(Dimethyl 1, 2-DiPyEt) (18). The possible photo-induced reactions are presented on Scheme 3.6. 
The transient spectra were recorded for each solution upon excitation at 330 nm, which is close 
to a 350-nm excitation wavelength used in the transient absorption spectroscopy experiments 
with 10, 11-DiPyridiniumPDHD-BF4 (5). The transient absorption spectra for each solution are 
presented on Figures 3.11, 3.12, 3.13.  
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Scheme 3.6. Possible Photo-Induced Electron Transfers Between (1) Acceptor (19) -Donor (20) 





























Figure 3.11. Transient Spectra of Acceptor (DQ (19)) + Donor (DABCO) (20) in Solvent       
(H2O Cacodylic Buffer:ACN = 1:1) (Concentration of DQ (19) 40 mM, Concentration of 






























Figure 3.12. Transient Spectra of Acceptor (DQ (19)) + Probe (Dimethyl 1,2-DiPyEt-BF4) (18) 
in Solvent (H2O Cacodylic Buffer:ACN = 1:1) (Concentration of DQ (19) 40 mM, 
Concentration of (Dimethyl 1,2-DiPyEt-BF4) (18) 40 mM, λ pump = 330 nm, λ probe = 340-615 
































Figure 3.13. a). Steady State UV Absorption Spectra of Probe (Dimethyl 1,2-DiPyET-BF4) (18) 
and Donor (DABCO (20)) + Probe (Dimethyl 1,2-DiPyET-BF4) (18) b). Transient Spectra of 
Donor (DABCO (20)) + Probe (Dimethyl 1,2-DiPyET-BF4) (18) in Solvent (H2O Cacodylic 
Buffer:ACN = 1:1) (Concentration of DABCO (20) 40mM, Concentration of (Dimethyl 1,2-
DiPyEt-BF4) (18) 40 mM, λ pump = 330 nm, λ probe = 340-615 nm, 2.4 mJ after the Berek 
polarizer, 2 mm rotating cuvette). 
















Laser flash photolysis (LFP) of DQ (19) with DABCO (20) generates the transient spectra of the 
DQ
-.
 (455 nm + 475 nm) (Figure 3.11). Similarly, LFP of DQ (19) with dimethyl 1, 2-DPiET
(21) can generate  the DQ
-.
 (455 nm and 475 nm) (Figure 3.12). The most valuable results are
coming from Figure 3.13- LFP of Dimethyl 1, 2-DPyEt (18) and DABCO (20).  LFP can 




. The transient spectra indicates the presence of
the band at 530 nm, which is similar to the band in transient absorption spectra of 10, 11-
DiPyridiniumPDHD-BF4  in cacodylic buffer  (Figure 3.4 A, 3.5, 3.6). Consequently, this 530 
nm band has been assigned to the pyridine radical in the electronically reorganized version of 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (16). 
A N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) cacodylic buffered solution with added HS 
DNA (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5)/HS DNA base pair = 1/20) (Figure 
3.14) was examined by transient absorption spectroscopy. This transient absorption spectra has 
many similarities to that of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) without DNA. 
Two absorption bands of 455 nm and 535 nm appear within the excitation pulse, 0.3 ps, and 
decay within 10 ps. The 535 nm band disappears within ca 6 ps, and the 455 nm band decays 
much more rapidly in the presence of DNA, ca. 10 ps, than in the absence of DNA, >1000 ps. 
Fitting of a triple exponential equation to this decay affords three components with time 
constants of 0.4, 2.2, 48.4, and a double exponential equation affords two components with time 
constants of 0.5, 22.9 ps (450 nm)). Such behavior can be explained by the ET from pyridine 
radical to DNA (reduction of DNA) and, also, by the electron transfer from DNA to the pyrene 














































Figure 3.14. Transient Absorbtion Spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
with DNA in Cacodylic Buffer (N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
Concentration 0.615 μM, HS DNA Concentration 12.3 μM, N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4(5)/DNA base pair = 1/20) (λ probe = 340-615 nm, λ pump = 350 nm,     
E = 7 µJ/pulse, ND = 0.03, 1 mm flow cell). 
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3.1.2. Photochemical Decomposition of 10, 10-BisPyridylPDHD and [Cu2+(10, 10-
BisPyridylPDHD)](ClO4)2 (9). 
Among the metal complexes of 10, 10-BisPyridylPDHD, the complex of 10,10-BisPyridylPDHD 
and copper(II) (9) has the highest quantum yield, 28.9% for o-quinone (3) release (calculated 
binding constant Kb= 11.08x10
4) (Table 3.1). This high quantum yield can be explained by the 
presence Cu in oxidation state 2+, which can be transformed into its 1+ oxidation state by the 
photochemically-induced ET from the pyrene moiety. The Cu1+ (10, 10-BisPyridylPDHD
.+
)
complex formed should be stable. Strong experimental evidence exists from 
crystallographic,61, 62 electrochemical,63, 64 and spectroscopic65 ,66 studies that significant inner-
sphere reorganizational changes accompany copper (II/I) redox processes. CuI(LL)+ compounds, 
where (LL) is a bipyridine or phenanthroline derivative, have d 10 electronic configurations and 
generally adopt pseudo-tetrahedral geometries.61 In this oxidized state, Cu(II) has a d 9 electronic 
configuration and the chelating ligands adopt a more planar geometry, often with a fifth, Jahn-
Teller distorted, axial ligand derived from solvent or a counterion, resulting in a distorted square 
pyramidal or trigonal bipyramidal geometry.62 Such charge separation is observed to be long-
lived.67  
The transient absortion spectra of pure 10, 10-BisPyridylPDHD at an excitation wavelength of 
325 nm and time delays up to 1 nanosecond afforded two broad bands at 375 nm and 475 nm, 
which, probably belong to the species formed by ET processes from the pyrene ring to the 
pyridine rings.  
Deconvolution of these band at 0.5 ps (Gaussian fit) shows presence of, at least, five different 
species centered at 370, 385, 450, 475, and 530 nm (Figure 3.15).  
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 0.5 ps 
 Gauss fit peak at 450 nm
 Gauss fit peak at 475 nm
 Gauss fit peak at 530 nm
 Gauss fit peak at 385 nm
 Gauss fit peak at 375 nm
10,10-Bis2pyridylPDHD-Cu2+ in ACN
∆A
Figure 3.15. Deconvolution of 350-600 nm Bands (Gaussian fit) of the 500 fs Absorption 
Spectrum of 10, 10-BisPyridylPDHD in Acetonitrile. 
Short-time (0.3 to 10 ps) transient absorption spectra of 10, 10-BisPyridylPDHD show only 
minor changes (Figure 3.16, 3.17). The 375 and 475 nm bands rise with a lifetime 8 ps 
accompanied by a minor decay at 400 (τ~10 ps) and 530 (τ~3 ps) nm. The band at 375 nm in the 
long-time transient absorption spectra (10 ps to 1 ns) does not change in intensity, whereas the 
475 nm band and two shoulders at 400 and 530 nm decay simultaneously with the same lifetimes 
of 1.5±0.3 ns.  
In transient absortion spectra of [Cu2+(10, 10-BisPyridylPDHD)](ClO4)2 (9) in acetonitrile, we 
observed the pyrene radical cation band at 450 nm which persists  for >500 ps,  a broad signal 
from 360 to 500 nm and a shoulder at 530 nm (Figure 3.16, 3.17). The broad band between 360 
and 500 nm decays double-exponentially with time constants around 1 ps and 20 ps, the peak at 
450 nm (shorter timescale) decays with two exponentials with a time constants τ1~32 ps and 
τ2~1 ns and the shoulder at 530 nm band decays with a time constant around 1 ps. Transient 
absorption spectra at longer timescales display a sharp peak at 450 nm and a broad band from 
380 to 420 nm. 
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 10, 10-BisPyridylPDHD in ACN
 9 in ACN
 ACN



























Figure 3.16. Short-Time Transient Absorption Spectra of
10, 10-BisPyridylPDHD and [Cu2+(10, 10-BisPyridylPDHD)](ClO4)2 (9) in Acetonitrile. 
(Concentration of 10, 10-BisPyridylPDHD 70 μM, Concentration of [Cu2+(10, 10-
BisPyridylPDHD)](ClO4)2 (9) 70 μM, λ pump = 325 nm, λ probe = 340-615 nm, ND = 0.03, 2 
mm rotating cuvette). 
Wavelength (nm) 
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 10, 10-BisPyridylPDHD in ACN




Figure 3.17. Long-Time Transient Absorption Spectra of
10, 10-BisPyridylPDHD and [Cu2+(10, 10-BisPyridylPDHD)](ClO4)2 (9) in Acetonitrile 
(Concentration of 10, 10-BisPyridylPDHD 70 μM, Concentration of [Cu2+(10, 10-
BisPyridylPDHD)](ClO4)2 (9) 70 μM, λ pump = 325 nm, λ probe = 340-615 nm, ND = 0.03, 2 
mm rotating cuvette). 
Wavelength (nm) 
195 
It was shown that the spectra of 10, 10-BisPyridylPDHD, Figure 3.15, is rather complicated and 
can be presented as a sum of five Gaussian functions. Both peaks at 375 nm and 475 nm are 
broad and can be assigned to different species. A triplet state of 10, 10-BisPyridylPDHD might 
be associated with a broad band at 375 nm. The presence of the broad peak at 475 nm are 
assigned to the pyrene radical cation species 21 or 22 (Scheme 3.7). The possible mechanisms of 
photodecomposition of 10, 10-BisPyridylPDHD are presented in Scheme 3.7. Path 1 involves 
formation of charge separated state 21 (pyrene radical cation and pyridine radical anion) of 10, 
10-BisPyridylPDHD via electron transfer (ET) from pyrene to pyridine ring followed by the
formation of a conjugated state 22. Path 2 involves formation of triplet state species 23. Further 


























Scheme 3.7. The Possible Mechanism   of o-Quinone (3) Release from 10, 10-BisPyridylPDHD.  
The possible mechanism of photodecomposition of [Cu2+(10, 10-BisPyridylPDHD)](ClO4)2 (9) 






the 530 nm band formed via electron (ET1) from pyrene ring to pyridine ring. Electron transfer 
(ET2) from pyridine radical anion to Cu2+ leads to formation of a long-lived Cu+1 radical cation 
species (25), the sharp peak at 450 nm. The further decomposition and quinone release is 
presented by Path 1 and Path 2. 
Scheme 3.8. The Possible Mechanism of o-Quinone (3) Release from [Cu2+(10, 10-




BET ET1 and ET2 - intramolecular
Electron Transfer 
BET - intramolecular

































































3.2. THEORETICAL CALCULATIONS OF N,N-DIMETHYL 10, 11-
DIPYRIDINIUMPDHD-BF4 (5), 10, 11-DIPYRIDINIUMPDHD-BF4 RADICAL CATION 
(16) AND 10, 10-BISPYRIDYLPDHD.
The CASPT2//CASSCF68, 69 calculations of the vertical excitation transitions (VET’s) and the 
corresponding oscillator strengths (f) were performed for N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) (Table 3.3, Figure 3.18) and N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 radical cation (16) (Table 3.3, Figure 3.19). The obtained 
CASPT2//CASSCF vertical excitations of the N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
show that the lowest energy transition corresponds to the S0 → S2 with an oscillator strength of  f  
= 0.0008 (λmax = 400 nm). The transition centered at λmax = 315 nm (f  = 0.0077) is referred to as 
S0 → S5. In turn, the highest energy transition, S0 → S8 (π, π*), is centered at λmax = 269 nm (f = 
0.0188) (Table 3.3). The S2, S5 and S8 states are (π, π*). Table 3.2 also shows the experimental 
absorption maxima and VET’s and oscillator strengths (f) obtained at the TD-M052X/cc-pVDZ 
level of    theory70 for N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5). S0 → S2 (π, π*) with 
oscillator strength 0.0342 is the lowest energy transition, the transition at 344 nm corresponds to 
S0 → S5 (π, π*) (f = 0.0183) and the transition at 252 nm refers to S0 → S8 (π, π*) (f = 0.2930). 
By comparison of the two methods of calculation, we found the TD-M052X/cc-pVDZ method to 
be more accurate than CASPT2//CASSCF(12,12)/6-31G*. 
The results obtained for N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 radical cation (16), 
based on CASPT2//CASSCF calculations, show that the energy transition corresponds to 
S0 → S4 (π, π*) with oscillator strength f =0.3726 (λmax = 439 nm) (Table 3.3).  
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Absorption maxima, VET’s and oscillator strengths for various species of 16, triplet biradical 
cation (26), singlet biradical cation (27) and, also, for pyridinium radical (28) (Figure 3.20) were 
calculated using the TD-M052X/cc-pVDZ level of theory (Table 3.3, Figure 3.21).  
According to the TD-M052X/cc-pVDZ level of theory the transition at 329 nm corresponds to 
S0 → S2 (π, π*) (f = 0.2668), the transition at 293 nm corresponds to S0 → S4 (π, π*) (f = 0.1934) 
and the transition at 250 nm to S0 → S7 (π, π*) (f = 0.4156) (Table 3.3).  
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Species λ, (nm)- 
CASPT2//CASSCF(12,12)/
6-31G*







5 S2 (400 nm) (0.0008)
S5 (315 nm) (0.0077) 
S8 (269 nm) (0.0188) 
S2 (331 nm) (0.0342) 
S5 (268 nm) (0.0183) 
S8 (252 nm) (0.2930) 
S2 (344 nm) 
S5 (282 nm) 
S8 (243 nm) 
16 
26 (triplet biradical) 
27 (singlet biradical) 
28 (radical) 
S4 (439 nm) (0.3726) S4(403 nm) (0.2914) 
S6(534 nm) (0.0792) 
S9(402 nm) (0.2263) 
S4(351 nm) (0.0225) 
S6(329 nm) (0.0369) 
S3(564 nm) (0.0072) 




- S2 (329 nm) (0.2668) 
S4 (293 nm) (0.1934) 
S7 (250 nm) (0.4156) 
S2 (347 nm) 
S4 (283 nm) 
S7 (242 nm) 
Table 3.3. Vertical Excitation Transitions, Oscillator Strengths and Absorption Properties of 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5), N,N-Dimethyl 10, 11-DiPyridiniumPDHD-
BF4 Radical Cation (16) and 10, 10-BisPyridylPDHD in Water Computed at the 
CASPT2//CASSCF(12,12)/6-31G* and TD- M052X/cc-pVDZ Levels of Theory. 
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Figure 3.18. The Diagonal Elements of the First-Order Density Matrix Reflecting the 
Occupancies of the Molecular Orbitals Included in the Active Space of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) (S, S-isomer) Calculated at the CASSCF(12,12)/6-31G* level of 
theory. These CASSCF(12,12)/6-31G* Molecular Orbitals are Displayed on the Top of Each 
Frame.  
Figure 3.19. The Diagonal Elements of the First-Order Density Matrix Reflecting the 
Occupancies of the Molecular Orbitals Included in the Active Space of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (S, S-isomer) Radical Cation (16) Calculated at the
CASSCF(12,12)/6-31G* Level of Theory. These CASSCF(12,12)/6-31G* Molecular Orbitals 
are Displayed on the Top of Each Frame.    
(2)(1) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12)
(2) (2) (1) (2) (2) (2) (1) (0) (0) (0) (0) (0)S2
(2) (2) (1) (2) (2) (2) (0) (0) (1) (0) (0) (0)S5
(2) (2) (2) (2) (2) (1) (0) (1) (0) (0) (0) (0)S8
(2) (2) (2) (2) (2) (2) (0) (0) (0) (0) (0) (0)S0
HOMO LUMO 
(6)(1) (2) (3) (4) (5) (7) (8) (9) (10) (11) (12)
(2) (0) (2) (2) (2) (2) (1) (0) (0) (0) (0) (0)S4 
















Figure 3.20. Triplet Biradical Cation (26), Singlet Biradical Cation (27) and Pyridinium Radical 
(28) of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5).
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Figure 3.21. Absorption Maxima and Oscillator Strengths of Triplet Biradical Cation (26), 
Singlet Biradical Cation (27) and for Pyridinium Radical (28) Calculated Using the TD-
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In order to confirm the suggestion that the 530 nm band is associated with the pyridine radical 
cation of dimethyl 1, 2-DiPyEt (18) we performed calculations of the vertical excitation 
transitions (VET’s) and the corresponding oscillator strengths at the TD-M052X/cc-pVDZ level 
of theory.  The calculations were performed in collaboration with Maxim Panov (Tarnovsky’s 
Lab). These structures were optimized using the TD-M052X/cc-pVDZ level of theory using the 
6-31 G basis sets (Figure 3.22).
Figure  3.22. The Pyridine Radical Cation of Dimethyl 1, 2-DiPyEt (18) Geometries Optimized 








Species λ, (nm)- 
TD-M052X/cc-pVDZ 




S1 1076 (0.0072) 
S2 866 (0.0033) 
S3 591 (0.0160) 
S4 305 (0.0001) 
S5 291 (0.0155) 
S6 286 (0.0002) 
S7 277 (0.0042) 
S8 262 (0.0610) 
S9 260 (0.0010) 
S10 243 (0.0005) 
530-540
2 
S1 905 (0.0016) 
S2 767 (0.0007) 
S3 501 (0.0004) 
S4 304 (0.0000) 
S5 290 (0.2000) 
S6 283 (0.0000) 
S7 276 (0.0027) 
S8 259 (0.0263) 
S9 258 (0.0343) 
S10 242 (0.0119) 
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1 
S1 3889 (0.1205) 
S2 997 (0.0073) 
S3 883 (0.0063) 
S4 292 (0.0062) 
S5 289 (0.0013) 
S6 283 (0.0158) 
S7 283 (0.0158) 
S8 272 (0.0154) 
S9 266 (0.0005) 
S10 263 (0.0038) 
Table 3.4. Vertical Excitation Transitions, Oscillator Strengths and Absorption Properties of the 
Pyridine Radical Cation of Dimethyl 1, 2-DiPyEt (18) in Water Computed at the TD- 
M052X/cc-pVDZ Levels of Theory.  
The presence of 591 nm band transition calculated for pyridine radical cation of dimethyl 1, 2-
DiPyEt (18) confirms that our initial suggestion and the conclusion from the transient 
spectroscopy experiment on the Donor (DABCO (20)) + Probe (Dimethyl 1,2-DiPyET-BF4 (18)) 
system that this band can be referred to a dimethyl 1, 2-DiPyEt (18) radical.  
3.3. SUMMARY OF TRANSIENT ABSORPTION SPECTRA AND THEORETICAL 
CALCULATIONS.        
The data presented (femtosecond transient absorption spectroscopy, theoretical calculations) 
shows that the decomposition of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) after 
irradiation at a single wavelength in the range of 325-350 nm goes through intra-molecular 
electron transfer with formation of a pyrene radical-cation 16 and a solvated electron. The 
release of o-quinone 3 is impeded of the BET of the pyrene radical-cation, which annihilates 




pyridine radicals to water producing solvated electrons. The low quantum yields and transient 
absorption decay studies confirm suggestions about the mechanistic pathway of o-quinone (3) 
release via formation of pyrene radical-cation with the possibilities of reformation of the N,N-
dimethyl 10, 11-DiPyridiniumPDHD-BF4 due to both intramolecular BET and recombination 
with solvated electron. Calculations of absorption maxima, VET’s and oscillator strengths 
performed at different levels of theory support the mechanism of o-quinone (3) release based on 
transient absorption spectroscopy experiments.  
In order to increase the yield of o-quinone (3) release from PDHD, the  10, 10-BisPyridylPDHD 




m+=Cu 2+, Ni2+, Co2+, Fe3+; Ann-=ClO4
-, NO3
-) were synthesized. 
In Chapter 2, the binding costants, Kb, for Me
m+ and 10, 10-BisPyridylPDHD were estimated. 
Only, Cu2+ and Ni2+ showed essential binding. The presence of copper in its high oxidation state 
(2+) drastically increased the quantum yield for o-quinone (3) release, in comparison to the other 
metals ions and pure 10, 10-BisPyridylPDHD after irradiation at 325 nm. Such phenomenon can 
be explained by the fact that CuI(10, 10-BisPyridylPDHD)2
+ has a d 10 electronic configurations 
and generally adopts pseudo-tetrahedral geometry, which is more stable than copper in its 
oxidized state. Cu(II) has a d 9 electronic configuration and the chelating ligand, 10, 10-
BisPyridylPDHD, adopts a more planar geometry, often with a fifth, Jahn-Teller distorted, axial 
ligand derived from solvent or counterion, resulting in a distorted square pyramidal or trigonal 
bipyramidal geometry.67 That suggestion is confirmed by femtosecond transient spectroscopy 
data, which, obviously, shows the presence of a sharp peak for the pyrene radical cation at 450 
nm in the case of [Cu2+(10, 10-BisPyridylPDHD)](ClO4)2 (9). In case of pure   10, 10-




of several species. Overall, the mechanism of quinone release for   [Cu2+(10, 10-
BisPyridylPDHD)](ClO4)2 (9) can be explained by ET from pyrene ring to the pyridinium ring 
followed by ET from pyridine radical to Cu2+. 
Transient absorption decay studies reveal that the lifetime of radical cation (16) in presence of 
DNA is considerably shorter lived than that without DNA. The shorter lifetime is probably 
because of ET from the DNA (one-electron DNA oxidation) to the radical cation (16). The 
mechanism of one-electron DNA oxidation will be discussed in Chapter 4. 
3.4. EXPERIMENTAL PART. PROCEDURES. 
DHD stock solutions were prepared in CB buffer (10 mM Sodium Cacodylate three hydrate,     
100 mM NaCl, 0.5 mM EDTA, pH = 7.1). 
3.4.1. Quantum yields. 71-74 
2K3[Fe(C2O4)3] 2 K2[Fe(C2O4)2] + K2C2O4 + 2CO2
K3[Fe(C2O4)3] + 1,10-phenanthroline
hv
[Fe(1,10-phenanthroline ) ]C2O4 + K2C2O4 
Scheme 3.9. Photochemical Decomposition of Actinometer (K3[Fe(C2O4)3]) under Irradiation. 
All procedures should be done under a red safe-light. Green crystals of K3[Fe(C2O4)3]
.3H2O are 
prepared by mixing 3 vol of 1.5 M K2C2O4 with 1 vol of 1 M FeCl3 solution, recrystallized 
three times from warm water, dried at 45 °C, and kept in the dark. Solutions used for actinometry 
were 0.006, 0.012, or 0.15 M (≥405 nm) in K3[Fe(C2O4)3]. A 0.006 M solution is prepared by 
dissolving 2.947 g of the green crystals in 100 mL H2SO4 (0.5 M) and dilution with distilled 
water to 1000 mL. An absorption spectrum of the solution is taken. Samples of 5 mL (V1) of the 
solution are irradiated (λ=325 nm or 442 nm, depending on the wavelenth for which quantum 
yield is determined) by a continuous wavelength Melles Griot® helium cadmium laser (He-Cd 




reactions in the solution). The irradiated solution, 1 mL (V2), is placed into a 10 mL (V3) 
volumetric flask containing a mixture of 4 mL of 0.1 % 1.10-phenanthroline solution and 0.5 mL 
of buffer (stock solution: 82 g NaC2H5CO2, 10 mL conc. H2SO4, diluted to 1000 mL with 
distilled water) which is then diluted to the mark with distilled water. It is essential that the 
irradiation time (𝜏𝜏) measurement (electronic shutter) as well as the pipetting is done very 
precisely. A reference solution is prepared in the same way except that it was not been irradiated. 
Both solutions were kept in the dark (about an hour) until full color development was achieved, 
and the absorbance difference (ΔA510) between the two samples is measured at 510 nm [optical 
pathlength l = 1 cm,   ε (510 nm) = 11 100 mol–1 cm–1].     ΔA (510 nm) should be within the 
range 0.2–1.8. Conversion should not exceed 5 %. After measuring absorbance of samples 
irradiated at different times, the linear regression curve for ΔA510 versus time is drawn (ΔA510 = 
k 𝜏𝜏 +c, k (second-1) and c is the constant of the linear regression curve. The photon flux for the 
wavelength of interest, amount photons, qn,p/einstein s
–1 , entering the sample cell is given by (in 
coherent SI units):  
 
Equation 3.2. Calculation of Flux for He-Cd Laser for Given Wavenumber (V1=5 cm
3; V2=1 
cm3; V3=10 mL; ε (510) =11100 M
-1cm-1 at 510 nm; ε (325) = 1.24 and ε (442) = 1.11; 𝜏𝜏 = 
irradiation time, l = 1 cm, ΔA510= A510(𝜏𝜏)-ΔA510(0) (change of Absorbance at 510 nm after 
irradiation for 𝜏𝜏 ) from the calculated linear regression equation ΔA=k 𝜏𝜏 +c). 
After the flux for given wavenumber is calculated, the quantum yields for N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4  (5) at specific wavenumber (λ, 325 nm or 442 nm) can be calculated 





Equation 3.3. Calculation of Quantum Yield at 325 nm for N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Cacodylic Buffer change of Absorbance at 343 nm 
after irradiation for 𝜏𝜏  at 325 nm, ε (343) = 77450 M-1cm-1 V-volume of N,N-Dimethyl 
10, 11-DiPyridiniumPDHD-BF4 (5) irradiated solution). 
 
Equation 3.4. Calculation of Quantum Yield at 442 nm for N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) in Cacodylic Buffer Change of Absorbance at 343 nm 
after irradiation at 442 nm, ε (343) = 77450 M-1cm-1, A (442)-Absorbance at 442, V-volume of 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) irradiated solution). 
The quantum yield at 442 nm calculated for N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
is presented in Table 3.5. 








(  change 
Absorbance at  
343 nm after irradiation 







5 2.82*10-8 442 2.49*10-5 
(-0.0013) 
5 0.017 




The attempt to calculate quantum yields for irradiation at 325 nm were inconsistent due to 
abnormalities in absorbance. This probably occurs due to the formation of several side products 
(Scheme 3.4). The quantum yield presented in the Table 3.5 is just the best trial. 
The calculation of the quantum yield for decomposition of 10, 10-BisPyridylPDHD in 
acetonitrile after irradiation at 325 nm was calculated by the equation 3.5: 
 
Equation 3.5. Calculation of Quantum Yield at 325 nm for 10, 10-BisPyridylPDHD in 
acetonitrile ( Change of Absorbance at 346 nm after irradiation at 325 nm, V-volume 
of 10, 10-BisPyridylPDHD irradiated solution, ε (346) = 14,500 M-1cm-1). 
The quantum yield data for 10, 10-BisPyridylPDHD in acetonitrile after irradiation at 325 nm are 
summarized in Table 3.6. 








(  change 
of Absorbance at  346 nm 
after irradiation for 


















The quantum yield of complexes 9, 10, 11, 12 at 325 nm are also calculated by Equation 3.5. The 
data are presented in Table 3.7. 









change of Absorbance at  
346 nm after irradiation 








9 2.82x10-8 325 0.023 
(0.133) 
5 28.89 
10 2.71x10-8 325 3.15x10-4 
(0.0053) 
5 0.4 
12 2.39x10-8 325 0.00121 
(9.97x10-5) 
3 1.0 
11 2.91x10-8 325 7.68x10-4 
(5.67x10-5) 
5 0.9 
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UM: ultrafast mirror (CVI and light conversion)
UBS: ultrafast wedged beamsplitter
DM: 760-840 dielectric mirror (Standa)
AlM: UV enhanced Al mirror (New Focus)





























3.4.2. Femtosecond Transient Absorption Spectroscopy. 
 The experimental set-up is based an amplified Ti:sapphire laser system (Hurricane, Spectra 
Physics) that generates a 1-kHz train of 90-fs (fwhm) 800-nm laser pulses with an energy of 1 


















Figure 3.23. The Experimental Set-Up Using Two TOPAS-C Optical Parametric Amplifiers for 




The Hurricane output is divided by a beam splitter into two parts which are used to pump two 
computer-controlled pump and probe TOPAS-C optical parametric amplifiers (Light Conversion 
Ltd.). Transient absorption (ΔA) spectra of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) 
and 10, 10-BisPyridylPDHD have been recorded in various solvents at excitation wavelengths of 
350 and 325 nm, respectively.  
A white-light continuum to be used as probe light in the 340-720 nm region was  generated by 
attenuating and focusing a small portion of the 800 nm amplified output into a 3 mm CaF2 
window. The ΔA spectra were obtained by diode-array detection of the multiple (512) ΔA kinetic 
traces within the white-light continuum spectrum and were chirp corrected for the group velocity 
dispersion (GVD) of the probe light with an accuracy of 30 fs by using the non-resonant or two-
photon absorption signals from neat solvent. The instrument response function (150 fs, fwhm) 
was characterized using a Gaussian-like transient absorption signal at time zero due to stimulated 
Raman scattering from neat solvent. 75 The attenuation of the excitation energy was carried out to 
minimize the two-photon absorption by the solvent and, as a result, to ensure the linearity of 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) and 10, 10-BisPyridylPDHD ΔA signals with 
excitation energy. The measurements of steady-state absorption spectra of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) and 10, 10-BisPyridylPDHD solutions before and after excitation 
revealed the sample decomposition less than <10%. All measurements are performed at magic 
angle polarization conditions and 22 °C. 
To characterize the temporal evolution observed following excitation of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) and 10, 10-BisPyridylPDHD, multiexponential fits of single-
wavelength ΔA kinetic traces was performed.  The region from -200 to 200 fs was not considered 










−∑+∆=∆ , where τi are the time constants, Ai are the amplitudes, ΔA0 is the 
permanent spectrum at infinitely long times (more than 1 ns). 
3.4.3. Computational Details. 
 All calculations were performed using the Gaussian 0976 and MOLCAS 7.477 software packages 
at the Ohio Supercomputer Center. The geometry optimization of the N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5), N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 radical cation (16) 
and 10, 10-BisPyridylPDHD in the gas phase, water and acetonitrile were performed using the 
hybrid functional of Truhlar and Zhao (M052X) and a correlation-consistent polarized valence 
double-zeta (cc-pVDZ)70 basis set. A conductor-like polarizable continuum model (CPCM), 
which is based on the self-consistent reaction field theory (SCRF) and defines the cavity as the 
union of series of interlocking atomic spheres,78 was used to take into account the solvent effect. 
Vertical excitation transition (VET) and oscillator strength (f) calculations were performed at the 
optimized geometries using time-dependent the M052X/cc-pVDZ level of theory and the 
complete active space self-consistent field (CASSCF) methodology with 6-31G* basis set68 
based on the use of a Douglas-Kroll-Hess Hamiltonian and the subsequent second order 
perturbation theory (CASPT2)69 to take into account the dynamic electronic correlations. The 
active space consisting of the 12 electrons in 12 orbitals, CASSCF(12,12), was used for N,N-
Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) and N,N-Dimethyl 10, 11-DiPyridiniumPDHD-
BF4 (5) radical cation (16). The optimized geometries of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5), N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 radical cation (16) 




Figures 3.24, 3.25 and 3.26, respectively. The CASPT2//CASSCF calculations of the vertical 
excitation transitions (VET’s) and the corresponding oscillator strengths (f) were performed for 








Figure 3.24. The N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) (S, S-isomer) Geometry 
Optimized at the M052X/cc-pVDZ Level of Theory in Water. Bond Angles (left) and Lengths 








Figure 3.25. The N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5) (S, S-isomer) Radical 
Cation (16) Geometry Optimized at the M052X/cc-pVDZ Level of Theory in Water. Bond 



















Figure 3.26. The 10, 10-BisPyridylPDHD Geometry Optimized at the M052X/cc-pVDZ Level 
of Theory in Water. Bond Angles (left) and Lengths (right) of Interest are Shown. 
The CASPT2//CASSCF(12,12)/6-31G* molecular orbitals for N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5) (S, S-isomer),  CASPT2//CASSCF(12,12)/6-31G* molecular 
orbitals for N,N-Dimethyl 10, 11-DiPyridiniumPDHD (S, S-isomer)  radical cation (16) included 






Figure 3.27. The CASPT2//CASSCF(12,12)/6-31G* Molecular Orbitals Included in the Active 
Space of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (5).  
Figure 3.28. The CASPT2//CASSCF(12,12)/6-31G* Molecular Orbitals Included in the Active 
Space of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 Radical Cation (16).  
The TD-M052X/cc-pVDZ molecular orbitals of N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 
(5), N,N-Dimethyl 10, 11-DiPyridiniumPDHD radical cation (16) and 10, 10-BisPyridylPDHD 
are shown on Figures 3.29, 3.30 and 3.31. 
Figure 3.29. The TD-M052X/cc-pVDZ Molecular Orbitals of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (5). 
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Figure 3.30. The TD-M052X/cc-pVDZ Molecular Orbitals of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 Radical Cation (16). 
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CHAPTER 4. INTRODUCTION. BINDING STUDIES OF N,N-DIMETHYL 10, 11-
DIPYRIDINIUM PDHD-BF4 TO DNA. DNA CLEAVAGE STUDIES BY 10, 11-
DIPYRIDINIUM PDHD-BF4. 
There are certain drugs that are shown to affect vital functions of living organisms, such as 
protein biosynthesis, nucleic acid replication and gene expression. These are collectively called 
antibiotics. For those drugs that target DNA over the past 20 years, enormous advancement has 
been made in our understanding of their interactions with DNA. Interest in these interactions is 
not limited to a pharmacological point of view, i.e., how a drug acts at a molecular level, with the 
expectation that relating its structure to its action would contribute to the specific design of 
clinically useful agents, but also from the appreciation that antibiotics of determined specificity 
of action can be used as powerful tools for elucidating the biochemistry of nucleic acids and their 
physiological roles. 
The presence of a quinone group in the structure of a compound has been shown to kill cell and 
induce DNA strand breaks by a mechanism involving free radicals and active oxygen species. 
The ability of the compound to bind to DNA appeared to increase the DNA damage induced and 
the cytotoxic activity. A wide series of model compounds has been used to investigate the role of 
the quinone group in the mechanism of action of quinone antitumor agents. 
Bis(dimethylamino)benzoquinone (1, Figure 4.1), which contains a quinone group, produced 
significant cell death of  L5178Y lymphoblasts and induced concentration-dependent single-
strand and double-strand breaks in the DNA of these cells.1  Benzoquinone dimustard (2, Figure 
4.1), which possesses a quinone moiety and active alkylating groups, was approximately 2500 
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Figure 4.1.  Bis(dimethylamino)benzoquinone (1), Benzoquinone dimustard (2). 
Benzoquinone dimustard induced no apparent DNA single-strand breaks, but produced 
significant DNA cross-linking, a process which interferes with the assay for single-strand breaks. 
The cell death produced by both quinone agents was inhibited by catalase, but not by superoxide 
dismutase. The cytotoxic activity of bis(dimethylamino)benzoquinone (1) and two other quinone 
model compounds, hydrolyzed benzoquinone mustard (3, Figure 4.2),  and benzoquinone 
mustard (4, Figure 4.2), appeared to correlate with the induction of DNA strand breaks, while 
there appeared to be no correlation between cell death and DNA double-strand breaks induced by 











Figure 4.2. Hydrolized Benzoquinone Mustard (3) and Benzoquinone Mustard (4). 
However, the cytotoxicity of benzoquinone dimustard appeared to be related to the cross-linking 
activity of this agent. These studies have provided additional evidence that the presence of a 




that appears to involve active oxygen species. Quinone containing agents can induce DNA strand 
breaks, and this effect is enhanced when the agent is able to bind to the DNA. The induction of 
DNA strand breaks appeared to correlate with cytotoxic activity for 
bis(dimethylamino)benzoquinone (1), hydrolyzed benzoquinone mustard and benzoquinone 
mustard, but not for benzoquinone dimustard, suggesting that the contribution of quinone-
induced strand breaks to the overall cytotoxicity of an agent may vary considerably. 
The recognition of one type of molecule by another is fundamental and a very common feature 
of all living organisms.2 The replication of DNA and its transcription to RNA, which provides 
the template for protein synthesis, is perhaps one of the best known example of molecular 
recognition. These nonprotein molecules that are known to bind DNA molecules include natural 
products such as antitumor antibiotics analogs of FDA intercaltors (approved by Food-Drug-
Administration) containing quinone ring, Daunorubicin (27, Chapter 1), Doxorubicin (28, 
Chapter 1) , Mitoxantrone (29, Chapter 1)  anthracyclins (Duanomycins (5, Figure 4.3), 
Nogalomycin (6, Figure 4.3), and Cinnerubins (7, Figure 4.3),3-5 and other secondary metabolites 
from bacteria and fungi6 and plants. Synthetic compounds, CC 1065 (8, Figure 4.4),7 
copperphenanthroline complex (9, Figure 4.4),5  alkylnitroso-urea (Streptozotocin, 10, Figure 
4.4)2, and also heterocyclic and multi ring heterocyclic aromatic compounds6 and 

















































































Figure 4.3. Duanomycins (5), Nogalomycin (6), Cinnerubins (7), CC 1065 (8), 
Copperphenanthroline Complex (9), Alkylnitroso-Urea (Streptozotocin, 10). 
The interaction of relatively small molecules of this type with DNA may lead to “useful” results 
such as antibacterial and anticancer activity, but may also involve undesirable biological 
responses, such as carcinogenesis or mutagenesis. 
For the preliminary confirmation of binding and/or bonding of a drug/ligand to a DNA, 




viscometric measurements, thermal denaturation studies, or association studies with radiolabeled 
version of the ligand, are implemented. Assays are available to evaluate the extent of DNA 
binding and to determine the sequence specificity. Calf thymus DNA is often used for physical 
studies because of its ready availability in a purified form and the fact that it contains a relatively 
even distribution of AT and GC base pairs. Three main techniques have an importance in 
determining these interactions. They are footprinting, NMR and X-ray crystallography. 
DNA "footprinting" is used for covalent and noncovalent binders, intercalators, and other types 
of adducts such as coordination complexes and triple helices.9 The ligand and radiolabeled DNA 
are incubated to allow binding and/or bonding to occur, and the adduct is then treated with 
Methidiumpropyl-EDTA (11, Figure 4.4), Methidiumpropyl-EDTA-Fe(II) (MPE-Fe(II)) is 
capable of cleaving DNA nonselectively at every base pair.10, 11 However, the regions of DNA 
bound to drug are protected from cleavage, which appear as gaps in the sequence of bands on the 
electrophoresis gel. The enzyme DNase I can also be used instead of MPE-Fe(II), but differs in 
that it produces larger footprints and reveals information about ligand-induced conformational 
changes of DNA. At sites of ligand attachment, the progress of the enzyme is impeded and a cut 
may occur. Identifiable "stop sites" appear as intense bands on the gel that can be related to 





















Figure 4.4. Methidiumpropyl-EDTA (11). 
4.1. PRELIMINARY CONFIRMATION OF BINDING of N,N-DIMETHYL 10, 11-
DIPYRIDINIUM PDHD-BF4 (DHD) TO DNA. SPECTROSCOPIC TOOLS OF 
ANALYSIS. 
Extensive research proves that while transport of intercalators through the human body, across 
the cell membrane and within the cell itself 12 affects the cytotoxicity of intercalating drugs, it is 
their interaction with DNA, and through this, their ability to prevent DNA transcription and 
replication that is of most importance. Examining the interaction of intercalating drugs with 
DNA provides an important step in determining structure-activity relationships.  
We applied several spectroscopic tools of analysis to examine DNA- N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (abbreviated as DHD or PDHD) complexation with DNA. We know 
from the calculations (Chapter 2), that DHD is a DNA intercalator bearing a planar pyrene ring. 
Footprinting studies were performed in order to recognize the specificity of binding site for DHD 




4.1.1. Visible Absorption Spectra Studies. 
Both DNA and RNA are able to cause a bathochromic shift from 479 nm to 516–518 nm in the 
absorption spectrum of ethidium bromide. This effect is evident as a change in color of the 
solution from yellow-orange to bright pink. Figure 4.5 shows the effect of increasing 
concentrations of DNA from T2 bacteriophage (“T2- DNA”) on the absorption spectrum of 
ethidium bromide.13 The peak progressively shifts toward a limit (curve E) that represents the 
spectrum of the drug in a fully complexed form. All the curves pass through an isosbestic point 
at 510 nm, indicating that they result from the contribution of two forms of ethidium, free and 
bound, each form having a characteristic absorption spectrum. The proportions of the free and 
bound drug can be estimated from measurements of the absorbance in the spectral region where 
the difference between curves A and E is greatest. 
 
Figure 4.5. Effect of DNA on the Absorption Spectrum of Ethidium Bromide. The Solution 
Contained 1.25x10-4 M Ethidium Bromide, and the Aborbance Was Measured Using a 1-cm 
Light Path. T2 DNA Was Present at the Following Concentrations: Curve A, zero; B, 1.5x10-4 




When all of the DNA binding sites for ethidium are the same and are independent of each other, 
the equilibrium binding process can be described by simple mass action terms, giving 
 or r/c =    
Equation 4.1. Dissociation Constant of Equilibrium Binding Process Described by Mass Action 
Terms. 
where k is the dissociation constant of the complex, c is the molar concentration of free drug, r is 
the number of drug molecules bound per nucleotide, and n is the number of total binding sites 
per nucleotide. 
A straight line with a gradient-1/k, and an intercept on the r axis equal to n.  
This type of stoichiometric analysis of drug–DNA interaction is simple and attractive. However, 
as was pointed out by McGhee and von Hippel,14 Equation 4.1 involves a serious defect in 
enumerating the number of free sites along the DNA duplex, as the number of free sites is 
assumed to be always proportional to the number of unoccupied base pairs. To solve this 
problem, they derived the following equation, to replace Equation 4.1. 
 
Equation 4.2. Modified Dissociation Constant of Equilibrium Binding Process Described by 
Mass Action Terms. 
where n* is the number of base pairs occupied by one drug molecule bound to DNA duplex. 
When r/c is plotted against r (Scatchard plot) using this equation, it is a curved, rather than 
straight, line. It should also be pointed out here that the dissociation constant k, or the 




Another approach for calculation of binding interactions between drugs and DNA was proposed. 
15, 16 When the ratio of bound drug to DNA base pairs is relatively low, the intrinsic binding 
constant, Kb, based upon these absorption titrations may be determined from a double-reciprocal 
plot of the changes in the apparent extinction coefficient of Drug versus DNA concentration (the 
same method was used to calculate 10, 10-BisPyridylPDHD-Metalm+):  
1 / ∆εap = 1/∆εKb[DNA] + 1/∆ε,  
Equation 4.3. Equation for Calculation of Intrinsic Binding Constant, Kb (Double-Reciprocal 
Plot Form). 
where ∆εap = |εap – εf|, ∆ε = |εb – εf|. 
The apparent extinction coefficient, ∆εap, is obtained by calculating Aobs/[Drug]. εb and εf are 
extinction coefficients of Drug free and Drug fully bound form respectively. 
[DNA]/∆εap = (1/∆ε)*[DNA] + 1/∆εKb 
Equation 4.4. Equation for Calculation of Intrinsic Binding Constant, Kb (Double-Reciprocal 
Plot Form).  
Hypochromic phenomenon is due to the strong interaction between the electronic states of the 
intercalated chromophore and DNA bases.17, 18 Strength of this electronic interaction is expected 
to decrease as the cube of the distance between the chromophore and the DNA bases. Marked 
hypochromism indicates a close proximity of the chromophore to the DNA bases.18  
The addition of DNA induces a hypochromic effect in DHD spectum (> 40% observed in all 
cases) and produces a bathochromic shift of >10 nm in the spectrum. The same effect is observed 
with both enantiomers of the DHD (enantiomers of DHD are denoted according to appearance of 
appropriate fractions in HPLC spectrum of chiral separation-Chapter 2, Part 2.6.6, DHD 




DNA (Herring Sperm DNA) helix.17  The magnitudes of hypochromic shifts are usually 
correlated with the strengths of the intercalative binding interactions. It is clear from the spectra 
(Figure 4.6 A and C) that we have a bathochromic shift and isosbestic points (295 nm and 352 
nm), which are indicative of the intercalation of DHD isomers within the HS DNA helix, which 
results in an ordered stacking of DHD molecules  between the aromatic heterocyclic base pairs. 
Thus, the DHD is sandwiched tightly between the base pairs and stabilized electronically in the 
helix by π–π stacking and dipole–dipole interactions.17 The UV-titartion studies were performed 

































Figure 4.6. The Absorption Spectra of Pure DHD Enantiomers 10 μM and DHD / HS DNA 
Complexes in Cacodylate Buffer (10 mM Sodium Cacodylate, 100 mM NaCl, 0.5 mM EDTA, 
pH 7.1) at 20° C. Panels A and B Related to DHD isomer #1 and panels C and D Related to 
DHD isomer #2  UV-Vis Curves, Respectively, with the Maxima at 343 nm Shifting to 356 nm 
with Increasing Concentrations of Herring Sperm DNA (25, 50, 75, 100, 125, 150, 175, 200 and 
225 mΜ of DNA basepair).  Insets are the Half-Reciprocal Plots of [DNA]/∆εap as a Function of 
DNA Concentration as Determined from the Absorption Spectral Data. The Solid Line 




A plot of [HS DNA]/∆εap versus [HS DNA] gives a slope of 1/∆ε and a y-intercept equal to 
1/(∆εKb) (Figure 4.6 Panels B and D). Kb is then given by the ratio of the slope to intercept. A 
double-reciprocal plot gives excessive weight to data points obtained at low [DNA] (the half-
reciprocal plot should generally be more accurate). The calculated intrinsic binding constants for 
DHD isomers with HS DNA are presented in Table 4.1. 
DNA Enantiomers apparent Kb 
(M-1) 
HS DNA DHD (racemic) - 
HS DNA DHD isomer #1 1.58±0.15 x 105 
HS DNA DHD isomer #2 2.34±0.2 x 105 
 
Table 4.1. Calculated Apparent Binding Constants from UV-vis Titration Data. Errors of Kb are 
from Three Independent UV-Titration Experiments. 
From the binding data it is obvious that DHD enantiomers bind HS DNA with high affinity. This  
magnitude of binding is comparable with those observed for known intercalators.19, 20 DHD 
isomer #2 has a slightly larger binding constant than DHD isomer #1.  
4.1.2. Circular Dichroism Spectra Studies. 
CD is a useful technique for determining whether drug intercalation induces any global DNA 
conformational changes and for determining the binding affinity of a drug. Due to their chirality, 
different DNA conformations are able to interact with polarised light in different ways, rotating 
it from its normal plane. This interaction gives rise to a CD spectrum, a measure of the difference 
in absorption of left and right handed circularly polarised light; however, the CD spectrum of 
DNA is a function of the base composition and sequence.21 The uncomplexed 10 base pair DNA 




and a negative CD signal at 250 nm, which are typical features of β-DNA.22 Upon addition of 
racemic DHD, the CD spectrum of the resulting DNA drastically changes: the positive band 








Figure 4.7. CD Spectra of 10 base pair DNA (5’- ATCGACCAAGC -3’/3’- TAGCTGGTTCG -
5’) in the Absence (Black Curve) (~50 µM) and Presence (Colored) of DHD (Recorded at 1 nm 
Intervals, Cuvette Path Length-0.1 cm. A Scan of the Buffer Alone Was Recorded to Provide a 
Baseline. DNA Duplex Was Titrated by the Addition of Aliquots of Concentrated Solution of 
Racemic DHD over the Range of 1:0 to 1:2, DNA:DHD). 
Intercalation DHD enhances the base stacking and stabilizes helicity by modifying the intensities 
of both bands, in contrast simple groove binding and the electrostatic interactions of small 
molecules show less or no perturbative effect on the base stacking and helicity bands.23 
Stootman have reported a new method for determining the binding constant of achiral 
intercalators to DNA which utilises a least squares fitting method.24 CD spectra are obtained by 





















 HS DNA(2.37 mM) 220 mL+Cacodylic Buffer 60mL + racemic DHD (4.1 mM) 20mL 
HS DNA(2.37 mM) 220 mL+ racemic DHD (4.1 mM) 80mL 
 HS DNA(2.37 mM) 220 mL+Cacodylic Buffer 20mL + racemic DHD (4.1 mM) 60mL 




Figure 4.8. CD Titration of HS DNA with Racemic DHD (Green Line-HS DNA(2.37 mM) 220 
mL + Cacodylic Buffer 80µL; Black Line- HS DNA(2.37 mM) 220 mL + Cacodylic Buffer 
60µL + Racemic DHD (4.1 µM) 20 µL; Blue Line- HS DNA (2.37 mM) 220 mL + Cacodylic 
Buffer 20µL + racemic DHD (4.1 µM) 60 µL; Red Line-HS DNA (2.37 mM) 220 mL+ Racemic 
DHD (4.1 µM) 80 µL). 
 Subtraction of the CD spectrum of the HS DNA in the absence of intercalator, from the spectra 
obtained with increasing intercalator concentration produces induced circular dichroism (ICD) 
spectra, from which a binding curve is generated. The binding constant then was determined 





y = 0.5R{A+ B + x + } 
Equation 4.5. Equation for Calculation of Intrinsic Binding Constant, Kb from CD Titration of 
HS DNA with Racemic DHD.  
where A = 1/Kb, B is the concentration of DNA (M), x is the variable concentration of 
intercalator (M), y is the change in molar ellipticity, and R=110 is a scaling factor. 
The concentration of DNA can be determined beforehand from UV-vis experiments: 
C = A/(lε) 
where C is the oligonucleotide concentration, A is the measured absorbance at 260 nm, ε is the 
molar extinction coefficient and b is the cell path length (usually 1 cm).  The DNA concentration 
estimation was based on the extinction coefficient for absorbance at 260 nm (1 cm path length) 
of 0.02 µg mL-1 or HS DNA with an absorption 1 = 50 µg mL-1.25 The 260/280 ratio was near to 
1.8 indicating good quality of the DNA.  In the case of HS DNA, 12858 M-1 (bp) taken as 
extinction coefficient at 260 nm and expressed the concentration in terms of base molarity.26 
The calculated binding constant for racemic DHD (1.23x105) from CD titration is comparable to 
one calculated by UV absorption titration (1.58±0.15 x 105) DHD isomer #1 (DHD 1). CD 
titration as well as UV titration confirms DHD binds HS DNA with high affinity. 
4.1.3. Evaluation of DNA-DHD interactions by Electrospray Ionization Mass Spectroscopy.  
The introduction of electrospray sources was a major breakthrough in the field of biomolecule 
mass spectrometry.27, 28 Electrospray allows one to observe intact ions directly from large 
biomolecules solutions of which are injected into the spectrometer vacuum chamber via a 
charged capillary nozzle.29 The softness of electrospray (the absence of fragmentation, thanks to 
the limited energy given by thermal heating and collisional activation) is such that even 




the case for DNA and RNA duplexes and noncovalent complexes (higher-order structures, 
nucleic acid complexes with small molecules or with proteins).30–34 Electrospray Ionization Mass 
Spectroscopy studies were performed in collaboration with Larry Sallans at University of 
Cincinnati. 
In order to obtain soft source conditions that are suitable to maintain complexes intact, it is 
necessary to change some instrumental parameters compared to those typically used for covalent, 
less fragile analytes. With the introduction of Fourier transform ion cyclotron resonance mass 
spectrometry (FTICR-MS or FT-MS) a means of analysis of compounds with a very high mass 
resolution, a mass spectrometric technique of high mass accuracy and high sensitivity has 
become available in comparison to linear trap quadrupole mass spectrometry (LTQ-MS). In 
combination with electrospray ionization (ESI), not only high throughput measurements via 
flow-injection analysis (FIA), but also coupling with separation techniques such as high-
performance liquid chromatography (HPLC) or capillary electrophoresis (CE) is possible. 
Electrospray ionization mass spectrometry (ESI-MS) has enabled the detection and 
characterization of DNA [ss-T7 and ss-A7] (single-strand and double-strand heptamers, thymine 
and adenine)-racemic DHD complexes, including evaluation of both relative binding affinities 
and selectivities of DNA-interactive ligands (Figure 4.10 and 4.11). The noncovalent complexes 
that are transferred from the solution to the gas phase remain intact, thus allowing the use of MS 
to screen DNA (ss-T7 and ss-A7)-racemic DHD racemic complexes, reveal the stoichiometries of 
the complexes, and provide insight into the nature of the interactions.  
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ss-A7 + ss-T7 ds-A7T7 (a)
ss-A7 + DHD ss-A7-DHD (b)
ss-T7 + DHD ss-T7-DHD (c)
ds-A7T7+DHD ss-A7T7-DHD1 (d)
ds-A7T7-DHD1+DHD ds-A7T7-DHD2 (e)
ds-A7T7-DHD2+3DHD ds-A7T7-DHD3 (f)  
Scheme 4.1. Formation of Various DNA [ss-T7 and ss-A7]-Racemic DHD Complexes Observed 
by FTICR-MS. 
The ITMS (LTQ-MS) spectra of DNA [ss-T7 and ss-A7]-racemic DHD complexes are presented 
on the Figure 4.9 (A-negative ion, B-positive ion). The formation of several species due to the 
complexation (Scheme 4.1) is observed:  [ss-T7DHD1], [ds-T7A7], [ds-T7A7DHD1], 




LS016-241A-20120710-R01 #280-565 RT: 3.02-3.58 AV: 70 NL: 8.82E4
F: ITMS + p ESI Full ms [190.00-2000.00]
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Figure 4.9. ITMS (LTQ-MS) Spectra of DNA [ss-T7 and ss-A7]-Racemic DHD (The solution 
(61 µM of ss-T7, 61 µM of ss-A7, and 40 µM of Racemic DHD in 150 mM NH4OAc buffer) 
was Diluted by a Factor of 3 (100 µl of Above Solution + 100 µl of Deionized Water + 100 µl of 
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acetonitrile) and Infused Directly into the Mass Spectrometer, a Thermo Scientific LTQ-FT™, a 
Hybrid Mass Spectrometer Consisting of a Linear Ion Trap and a Fourier transform Ion 
Cyclotron Resonance (FT-ICR) Mass Spectrometer. The Infusion Rate Was 10 µl/min and the 
Resolution of the FT-ICR was Set at 100,000 at m/z 400). 
In comparison to the ITMS (LTQ-MS) spectra, the FTMS spectra (FT-ICR-MS) give better mass 
accuracy and resolution (Figure 4.10).  
LS016-241A-20120710-R01 #1-903 RT: 0.22-9.21 AV: 284 NL: 8.27E4
F: FTMS - p ESI Full ms [190.00-2000.00]
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(too low to see on this slide)
Negative Ion
Figure 4.10. FTMS (FT-ICR-MS) of DNA [ss-T7 and ss-A7]-Racemic DHD (The solution (61 
µM of ss-T7, 61 µM of ss-A7, and 40 µM of Racemic DHD in 150 mM NH4OAc buffer) was 
Diluted by a Factor of 3 (100 µl of Above Solution + 100 µl of Deionized water + 100 µl of 
Acetonitrile) and Infused Directly into the Mass Spectrometer, a Thermo Scientific LTQ-FT™, a 
Hybrid Mass Spectrometer Consisting of a Linear Ion Trap and a Fourier Transform Ion 
Cyclotron Resonance (FT-ICR) Mass Spectrometer. The Infusion Rate was 10 µl/min and the 
Resolution of the FT-ICR was Set at 100,000 at m/z 400). 
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The calculation of equilibrium association constants (Ka,n) for formation of
[dsT7A7DHD1] (Equation 4.5 d) complex was performed according to the equation (only DNA 
strand containing A7 are included in calculation):
35 
Ka,n= =  ; 










Equation 4.6. Equilibrium Association Constants (Ka,n) for Formation of  [ds-T7A7DHD1] 
(A-Peak Areas in MS Spectra of Individual Species (not Including the Areas of the Peaks 
Appeared due to Various Isotope Content): A[ss-T7], A[ss-A7], A[ds-T7A7], A[ss-T7DHD1], 
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A[ds-T7A7DHD1], A[ds-T7DHD2], A[ds-T7DHD3], CDNA=20.3 µM and CL =13.3 µM, Accepted 
that [ss-A7DHD1]= [ss-T7DHD1] ). 
The calculated Equilibrium association (9x104 M-1) reveals that DHD binds to ds-T7A7 with high 
affinity. This result is in agreement with the binding constant calculated by UV and CD 
titrations. 
4.1.4. Sequence Specific Binding Studies-Footprinting. 
Footprinting is a technique widely used in the analysis of sequence-specificity of proteins and 
drugs which bind to DNA in an equilibrium manner.36 Footprinting studies combine the 
enzymatic or chemical cleavage of DNA with the analysis of the resulting products by 
sequencing gels, thus revealing the position and length of individual binding sites. This review 
compares the information that can be obtained by using different footprinting agents and the 
characteristics of DNA-drug interactions that can be inferred from footprinting results. The 
Sequence Specific Binding Studies-Footprinting were performed in collaboration with Emil 
Khisamutdinov. 
The results of a typical DNase I footprinting experiment using the 32P-5’-end-labeled 38-mer 
synthetic DNA is shown on Figure 4.11. The cleavage reaction was implemented in the absence 
and presence of increasing concentrations of DHD isomer #1 (DHD I). (The products of a 
Maxam–Gilbert sequencing reaction on the same radiolabeled DNA molecules were separated 
by electrophoresis in parallel to allow for identification of the sequences protected from cleavage 
by the nuclease. A region that was protected from digestion by the enzyme is clearly visible on 
this gel). Dose-dependent enhancements of cleavage rates relative to those in DHD-control lanes 
occur at sequences flanking the DHD binding sites and the most inhibition of cleavage is 
observed at the 5’- G10G9 site. The site to which DHD binds tightly contains GG step (the 
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footprint extends up to 3 basepairs). UV-, CD- titrations and ESI MS and footprinting studies 
shows that DHD binding to DNA is relatively strong with selectivity for 5’-GGT site. 
The footprint extends up to 3 base-pairs, suggesting the presence of overlapping binding sites 
which is in agreement with UV-titration data (napp for DHD I = 3.1). 
Figure 4.11. Specificity of 32P-5’-End-Labeled 38-mer Synthetic DNA Cleavage Using 
Enantiomer DHD I. Left Panel is a Picture of 15 % Denaturing Polyacrylamide Gel. Lanes: Lane 
1- GA is DNA Ladder (Maxam-Gilbert Sequence Cleavage at Purine Bases); Lane 2 -DNAse is
DNA 38-mer Treated with DNAse I; Lane 3-DNA 0’ is the DNA with Presence of DHD I no 
Irradiation; Line 4-DNA-5’ is the DNA with Presence of DHD I after 5 min Irradiation at 442 
G’s 
and 
A’s DNase DNA-0’ DNA-5’ DNA-10’ 
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nm He-Cd laser; Lane 5- DNA-10’ is the DNA with Presence of DHD I After 10 Min Irradiation 
at 442 nm He-Cd Laser. Right Panel is the Picture of 15 % Denaturing Polyacrylamide Gel of 
DNAse I Footpringting Experiment (Lanes 6-10 from Left to Right are the DNA 38-mer in 
Presence of Different Concentration of DHD I from 0.01 mM to 100 mM).   
4.2. CLEAVAGE of DNA with DHD: EXPERIMENTAL CONFIRMATION AND 
POSSIBLE MECHANISMS. 
Oxidative DNA damage can result from ROS produced during normal metabolic processes 
inside the cell. The most vulnerable site for oxidative damage on DNA is on guanosine (12, 
Scheme 4.2), specifically at the position C-8.37 This site is not normally involved in bonding 
between guanosine and cytosine. As a result, it can be attacked in both single- and double-
stranded DNA. The radical cation formation with attack of water at C-8 intiates the process 
leading to the production of 8-hydroxy guanine (8-OH-dG). Tautomerization with N-7 produces 
8-oxo-2’-deoxy guanosine (8-oxo-dG) (13, Scheme 4.2), in reference to the carbonyl group at C-


































































Scheme 4.2. Possible Oxidation Oxidation of Guanosine in DNA. 
Other bases can undergo oxidative damage as well. 38, 39 The other purine, adenosine, can be 












































Scheme 4.3. Possible Oxidation Path of Adenosine in DNA. 
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Scheme 4.5. Possible Oxidation Path of Thymine in DNA. 
Oxidation reactions in duplex DNA occurring at bases other than guanine have been reported. 
Benzophenone-sensitized photooxidation of calf thymus DNA (ct-DNA) gives the adenine 
oxidation product 8-oxo-7,8-dihydroadenine (8-oxoA) to a few percent of the guanine oxidation 
product 8-oxo-7,8-dihydroguanine (8-oxoG), while cytosine and thymine oxidation products are 
detected in trace amounts.40 Oxidation of DNA by photoionization with 193 nm light results in 
reaction of guanine in ‘‘guanine poor regions’’, reaction of adenine is also observed.41 These 
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results are consistent with the idea that the relative Eox of the base determines the reaction site 
for radical cations in DNA. Because the Eox of adenine is higher than that of guanine, and the 
pyrimidines, T and C, are much more difficult to oxidize than are the purine bases, purines are 
more easily oxidized than pyrimidines.42, 43 Thymine has an Eox of 2.1 V vs. NHE, is the 
nucleobase that is most difficult to oxidize.44 Reaction at thymine is reported when DNA is 
oxidized by photosensitization with menadione (2-methyl-1,4-naphthoquinone).45 Subjecting 
aqueous solutions of calf thymus DNA to ionizing radiation reveals approximately equal 
amounts of reaction occurring at guanine and thymine.46, 47 The formation of thymine oxidation 
products in these experiments is unexpected if Eox is the primary factor controlling the site of 
reaction. To explore this fact, the oxidative reactions of duplex DNA oligomers consisted of A/T 
base pairs has been examined.48 Oxidative damage in A/T rich sequences occurs mostly at 
thymine, even though adenine has a much lower Eox than thymine. This preferential reactivity 
was explained by a proton coupled electron transfer (PCET) mechanism for the formation of a 
thymine radical and by the Curtin–Hammett principle which states that the major products 
observed are those that come from the most reactive species, which in this case is oxidized 
thymine. 
Sequence selectivity of DNA base damage induced by 10, 11-DiPyridiniumPDHD-BF4 (DHD) 
was studied using 22-mer oligodeoxyribonucleotide duplexes, which consisted of 32P-5’-end-
labeled strands containing all of the unique 10 base pairs steps of DNA and the complementary 
strand. The 22-mer duplex was incubated with DHD enantiomers in 10 mM sodium cacodylate 
buffer (pH 7.0) at 37 °C for 1 hour in the dark. Aliquots were exposed to 442 nm He/Cd laser 
light as described in experimental part. The damaged nucleotides sites were detected as cleavage 
bands generated by hot piperidine treatment (piperidine causes breakage of DNA at a sugar with 
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a modified base or a sugar without a base) and analyzed on 20% polyacrylamide gel 
electrophoresis (20 % denaturing PAGE). The results of this PAGE anaylysis are shown in 
Figure 4.12.
Figure 4.12. Autoradiography of 20 % Denaturing Polyacrylamide Gel of 5’-end 32P-ATP 
Labeled 22-mer DNA Fragments. Panel A. Cleavage of the PDHD 1:DNA Complexes upon 
Irradiation at 442 nm 80 mW (He/Cd laser system). Lanes 1, 3, and 5 are Controls with no 
Irradiation of PDHD II : DNA, PDHD I : DNA, and Racemic PDHD (PDHD rac) : DNA 
Complexes (50 µM PDHDs : 2.5 µM DNA in 10 mM CB buffer, pH = 7.0), respectively. 
Irradiated for 10 Min with no Piperidine Treatment; Lanes 2, 4, and 6 are PDHD II : DNA, 
PDHD I : DNA, and PDHD rac : DNA Complex (50 µM PDHDs : 2.5 µM DNA in 10 mM CB 
buffer, pH = 7.0) Respectively, Irradiated for 10 min, with Piperedine Treatment; Lane 7- DNA 
is DNA 22-mer Control in Absence of DHDs after 10 Min Irradiation (control); Lane 8- Gs is 
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Maxam-Gilbert Sequencing Reaction Specific for Guanines.49 Panel B. Incubation of Complexes 
at 37° C for 1 Hour, Samples were not Kept in the Dark. Lane G’s and A’s is Maxam-Gilbert 
Sequencing Reaction Specific for A’s and G’s.    
Treatment of the 22-mer DNA with DHD enantiomers with irradiation at 442 nm afforded strong 
cleavage bands at the all DNA base pairs with no specificity (Figure 4.12, Lane 2, 4 and 6). 
However, the intensities of cleaved bases are different for PDHD II and PDHD I; irradiated 
PDHD II: DNA complex exhibit more significant DNA base damage than irradiated PDHD I: 
DNA, lanes 2 versus 4. It can be concluded that base alteration and/or liberation can occur 
randomly with exposure to 442 nm light and in the presence of PDHD’s. The faint bands in the 
“unirradiated” lanes of A, lanes 1, 3 and 5, may be caused by ambient light and seem to be 
localized to guanosine and adenosine residues in Figure 4.6 Panel B. 
Strand cleavage of 22-mer DNA and the 38-mer DNA with DHD enantiomers and racemic 
mixture without treatment with hot piperedine was performed (Figure 4.11 Lanes 3, 4 and 5 and 
Figure 4.12 Lanes 1, 3 and 5) and cleaved DNA at guanine specific positions. Comparison 
different irradiation dose 5 min and 10 min (Figures 4.11 and 4.12. Lane 2, 4, 5) suggest that 
with longer irradiation time more cleavage at “G” positions is produced. In Figure 4.11, the G9 
and G10 nucleotides are more easily damaged by DHD irradiation, while nucleotides G13, G18, 
G21 and G25 are damaged at the same lower level. 
ESI-MS experiments (Figure 4.13 and 4.14) of irradiation of the solution containing ss-A7 and 
ss-T7 confirms conclusions of electrophoretic experiments that DHD causes the DNA cleavage.  
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Figure 4.13. FTMS (FT-ICR-MS) of DNA [ss-T7 and ss-A7]-DHD (The Solution (61 µM of ss-
T7, 61 µM of ss-A7, and 40 µM Racemic DHD in 150 mM NH4OAc Buffer was Diluted by a 
Factor of 3 (100 µl of Above Solution + 100 µl of Deionized Water + 100 µl of Acetonitrile), 
Irradiated for 0, 1, 10 and 72 Minutes at 325 nm and Infused Directly into the Mass 
Spectrometer, a Thermo Scientific LTQ-FT™, a Hybrid Mass spectrometer Consisting of a 
Linear Ion Trap and a Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass 
Spectrometer. The Infusion Rate was 10 µl/min and the Resolution of the FT-ICR was set at 
100,000 at m/z 400). 
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Figure 4.14. FTMS (FT-ICR-MS) of DNA [ss-T7 and ss-A7]-DHD (The Solution (61 µM of ss-
T7, 61 µM of ss-A7, and 40 µM Racemic DHD in 150 mM NH4OAc Buffer was Diluted by a 
Factor of 3 (100 µl of Above Solution + 100 µl of Deionized Water + 100 µl of Acetonitrile), 
Irradiated for 0, 1, 10 and 72 Minutes at 325 nm and Infused Directly into the Mass 
Spectrometer, a Thermo Scientific LTQ-FT™, a Hybrid Mass Spectrometer Consisting of a 
Linear Ion Trap and a Fourier Transform Ion cyclotron Resonance (FT-ICR) Mass Spectrometer. 
The Infusion Rate was 10 µl/min and the Resolution of the FT-ICR was Set at 100,000 at m/z 
400). 
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The areas of peaks referred to as [ss-T7DHD1], [ds-T7A7], [ds-T7A7DHD1], [ds-T7DHD2], [ds-
T7DHD3] are decreasing as the peak areas of the products of photochemical oxidation are 
increasing in areas (Figure 4.13 and 4.14).   
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C86 H89 N35 O35 P6: 
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Possible ss-A7DHD1 -2H+ 
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(ΔDHD->quinone but loosing dication)?
or ss-A7 -2H+ + C16H8O2 -2H
C86H89N35O35P62-
Error = 565 ppb
Observed
Theoretical
Figure 4.15. FSI-MS/MS spectrum of of 2357.482- species of DNA [ss-T7 and ss-A7]-DHD (The 
solution (61 µM of ss-T7, 61 µM of ss-A7, and 40 µM DHD in 150 mM NH4OAc buffer was 
Diluted by a Factor of 3 (100 µl of Above Solution + 100 µl of Deionized Water + 100 µl of 
Acetonitrile), a Thermo Scientific LTQ-FT™, a Hybrid Mass Spectrometer Consisting of a 
Linear Ion Trap and a Fourier Transform Ion Cyclotron Resonance (FT-ICR) Mass 
Spectrometer. The Infusion Rate was 10 µl/min and the Resolution of the FT-ICR was Set at 
100,000 at m/z 400). 
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ESI-MS/MS spectrum of 2357.482- specie (Figure 4.15) allows us to propose the following 
































































































Scheme 4.6. Possible Products of photooxidation of  DNA by DHD (The solution (61 µM of ss-
T7, 61 µM of ss-A7, and 40 µM DHD-BF4 in 150 mM NH4OAc buffer)- adduct of SS-
A7(oxidized) with o-quinone (reduced). 
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4.3. MATERIALS AND METHODS. 
All chemicals were obtained from commercial suppliers and were of analytical grade, and 
used without further purification unless otherwise noted. Detailed descriptions of the 
synthesis of enantiomeric PDHDs and separation of enantiomers on chiral HPLC column are 
available in previous section (Chapter 2).  PDHD stock solutions (100 mM) were prepared in 
CB buffer (10 mM sodium cacodylate trihydrate, 100 mM NaCl, 0.5 mM EDTA, pH = 7.1) 
using the empirically determined extinction coefficient ε343 = 77459 M-1 cm-1. 
Synthetic DNA oligonucleotides: 
DNA oligomers used in this work included the 11-mer or 10 base-pair-step (10 bps) (5’-
ATCGACCAAGC-3’/3’- TAGCTGGTTCG -5’), the 12-mer (5’-GTTAGTATATGG-3’/3’–
CAATCATATACC-5’), the 22-mer (5’-ATCGACCAAGCTAGCTGGTTCG-3’/3’-
TAGCTGGTTCGATCGACCAAGC-5’) and the 38-mer (5’-
ATAAGTAAATAAACAATCAACAAAGCAACCAATAGACU-3’/3’-
TATTCATTTATTTGTTAGTTGTTTCGTTGGTTATCTCA-5’) These oligomers were 
purchased from DNA Integrated Technology (www.idtdna.com) and purified on 20% 
denaturing PAGE in the presence of 7 M UREA, using standard crush and soak protocol to 
extract DNA from gel slices.12 DNA strands were annealed at a concentration of 100 mM of 
each strand in CB buffer by heating to 100° C and slow cooling to room temperature. The 
concentration of purified stock solutions was determined by absorbance  at 260 nm using 
extinction coefficients calculated by the supplier: ε260 211,100 M-1 cm-1 (11-mer DNA), 
244,600 M-1 cm-1 (12-mer DNA), 419,600 M-1 cm-1 (22-mer DNA), and  762,200 M-1 cm-1 
(38-mer DNA) at 25° C.  
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Commercially prepared Herring Sperm DNA (HS DNA) was obtained from Sigma-Aldrich 
Co. (www.sigmaaldrich.com) and dissolved in double deionized water (dd H2O) containing 
50 mM NaCl with further dialysis for 24 h at 4° C against a buffered solution (pH 7.1, sodium 
cacodulate). The removal of protein was monitored using the ratio of Abs (260 nm) / Abs 
(280 nm).13 A stock solution of HS DNA (1 mol/L in nucleotide phosphates) was prepared by 
directly dissolving DNA in dd H2O, and quantified using ε260 = 6,600 M-1 cm-1, as described 
in the literature.7b  
UV-Vis absorption spectroscopy  
UV-Vis spectra and melting curves were measured using a 100 CARY-BIO UV-Visible 
spectrophotometer (Varian Inc.) equipped with a thermoelectrically controlled cell holder and 
a cuvette with 1.00 cm path length. UV-Vis titrations were conducted at 20° C in CB buffer 
by manually injecting 1-10 mL aliquots of HS DNA or oligonucleotide DNA solution into 1 
mL of PDHD sample at 10 mM concentration in the same buffer and recording spectra 
between 200 and 500 nm after each injection. The resulting DNA concentration ranged from 0 
to 225 mM. 
Circular Dichroism (CD) spectropolarimetry 
CD measurements were performed in an AVIV model 62A DS spectropolarimeter (Aviv 
Associates, Lakewood, NJ) equipped with a thermoelectrically controlled cell holder and a 
cuvette with a path length of 0.1 cm. The wavelengths studied ranged from 240 to 400 nm. 
Scans of DNA duplexes (~50 mM) were recorded at 1 nm intervals. A scan of the buffer alone 
was recorded to provide a baseline. DNA duplex was titrated by the addition of a concentrated 
PDHD solution to cover DNA : PDHD ratios over the range of 1:0 to 1:2. 
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Sequence selectivity of a DNA oligonucleotide 
Deoxyoligonucleotides, 22-mer and 38-mer, were 32P-5’-end-labeled with T4 polynucleotide 
kinase (New England Biolabs Inc.) and [γ-32P] ATP (PerkinElmer Co.) according to a 
described procedure.17  The end-labeled DNA strands were hybridized to the complementary 
strand (2.5 mM strand concentration) in 10 mM sodium cacodylate buffer, pH 7.0 in the 
presence of 100 mM NaCl.  
The 22-mer DNA duplex was incubated with PDHD enantiomers (50 mM) at 37° C for 1 
hour. Aliquots of 40 mL were subjected for DNA photocleavage using 442 nm He-Cd laser 
light as described above for 10 min.  After piperidine treatment (94° C, 20 min), the samples 
were resuspended in formamide loading dye (50% formamide, 10 mM EDTA 0.01% 
bromphenol blue), loaded onto a 20% denaturing polyacrylamide sequencing gel, and 
electrophorezed at 1800 V for approximately 3 h. DNA fragments were visualized using the 
Storm phosphoimager (Amersham, Storm 860).  The 38-mer DNA duplex samples, after 
incubation with PDHD I for 5 min at 37° C, were irradiated at 442 nm and directly subjected 
to 15% polyacrylamide gel electrophoresis. The piperidine treatment step was not applied.   
DNAse I footprinting assay  
DNA 38-mer was used in this assay. The 32P-5’-end-labeled 38-mer DNA 2 mL was combined 
with 4 mL of PDHD I in 10 mM CB buffer. Individual reactions were performed in 1.5 mL 
Eppendorf tubes with increasing concentrations of PDHD I. The final concentration of the 
PDHD enantiomer covered the range of 0.01 – 100 mM. The mixtures were incubated in the 
dark for 2 hours to obtain equilibrium at room temperature. The cleavage reaction was 
initiated by adding 2 mL of DNAse I (Promega Co.) (0.05 U/mL) and incubating for 8 min at 
room temperature. The reaction was stopped by transferring the tubes to a dry ice followed by 
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lyophilization with a SpeedVac for 40 min. Then, the dry products were dissolved in 5 mL 
formamide loading dye solution and loaded onto 15% denaturing polyacrylamide sequencing 
gel, and electrophoresed at 1700 V for approximately 2 hours. DNA fragments visualization 
was performed using phosphor imaging screen and the Storm phosphoimager (Amersham, 
Storm 860). 
Electrospray ionization  mass-spectrometry experiments were performed on a Thermo Fisher 
Scientific LTQ-FT, a hybrid instrument consisting of a linear ion trap and a Fourier transform 
ion cyclotron resonance (ICR) mass spectrometer. The sample was introduced into the LTQ-
FT using the standard electrospray ionization source for the instrument with a spray voltage of 
5 kV and a capillary temperature of 275°C. Autogain control was used and set at 500,000 with 
a maximum injection time of 1250 ms for FT-ICR full scans. Collision-induced dissociation, 
MS/MS, was executed in the linear trap with an autogain control setting of 10,000 and a 
maximum injection time of 250 ms. FT-ICR full scans were acquired in the positive ion mode 
at 100,000 resolving power at m/z 400. The positive-ion MS/MS experiments were performed 
in the linear trap portion of the instrument using helium as a collision gas, isolation widths of 
2 atomic mass units, normalized collision energies of 20 to 35 %, a q value of 0.250, and an 
excitation time of 30 ms. 
4.4. DISCUSSION AND CONLUSIONS. 
A clear understanding of DNA damage mechanism is necessary because these processes are 
responsible for mutations, aging and disease.50 In case of 10, 11-DiPyridiniumPDHD-BF4 
(DHD) the oxidative damage of DNA can happen due to several species (Scheme 4.7): radical 
cation of DHD, excited triplet state of o-qiunone (25) and ROS formed by reaction of molecular 
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Scheme 4.7. Species Forming from N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23) 
upon Irradiation. 
A long-living ( > 100 ps) radical cation (1) can abstract an electron from a neighboring base 
creating a nucleobase radical cation by ET(e-) (Scheme 4.7, Pathway 1),  also forming o-quinone 
in its triplet state (Scheme 4.8)51, 52 from  350 nm or 442 nm irradiation of N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (DHD) (23) (coordinated inside DNA double helix can abstract an 
electron (ET(e-)) from a neighboring base with formation of nucleobase radical cation (Scheme 














Scheme 4.8. o-Quinone Cycle upon Irradiation at 350 nm. 
 The efficiency of electron abstraction by o-quinone (25) with formation of a nucleobase radical 
cation (Scheme 4.9) is sensitive to the bases nearest to the o-quinone.  
o-quinone*+ N o-quinone .-   + N.+
Scheme 4.9. Oxidation of Nucleobase with o-Quinone. 
Experimentally it was observed that highest electron abstraction efficiency is obtained in 
sequences where the intercalated o-quinone group is followed by at least three A’s (5’-AQ-
AAA-3’-oligomer). UV-, CD- and ESI-MS proved that N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (DHD) (23) (bids tightly to DNA double and single helix and the o-
quinone (25) stays bound to DNA after its photochemical release from N,N-Dimethyl 10, 11-
DiPyridiniumPDHD-BF4 (DHD) (23) (Figure 4.15 and Scheme 4.6). This phenomenon enhances 
the probability of greater electron abstraction directly inside the DNA molecule, which is 
apparent from the elecrophoretic studies (Figure 4.11). An important implication of this fact is 
that N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23)  should be bound to the DNA in 
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order for the ET and then cleavage to happen. It must be noted that o-quinone (25) alone is 
ineffective at oxidation of simple mononucleosides.53 The geometry and conformation of the 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23) and o-quinone (25) intercalated in 
DNA have a significant role to play in radical cation formation and migration. The charge 
transfer properties are affected considerably by the DNA sequence in the surroundings of the 
N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23) and o-quinone (25). All these factors 
contribute towards the charge transfer properties in DNA and determine whether the DNA 
radical cation will form, migrate or form cross links or other products.54, 55 Studies of N,N-
Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23) intercalation into DNA have shown that 
the long axis of the N,N-Dimethyl 10, 11-DiPyridiniumPDHD-BF4 (DHD) (23) is parallel to the 
long axis of the base pairs at the intercalation site (Figure 2.4, Chapter 2). As a result, the radical 
cation can be formed and moved either in the 3’- or the 5’-direction on the o-quinone containing 
strand and also in its complementary strand. Calculations of standard free energy changes 
(Δ  for ET (Scheme 4.8) by Rehm-Weller Equation56 (Equation 4.6) of the reaction of single 
nucleotide oxidation by o-quinone (25) cannot be made due to the lack of data on reduction 
potentials of o-quinone (25) in water. The only available data on reduction potentials were 
published recently  57 
Δ
Equation 4.7. Rehm-Weller Equation. 
where Δ  contains two correction terms based on the Born equation (Equation 4.7): (I) the 
interaction energy of radical ions with radius rIon in a complex with a center to center distance 
aEC; (II) the difference of ion solvation between a solvent of interest, in this case water with a 
dielectric constant W =78, and an organic solvent 0 =78. 
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Equation 4.8. Born Equation. 
It was shown that in one electron oxidation and electron transfer experiments in DNA, a radical 
cation (“hole”) is introduced into a duplex DNA in solution and can migrate long distances by a 
“Phonon assisted Polaron-like Hopping mechanism” before being irreversibly trapped by 
reaction with water or molecular oxygen.58-61 In this process, the radical cation is stabilized in a 
distortion of the DNA and its nearby environment that spreads the charge over several bases 
(polaron). Thermal activation (phonons) causes the polaron to hop from one site to a neighboring 
site. The number of hops required is determined by the extent of charge delocalization, whereas 
the activation barrier determines the time scale of hops. To adequately study the properties of 
photoinitiated oxidation of DNA by ET(e-) and charge migration through DNA, a sufficient 
method has to be determined for one electron oxidation of at least one of the DNA bases.  
Either o-qiunone radical anion (27) or hydroquinone (28) may be re-oxidized to the quinone by 
molecular oxygen (on Scheme 4.7 processes as 4 and 5). These steps can give rise to reactive 
oxygen species ROS such as peroxides or hydroxyl radicals which cause DNA damage. 62 
The dihydrocyclobuta[e]pyrene (20, Chapter 2) might be used for synthesis modified 1, 2-
dihydrocyclobuta[e]pyrene (29). Considering the similarity in structure with N,N-Dimethyl 
10, 11-DiPyridiniumPDHD-BF4 (DHD) (23), we might expect the same binding properties and 
behavior upon radiation (Scheme 4.10). Pyrene 29 intercalated inside DNA upon irradiation 















Scheme 4.10. Species forming from modified 1, 2-dihydrocyclobuta[e]pyrene upon irradiation. 
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